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ABSTRACT
This dissertation is based on three essays that examine how to measure the hetero-
geneity of patient outcomes using readily available data, how to use the results to
generate patient-centric outcome information, and how outcome data can be used to
beneﬁt patients, payers, and providers. In the ﬁrst essay, we document a wide vari-
ation in quality among 188 surgeons at 35 hospitals in New York State that perform
mitral valve surgery. Our analysis shows that patients of diﬀerent demographics and
levels of acuity beneﬁt diﬀerently from elite surgeons. We estimate that the total so-
cietal beneﬁts from using our proposed patient-centric information are comparable to
those achievable by enabling the best surgeons to treat 10%–20% more patients under
currently available population-average information. In the second essay, we develop
a technique that incorporates the instrumental variable method into a causal tree to
correct for potential endogeneity biases in heterogeneous treatment eﬀect analysis us-
ing observational data. The resulting instrumental variable tree (IV tree) approach
partitions subjects into subgroups with similar treatment eﬀects within subgroups and
diﬀerent treatment eﬀects across subgroups. In the third essay, we provide empiri-
cal evidence that outcome diﬀerences between health care providers are heterogeneous
across diﬀerent patients. We then use the IV tree approach to identify patient types
that exhibit signiﬁcant diﬀerences in outcome quality. After that, we quantify the dif-
ferences in patient outcomes between providers in a (patient-centric) manner that is
useful to individual patients. Lastly, we show that providing patient-centric outcome
information not only helps patients choose providers but also helps providers identify
areas for improvement and payers design cost-eﬀective payment.
ix
CHAPTER 1
Introduction
Patients diﬀer not only in their demographics and medical conditions but also in their
responses to a treatment. While some patients respond positively to a particular treat-
ment, others may see little response or even experience serious negative eﬀects from
the same treatment. However, most studies of treatment eﬀects have focused on the
average eﬀect across all patients in a sample. The lack of a large sample and an eﬀective
methodology for analyzing heterogeneous treatment eﬀects has led to “one-size-ﬁts-all”
approaches that may not help, or may even harm, some patients.
The growing availability of observational data provides a unique opportunity for
personalize health care outcome analysis. However, there are two main challenges of
using big observational data for heterogeneous treatment eﬀect analysis. First, the
high-dimensionality of big data makes it unclear how to partition patients into sub-
groups with similar treatment eﬀects within subgroups and diﬀerent treatment eﬀects
across subgroups. Second, the uncontrolled nature of observational data introduces
potential endogeneity issues because the data often do not include all features that af-
fect treatment assignment and outcome. We consider health care providers as diﬀerent
treatments and address both challenges.
In the ﬁrst study, we document a wide variation in quality among 188 surgeons at
35 hospitals in New York State who perform mitral valve surgery. Our analysis shows
that patients of diﬀerent demographics and levels of acuity beneﬁt diﬀerently from elite
surgeons. However, existing healthcare provider quality information is based on pop-
ulation averages, so it does not diﬀerentiate patients of diﬀerent medical conditions.
This implies that patient-centric quality information, which calibrates outcome statis-
tics by patient demographics and acuity, can increase the ability of patients to choose
the most appropriate surgeon. In this study, we develop an econometric model for
computing patient-centric information from outcome data and evaluate the potential
health beneﬁts from using such information to guide patients to surgeons. We estimate
that the total societal beneﬁts from using patient-centric information are comparable
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to those achievable by enabling the best surgeons to treat 10%–20% more patients
under population-average information.
In the second study, we develop a technique that incorporates the instrumental
variable method into a causal tree to correct for potential endogeneity biases in hetero-
geneous treatment eﬀect analysis using observational data. The resulting instrumental
variable tree approach partitions subjects into subgroups with similar treatment ef-
fects within subgroups and diﬀerent treatment eﬀects across subgroups. The estimated
treatment eﬀects are asymptotically consistent under very general assumptions. Us-
ing simulated data, we show that our approach has better coverage rates and smaller
mean-squared errors than the conventional causal tree, and that a forest constructed
using instrumental variable trees has better accuracy and interpretability than the
generalized random forest.
In the third study, we focus on six cardiovascular surgical procedures and provide
empirical evidence that outcome diﬀerences between health care providers are hetero-
geneous across diﬀerent patients. We then use the instrumental variable tree approach
to identify patient types that exhibit signiﬁcant diﬀerences in outcome quality. After
that, we quantify the diﬀerences in patient outcomes between providers in a (patient-
centric) manner that is useful to individual patients. Lastly, we show that providing
patient-centric outcome information not only helps patients choose providers but also
helps providers identify areas for improvement and payers design cost-eﬀective payment
programs.
2
CHAPTER 2
Using Patient-Speciﬁc Quality Information
to Unlock Hidden Health Care Capabilities
2.1 Motivation
How to “ﬁx health care” is one of the most hotly debated topics in all of Ameri-
can society. Academic articles, media programs, legislative debates and water cooler
conversations are rife with recommendations on how to provide patients with better
and more cost eﬀective health care. The vast majority of these proposals, from reim-
bursement bundling and accountable care organizations to patient care paths and lean
transformations, are aimed at changing health care delivery and/or payment structure.
However, a widely overlooked reality is that better health care is available right now
within the American system. But too often patients can’t ﬁnd it.
To understand what is possible and how it might be achieved, we delve into the
details of a speciﬁc medical condition at the surgeon level by focusing speciﬁcally
on patients with mitral valve disease and addressing two key questions: (1) how do
diﬀerent types of patients beneﬁt diﬀerently from elite surgeons (i.e., those perform
signiﬁcantly better than the state average), and (2) How can outcome data be used to
improve health care at both the individual and societal levels? Unfortunately, while
simple to state, these questions are not straightforward to analyze using currently
available data.
To answer the ﬁrst question, we need to characterize the performance of the surgeons
that treat mitral valve patients. There are various consumer-oriented healthcare rating
systems that attempt to do this by providing provider quality information. For exam-
ple, the Centers for Medicare and Medicaid Services maintain the Hospital Compare
website that reports on over 4,000 Medicare-certiﬁed hospitals across the country with
regard to quality of care, safety measures and patient satisfaction. Various non-proﬁt
organizations, including the Leapfrog Group, Consumer Reports and the California
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Health Care Foundation, and private companies such as US News and Healthgrades,
also share self-reported hospital quality information and rankings via websites.
While these sources provide useful information, they fall well short of providing the
data mitral valve patients need to make accurate comparisons of providers because:
(1) they generally aggregate ratings into broad categories such as heart surgery, rather
than reporting them for individual procedures such as mitral valve surgery; (2) most
of these analyses are performed at the hospital level and do not provide information
about individual surgeons within a hospital; and (3) most ratings do not indicate the
magnitude of the diﬀerence between levels (e.g., between “1-star” and “3-star”, or
between “average” and “above average”).
Some states, such as New York, address these issues by compiling risk-adjusted
mortality rates for individual hospitals and surgeons that perform CABG and/or mitral
valve surgery.1 They also indicate whether a hospital or a surgeon is statistically
signiﬁcantly better or worse than the state average. However, there are still some
remaining issues. First, they focus primarily on mortality rates (and sometimes on
complication and readmission rates), where the low probability of events can make it
diﬃcult to discern statistical diﬀerences among providers. When all or most providers
are not statistically diﬀerent from the state average, patients don’t have a basis for
identifying better health care. However, if we focus on a speciﬁc medical condition,
there may be measures of quality that show more variation across providers. In this
study, we focus on mitral valve surgery and introduce mitral valve repair rate to the
conventional quality metrics (i.e., rates of mortality, complication and readmission). As
we will show later in the paper, repair rate is an informative measure of surgeon quality
and patient beneﬁt, and a metric that shows signiﬁcant variation among providers.
Second, all existing quality ratings are based on population-average outcome mea-
sures,2 and therefore do not provide personalized guidance to patients of diﬀerent de-
mographics and levels of acuity. Population-average quality information has two major
issues. First, patients care more about quality information speciﬁc to their procedure
types and medical conditions than about information about an average patient who
may not even exist. Second, population-average information suggests that all patients
will beneﬁt equally from an elite surgeon. However, it isn’t reasonable to expect all
1The NY state cardiac surgery reporting system includes patient demographics (age, gen-
der), comorbidities (e.g., lung disease, diabetes and renal failure), previous procedures, hemo-
dynamic state, ventricular function and vessel diseased as control variables in the model. See
https://www.health.ny.gov/statistics/diseases/cardiovascular for more details.
2Population-average outcome measures refer to those focusing on the “average eﬀect” or “homo-
geneous eﬀect” of a given treatment (Kravitz et al. 2004).
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patients to go to the single best surgeon, since this would create an impossible capacity
imbalance. But, with patient-speciﬁc quality information, as we will show for the case
of mitral valve surgery, it is possible to achieve substantial improvements in outcomes
without overloading any single surgeon.
To address the second question of how outcome data can be used to improve health
care, we examine two potential approaches for leveraging patient outcome data: (1)
using population-average information, possibly accompanied by measures to increase
surgeon capacity so that more patients can be treated by the best surgeons, and (2)
providing patient-speciﬁc information so that patients can better balance beneﬁts with
costs of traveling/waiting to see an elite surgeon for treatment. The second approach
is motivated by the fact that existing quality information is almost always based on
population averages and so does not indicate diﬀerences in patient beneﬁts from elite
surgeons. Consequently, patients who are treated by these surgeons may not be those
who beneﬁt the most. If patients, and the cardiologists who refer them, have access to
patient-speciﬁc quality information and use it in selecting a surgeon, the patients with
the most to gain will be those most inclined to incur additional costs associated with
being treated by an elite surgeon. We will make use of empirical and analytical mod-
els to estimate how much the resulting alignment of patients with surgeons improves
aggregate patient welfare.
Our work makes two contributions to existing studies of provider quality and health
care quality information. First, we ﬁnd that the quality gap (e.g., diﬀerence in repair
rate) between surgeons is heterogeneous for diﬀerent patients. For the same level of
increase in repair rate, younger patients have more years to live and healthier patients
have a higher quality of life. To account for such diﬀerences, we create a model to cal-
culate quality-adjusted life expectancy that combines many of short- and long-term ef-
fects of the single number quality metrics. Second, we construct a patient choice model
to compare scenarios where patients choose providers based on population-average or
patient-speciﬁc information. We ﬁnd that providing patient-speciﬁc information helps
patients to ﬁnd better care. The societal beneﬁts from using patient-speciﬁc informa-
tion are comparable to those achievable by enabling the best surgeons to treat 10–20%
more patients under population-average information.
2.2 Literature Review
There has been growing interest in studying hospital quality since 1989 when the
Agency for Health Care Policy and Research was created by Congress in response to a
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report of wide geographic variations in practice patterns among hospitals in the US (see
e.g., Chassin et al. 1987). In a seminal paper, Keeler et al. (1992) compared 297 US
hospitals for congestive heart failure, acute myocardial infarction, pneumonia, stroke or
hip replacement, and found that quality varied from state to state, but that quality was
generally better in teaching, large, and urban hospitals than in non-teaching, small, and
rural hospitals. Subsequent studies have also found that high-volume hospitals tend to
perform better than low-volume hospitals (Birkmeyer et al. 2002, Gammie et al. 2009,
Vassileva et al. 2012) and that high-volume surgeons tend to perform better than low-
volume surgeons (Birkmeyer et al. 2003, Bolling et al. 2010, Kilic et al. 2013). Instead
of studying hospital characteristics that are associated with performance, a number
of studies looked directly at hospital ﬁxed eﬀects and found similar quality variations
across hospitals (Lingsma et al. 2010, McClellan et al. 1994, Moran et al. 2014).
Note that, in these studies, the eﬀects of hospital volume and other characteristics are
absorbed by hospital ﬁxed eﬀects. By using a multilevel model, we are able to separate
out volume eﬀects and unobservable hospital speciﬁc eﬀects beyond those captured by
volume.
In the operations management literature, a number of studies have examined factors
aﬀecting health care quality. Some of these have focused on surgeon experience and its
impact on surgical outcome. For example, KC and Staats (2012) investigated the dif-
ferential eﬀects of focal and related experience, and found that surgeon focal experience
has a greater eﬀect than related experience on surgeon performance. KC et al. (2013)
examined how surgeons learn from their own and others’ experiences, and found that
individuals learn more from their own successes but also from others’ failures. Ramdas
et al. (2017) studied how learning and forgetting aﬀect surgical outcomes by analyz-
ing a surgeon’s experience with speciﬁc surgical device versions and the time between
their repeated uses. Other studies have analyzed the impact of workload on quality
and patient outcome. For instance, Kim et al. (2014) examined the impact of ICU
congestion on a patient’s care pathway and the subsequent eﬀect on patient outcomes,
and found that the impact of ICU admission is highly variable for diﬀerent patients
and diﬀerent outcomes. Jaeker and Tucker (2016) studied the relationship between
workload and patient length of stay (LOS), and found that the eﬀects of inpatient
workload on LOS propagate across patient types. Freeman et al. (2016) show that
gatekeeper providers (midwives in their study) ration resource-intensive discretionary
services and also increase the rate of specialist referrals when workload increases. In
addition to surgeon experience and workload, queue management (Song et al. 2015)
and secure messaging between patients and physicians via patient portals (Bavafa et
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al. 2018) have also been found to aﬀect productivity and patient outcome. However,
none of these studies have compared quality among health care providers or studied
the impact of patient-speciﬁc information on outcomes.
The ﬁndings from this line of research suggest that: (1) both hospitals and surgeons
play pivotal roles in determining healthcare quality; (2) experience at both institutional
and individual levels signiﬁcantly aﬀects quality; and (3) in addition to experience,
many other nuanced factors aﬀect provider quality.
We contribute to the literature of healthcare provider quality evaluation by incor-
porating hospital and surgeon volume eﬀects, as well as hospital and surgeon speciﬁc
eﬀects, in our model. However, unlike the aforementioned studies, our focus is not to
identify the eﬀect of a speciﬁc factor on provider quality, but rather to examine the
quality gap among providers, which allows us to oﬀer insights on how to best utilize
the capabilities of existing healthcare system.
To accomplish this, we ﬁrst need to identify elite surgeons who produce better qual-
ity outcomes. More importantly, we need to quantify the quality gap between an elite
surgeon and an average surgeon for patients of diﬀerent demographics and levels of
acuity. Most prior studies have focused on measuring provider quality based on the
population average (i.e., risk adjusted) outcomes, and thereby assume away hetero-
geneity in outcomes among patients of diﬀerent demographics and levels of acuity. As
a result, their assessments of provider quality apply to average patients (who may not
even exist) but may not be useful for a given patient. Recognizing this ﬂaw in pop-
ulation average information, a number of observers have called for a patient-centered
focus in both patient care and in quality assessment (see, e.g., FDA 2013, Gerteis 1993,
IOM 2011, Kattan and Vickers 2004, Kent and Hayward 2007, Kravitz et al. 2004).
Our study contributes to the literature on patient-centered care by proposing patient-
speciﬁc quality information as a means to help patients ﬁnd care best suited to their
needs.
2.3 Empirical Setting and Data
We choose mitral valve surgery as the empirical setting for our analysis of health care
provider quality for several reasons. First, mitral valve disease is the most common
form of heart valve disease in US. It aﬀects 5% of the population and results in over
500,000 hospital admissions per year.3 Second, mitral valve repair is a relatively new
and complicated procedure. Because of the high level of skill required, surgeons may
3http://heartvalvedisease.nm.org/mitral-valve-disease.html
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diﬀer substantially in their outcomes. Third, there are many extant medical studies
that provide data on the clinical outcomes of treatments available to mitral valve
patients.
2.3.1 Mitral Valve Disease
The mitral valve is located between the left chambers of the heart. Its main function
is to allow blood to ﬂow from the left atrium to the left ventricle but not in the other
direction. Mitral valve disease refers to conditions that compromise the ability of the
mitral valve to seal against the backﬂow of blood.
There are two clinical options for the correction of mitral valve disease — mitral
valve repair and mitral valve replacement. Mitral valve repair restores the function of
the original valve, and is therefore the preferred option (Bolling et al. 2010). Table 2.1
compares the risks of mortality and complications associated with both procedures for
a 60-year old male patient without major comorbidities (Society of Thoracic Surgeons,
2016). We see that the risks associated with replacement are 44.8% to 94.3% higher
than those associated with repair.
Table 2.1: Comparison of Mitral Valve Repair and Replacement
Mitral Valve Mitral Valve Relative
Repair Replacement Gap
Operative Mortality 0.4% 0.7% 94.3%
Prolonged Ventilation 2.7% 5.1% 85.8%
Renal Failure 0.9% 1.5% 63.5%
Reoperation 4.7% 6.8% 44.8%
Source: Society of Thoracic Surgeons Risk Evaluator (2016).
Consequently, surgeons strive to repair a mitral valve whenever possible. However,
since it is impossible to guarantee a repair, surgeons always have either a biological
valve (from a cow or pig) or a mechanical valve (made of special carbon compounds
and titanium) ready as a backup. If, during the procedure, visual inspection reveals
the valve is not repairable, or a repair is attempted but fails (e.g., leaks), a replacement
valve will be installed. The likelihood of a repair depends on both patient characteristics
and surgeon skill. Hence, repair rate (fraction of patients whose valves are repaired) is
an indicator of surgeon quality after controlling for the mix of patients.
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2.3.2 Data Description
We used data from New York State that describe 10 million in- and out-patient dis-
charges from all hospitals in New York from 2009–2012. These data contain patient-
level clinical and resource-use information, including admission status (e.g., elective,
emergent and urgent), patient demographics and comorbidities, hospital and physician
identiﬁers, and principal and secondary diagnoses. For each discharge, the data record
whether a patient received a mitral valve repair or replacement. They also indicate
whether a patient died or experienced other complications during the procedure or
post-surgery hospitalization. Because they record all visits, we are able to identify
readmissions for the same patient across hospitals and time. Finally, the data include
5-digit zip codes of patients’ home and hospital addresses, which allow us to estimate
travel distance from each patient’s home to any hospital.
2.3.3 Data Preparation
We identiﬁed discharges related to mitral valve surgery by using the clinical codes 35.12,
35.23 and 35.24 in the International Classiﬁcation of Disease (9th revision). To focus on
isolated mitral valve surgery, we followed previous studies (e.g., Vassileva et al. 2012)
in excluding patients who were less than 30 years old, had coronary revascularization,
congenital heart disease, excision of ventricular aneurysm, replacement of thoracic
aorta, aortic fenestration procedure, closed heart valvuloplasty, heart transplant, or
other valvular repair.
Because the ultimate objective of this study is to allow patients to choose the most
appropriate care for them, we focused on elective patients only, as opposed to emergent
or urgent patients whose choice of providers may have been constrained by the urgency
of their medical condition (Batt and Terwiesch 2015). An elective mitral valve patient
can wait for a year or more from diagnosis to treatment (Carroll et al. 1995), which
allows for considerable ﬂexibility in the choice of providers.
Lastly, we focused on New York patients who were treated in New York hospitals.
We do not directly observe New York residents who were treated outside New York
because we lack data to compute patient-to-hospital distances for these patients.4 This
is unlikely to cause a sampling concern in our context, because New York has 4 out
of the 50 nationally ranked heart programs.5 If a patient decides to seek a better
4Although many others states in the US make their inpatient and outpatient discharge data avail-
able, most do not contain patient-level zip code information without which we cannot estimate dis-
tances to out-of-state providers.
5http://health.usnews.com/best-hospitals/rankings/cardiology-and-heart-surgery
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provider than those available locally, the best providers in New York are comparable
to the best providers in the country. We also excluded patients who traveled from other
states to New York for mitral valve surgery, because we do not have suﬃcient data on
out-of-state hospitals to describe these patients’ local treatment options.6 We believe
this exclusion also does not bias the estimation of provider quality, because it is very
unlikely that provider quality varies for in-state vs. out-of-state patients conditional
on patient demographics and medical conditions.
2.3.4 Measures of Provider Quality
We use the rates of mortality, complication, readmission and mitral valve repair as
measures of quality for two main reasons. First, mortality, complication and readmis-
sion rates are commonly used measures of health care provider quality in both hospital
rating systems (e.g., US News, the Leapfrog Group, Healthgrades, Hospital Compare,
and New York State Cardiac Surgery Reporting System) and existing literature (e.g.,
Birkmeyer et al. 2002, Brooks et al. 2006, Gupta et al. 2014). They describe important
short-term risks to patients while they are staying in hospitals and the time shortly
after discharge. Because these quality metrics capture diﬀerent aspects of short-term
risks patients care about, we include all three of them in this study. To capture the
long-term risks, we follow existing medical literature by including mitral valve repair
rate as an additional quality metric (see e.g., Vassileva et al. 2012). The inclusion of
multiple metrics ensures that the conclusions we draw from this study is not driven by
the choice of a speciﬁc quality metric.
Second, the above metrics provide the basis for constructing a single metric that
captures beneﬁts from visiting elite surgeons. In Section 2.5.3, we describe a quality-
adjusted life expectancy metric that combines the main short- and long-term eﬀects of
the single number metrics. This allows us to incorporate the heterogeneity in multiple
aspects of provider quality, capture diﬀerent aspects of patient beneﬁts, and assess the
value of patient-speciﬁc information.
In this study, the quality measures are operationalized as follows. Mortality is
measured as death during hospitalization.7 Complication is measured as occurrence of
one or multiple mitral valve related complications including stroke, wound infection,
renal failure, reoperation and ventilation observed during hospitalization (Society of
6Among all the patients treated at NY hospitals, around 90% of them were from NY. Most of the
other 10% of patients came from nearby states such as New Jersey (7%).
7The New York in- and out-patient discharge data do not track post-discharge death or complica-
tion.
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Thoracic Surgeons 2016). To analyze readmission rate, we focus on 30-day readmission
by identifying patients who were admitted to the same or other hospitals within 30
days after discharge.8 Lastly, we observe from the data whether a patient received
mitral valve repair or replacement based on the clinical procedure codes.
2.4 Empirical Model of Provider Quality
While it is widely accepted that health care providers diﬀer with regard to quality, it is
not clear whether the outcome diﬀerences between providers are heterogeneous across
patients of diﬀerent demographics and levels of acuity, and if so, to what extent. In
this section, we construct an econometric model of provider quality to evaluate how
diﬀerent types of patients beneﬁt diﬀerently from elite surgeons.
2.4.1 Factors Aﬀecting Surgical Outcomes
Surgical outcomes can be aﬀected by patient, hospital and surgeon characteristics.
For example, old age correlates with increased risks of mortality, complication and
readmission (Gupta et al. 2014, Merkow et al. 2015, Society of Thoracic Surgeons
2016). Studies have found that white patients are less likely to have complications and
unplanned readmissions than are black and Hispanic patients, and that female patients
are more likely than male patients to have these undesired events (Iribarne et al. 2014,
Merkow et al. 2015, Society of Thoracic Surgeons 2016). Such diﬀerences can be the
result of medical (e.g., comorbidities) or behavioral (e.g., delay in undergoing cardiac
surgery) diﬀerences between various patient groups (Fasken et al. 2001). Comorbidities
that increase the risk of mortality, complication and readmission include diabetes,
chronic obstructive pulmonary disease, hypertension and renal failure (Gupta et al.
2014, Iribarne et al. 2014, Merkow et al. 2015, Society of Thoracic Surgeons 2016).
With respect to repair rate in mitral valve surgery, Bolling et al. (2010) and Vas-
sileva et al. (2013) separately found that younger and white patients are more likely
to receive a repair, whereas females are less likely to receive a repair. Presence of var-
ious comorbidities including atrial ﬁbrillation, chronic obstructive pulmonary disease,
diabetes, heart failure, renal disease and hypertension also reduces the likelihood of
mitral valve repair (Daneshmand et al. 2009, Savage et al. 2003, and Vassileva et al.
2013).
8https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-
reduction-program.html
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Of more direct interest to us in this study is the impact of hospitals and surgeons
on surgical outcomes. Presumably a hospital with more skilled surgeons, as well as
more experienced support teams and an organizational structure that promotes learn-
ing and quality improvement, will have better quality than a hospital without these
assets. However, because quality and its antecedents are challenging to measure, pa-
tients and researchers alike must often rely on proxies to gauge the provider (hospital
and/or surgeon) eﬀect on quality. One of the most common proxies is surgical volume
(Birkmeyer et al. 2002, Birkmeyer et al. 2003, Gammie et al. 2009, Kilic et al. 2013,
Vassileva et al. 2012, Vassileve et al. 2013).
Note, however, volume alone is not suﬃcient to capture all variations in surgeon
skills or hospital eﬀects. Some surgeons may have better training or higher innate
ability. At the hospital level, initiatives focused on quality improvement have also
proven to be very eﬀective (Barr et al. 2006, Lindenauer et al. 2007). Therefore, it
is imperative to account for variations in surgeon and hospital quality beyond those
captured by surgical volume.
2.4.2 Quality Model
To evaluate the impact of surgeon and hospital on patient outcomes, we need an
econometric model that can address the following three issues. First, our data has a
nested structure, i.e., patients are grouped under diﬀerent surgeons and surgeons are
grouped under diﬀerent hospitals. Second, outcomes of patients treated by the same
surgeon/hospital may correlate with each other due to unobservable surgeon/hospital
characteristics. Third, we want to separately identify surgeon and hospital eﬀects
as well as their volume eﬀects. To address these issues, we follow the approaches
of Healthcare Cost and Utilization Project9 and Centers for Medicare and Medicaid
Services10 and use a multilevel probit model (Gibbons and Hedeker 1997).
Let Y ∗ijk denote the latent variable associated with the outcome measure (i.e., mor-
tality, complication, readmission, or repair) of patient i treated by surgeon j at hospital
k. Y ∗ijk can be measured as a function of patient, surgeon and hospital characteristics:
Y ∗ijk = γ0 + γ1Agei + γ2Genderi + γ3Racei + γ4Comorbi (2.1)
+γ5SurgV oli + γ6HospV oli + αk + βjk + ijk
Yijk = 1{Y ∗ijk > 0}
9https://www.hcup-us.ahrq.gov/reports/methods/2007 01.pdf
10https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
Instruments/HospitalQualityInits/Measure-Methodology.html
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where SurgV oli and HospV oli are measures of surgeon and hospital volumes of the
procedure received by patient i,11 αk represents the unobserved eﬀect of hospital k,
and βjk represents the unobserved eﬀect of surgeon j at hospital k.
12 We assume these
unobserved eﬀects are drawn from two normal distributions:
αk ∼ N(μα, σ2α), βjk ∼ N(μβ, σ2β)
where μα and μβ represent the mean hospital and surgeon eﬀects, and σ
2
α and σ
2
β
represent between-hospital and between-surgeon variations after accounting for hospital
volume, surgeon volume and patient conditions at admission. If there are no between-
hospital or between-surgeon diﬀerences in the outcomes beyond those captured by
surgical volume and patient characteristics, then σ2α = 0 (i.e., α1 = α2 = ... = αK) or
σ2β = 0 (i.e., β1 = β2 = ... = βJ).
For all models, we have robust standard errors clustered by surgeon to allow for
diﬀerences in the variance/standard errors due to arbitrary intra-group correlation (KC
and Terwiesch 2011, Jaeker and Tucker 2016).
The model speciﬁed above is essentially a random eﬀects model. Alternatively, one
could also specify a ﬁxed eﬀects model at the surgeon level. There are two approaches
to account for surgeon ﬁxed eﬀects. One approach is to include dummies for surgeons.
This approach estimates surgeon ﬁxed eﬀects explicitly. In our setting, however, this
would require a total of 187 surgeon dummies, which would create a collinearity issue
preventing us from identifying the ﬁxed eﬀects of 75 surgeons. Moreover, many surgeon
ﬁxed eﬀects would not be able to be estimated reliably because over 50% of surgeons
performed fewer than 10 cases during our study period. The other approach to account
for surgeon ﬁxed eﬀects is to specify them as unobserved error terms. In particular,
this could be done through ﬁxed eﬀects logit model (Wooldridge 2010, Chapter 15.8),
which does not treat ﬁxed eﬀects as parameters to estimate and uses only within-subject
variations for estimation. Also, it allows for any association between the unobserved
surgeon ﬁxed eﬀects and patient characteristics (observed and unobserved). However,
because it lacks estimates of ﬁxed eﬀects, this model cannot be used to predict the
outcome of a patient treated by a diﬀerent surgeon.
We note, however, that a random eﬀects model assumes that the random eﬀects are
11We follow the notation of KC and Terwiesch (2011) and use i to associate surgeon and hospital
volumes with patients.
1212 out of the 188 surgeons performed surgeries at multiple hospitals. Because surgeon perfor-
mance is institution-speciﬁc and not fully transferable across hospitals (Huckman and Pisano 2006),
we assume that these surgeons have independent unobserved eﬀects. This assumption allows us to
estimate provider quality using the multilevel probit model.
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uncorrelated with other regressors in the model while a ﬁxed eﬀects model allows for
correlation between the ﬁxed eﬀects and other regressors. If this assumption is wrong,
estimates from the random eﬀects model will be inconsistent and systematically diﬀer-
ent from those estimated from the ﬁxed eﬀects model. We check this assumption using
the Hausman test (Hausman 1978) with the null hypothesis that the diﬀerence between
the random eﬀects and ﬁxed eﬀects estimates is not signiﬁcant. A p-value of 0.575 from
the Hausman test (see Appendix A.1) indicates the diﬀerence between the two sets of
estimates is not statistically signiﬁcant, which provides additional justiﬁcation for using
the random eﬀects model.
2.4.3 Estimation of Hospital and Surgeon Eﬀects
Because our primary goal is to help patients ﬁnd better care, our main interests are
the hospital speciﬁc eﬀect αk and the surgeon speciﬁc eﬀect βjk on patient outcomes.
To estimate these eﬀects, we use an orthogonal transformation as in Gibbons and Bock
(1987). That is, we rewrite the hospital and surgeon speciﬁc eﬀect as αk = μα + θkσα
and βjk = μβ + θjkσβ, where θk and θjk follow the standard normal distribution.
Note that, conditional on hospital and surgeon speciﬁc eﬀects θk and θjk, the out-
comes of all patients treated by surgeon j at hospital k are independent; therefore, the
marginal probability of observing the set of outcomes at a hospital k can be expressed
as:
h(Yk) =
∫
θk
( Jk∏
j=1
∫
θjk
( Njk∏
i=1
l(Yijk|Xijk, θjk, θk, μ, σ, γ)
)
φ(θjk)dθjk
)
φ(θk)dθk.
The individual likelihood function l(Yijk|Xijk, θjk, θk, μ, σ, γ) equals:
l(Yijk|Xijk, θjk, θk, μ, σ, γ) =
[
Φ(zijk(Xijk, θk, θjk;μ, σ, γ))
]Yijk[1− Φ(zijk(Xijk, θk, θjk;μ, σ, γ))]1−Yijk ,
where
zijk(Xijk, θk, θjk;μ, σ, γ) = γ0 + γ1Agei + γ2Genderi + γ3Racei + γ4Comorbi,
+γ5SurgV oli + γ6HospV oli + μα + θkσα + μβ + θjkσβ.
We can now estimate (γ, μ, σ) by maximizing the log likelihood of observing the
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outcomes at all hospitals, which is expressed as:
logL =
K∑
k=1
log h(Yk).
Upon obtaining estimates (γˆ, μˆ, σˆ), we calculate θˆk and θˆjk for each hospital and
each surgeon using the expected a posteriori (EAP) value (Bayes estimate) of θj and
θjk (Bock & Aitkin 1981, Gibbon & Hedeker 1997).
θˆk =
∫
θk
θk
(∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
)
φ(θk)dθk
∫
θk
(∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
)
φ(θk)dθk
,
θˆjk =
∏Jk
j=1
∫
θjk
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θˆk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θˆk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
.
These quantities can be evaluated using Gauss-Hermite quadrature as described in
Gibbons and Bock (1987) or Bock and Aitkin (1981). Estimates of αk and βjk can be
recovered by αˆk = μˆα + θˆkσˆα and βjk = μˆβ + θˆjkσˆβ. Finally, the standard errors can
be estimated using
σ(θˆk) =
∫
θk
(θk − θˆk)2
(∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
)
φ(θk)dθk
∫
θk
(∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
)
φ(θk)dθk
,
σ(θˆjk) =
∏Jk
j=1
∫
θjk
(θjk − θˆjk)2
(∏Njk
i=1 l(Yijk|Xijk, θjk, θˆk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk∏Jk
j=1
∫
θjk
(∏Njk
i=1 l(Yijk|Xijk, θjk, θˆk, μˆ, σˆ, γˆ)
)
φ(θjk)dθjk
.
2.5 Generating Patient-Speciﬁc Quality Informa-
tion
In this section, we ﬁrst summarize results from the above model (i.e., Equation 2.1)
applied to diﬀerent quality metrics. Then we examine quality gaps between surgeons
and show that the quality gaps are heterogeneous for diﬀerent patients. Finally, we
make use of the quality-adjusted life expectancy metric to show how patients of diﬀerent
demographics and levels of acuity beneﬁt diﬀerently from elite surgeons.
15
2.5.1 Summary Statistics and Estimation Results
Between 2009 and 2012, 2,718 patients of New York State underwent elective mitral
valve surgery performed by 188 surgeons at 35 New York hospitals. Among these
patients, 26% bypassed their local hospitals (i.e., those within 5 miles of the nearest
hospital) and chose a hospital they had not visited for one year or more. Table 2.2
summarizes their characteristics. These data reveal some insights into patient choices.
For example, the average travel distance is longer for patients under 60 than for older
patients. This may be because younger patients are better able to travel. However,
patients over 80 travelled on average further than patients in their 60s and 70s. This
could be because their medical condition is often too delicate for a local hospital to
handle. Overall, the average observed mortality rate was 1%, complication rate was
11%, readmission rate was 4%, and repair rate was 57%. However, all of these metrics
worsen as the age of the patient increases.
Table 2.2: Summary of Patient Characteristics
Patients Travel Dist. (miles) Repair Rate Mortality Rate Complication Rate Readmission Rate
% mean s.d. mean s.d. mean s.d. mean s.d. mean s.d.
Age
below 50 12% 19 29 67% 47% 0% 5% 5% 22% 3% 17%
50 to 60 22% 22 29 72% 45% 1% 7% 5% 22% 2% 15%
60 to 70 27% 18 26 60% 49% 2% 13% 9% 29% 4% 21%
70 to 80 27% 17 22 47% 50% 1% 12% 15% 36% 5% 21%
above 80 13% 19 22 39% 49% 3% 16% 20% 40% 9% 28%
Gender
male 55% 20 26 63% 48% 1% 11% 11% 31% 4% 20%
female 45% 18 27 51% 50% 1% 12% 11% 31% 5% 22%
Race
asian 2% 18 22 42% 50% 2% 14% 9% 30% 8% 27%
black 8% 8 19 52% 50% 1% 12% 16% 37% 4% 19%
hispanic 5% 8 17 44% 50% 0% 0% 11% 32% 5% 22%
others 13% 18 22 64% 48% 1% 12% 10% 31% 10% 30%
white 73% 21 28 58% 49% 1% 11% 10% 30% 3% 18%
Total 2,718 19 26 57% 49% 1% 11% 11% 31% 4% 21%
To compute risk adjusted quality metrics, we estimate the quality model (i.e., Equa-
tion 2.1) from Section 2.4. Table 2.3 summarizes the results. We ﬁrst examine how
patient characteristics aﬀect outcomes. Not surprisingly, repair rate decreases and rates
of mortality, complication and readmission increase as patient age increases. Compared
with male patients, female patients are less likely to receive mitral valve repair, and are
more likely to have deaths. Compared with white patients, Hispanic patients are less
likely to receive mitral valve repair, and are more likely to have complications. Finally,
mitral valve repair rate is lower for patients with comorbidities of atrial ﬁbrillation,
chronic lung disease or renal disease. These results are consistent with those of pre-
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vious studies (see e.g., Bolling et al., 2010 and Vassileva et al. 2013). Comorbidities
such as atrial ﬁbrillation and chronic lung disease aﬀect other measures of quality as
well, but the impact and signiﬁcance level vary for diﬀerent quality metrics.
Surgical volume also inﬂuences outcomes. For mitral valve repair, we see that
the coeﬃcients of both hospital and surgeon volumes are positive and signiﬁcant at
the 5% level, suggesting that repair rate increases with volume. For complication
and readmission, we see that complication rate decreases with surgeon volume and
readmission rate decreases with hospital volume. These results are consistent with
those of previous studies (see e.g., Birkmeyer et al. 2003 and Kilic et al. 2013). For
mortality, we do not observe a statistically signiﬁcant eﬀect of volume, partly because
the events measured are relatively rare. In addition, we do see that repair leads to a
lower level of complication than replacement, as suggested by the medical literature
(LaPar et al. 2010).13
Table 2.3: Estimation Results of the Quality Model
Repair Mortality Complication Readmission
Coeﬃcient Std. Err. Coeﬃcient Std. Err. Coeﬃcient Std. Err. Coeﬃcient Std. Err.
Surgical Volumes
hosp vol 0.21 ∗ ∗ 0.09 0.14 0.12 −0.05 0.04 −0.18 ∗ ∗ 0.08
surg vol 0.13 ∗ ∗∗ 0.04 −0.01 0.04 −0.04 ∗ ∗ 0.02 0.00 0.05
Patient Demographics
age −0.02 ∗ ∗∗ 0.00 0.02 ∗ ∗∗ 0.01 0.02 ∗ ∗∗ 0.00 0.02 ∗ ∗∗ 0.00
female −0.31 ∗ ∗∗ 0.07 0.24 ∗ ∗ 0.10 0.06 0.05 0.12 0.10
black −0.17 0.17 0.14 0.19 0.14 0.15 0.14 0.17
hispanic −0.32∗ 0.17 −5.45 −0.01 0.13 0.29 0.20
asian −0.29 ∗ ∗ 0.15 0.07 0.47 −0.07 0.17 0.62∗ 0.34
others 0.13 0.09 −0.09 0.22 −0.21 ∗ ∗ 0.10 0.62 ∗ ∗∗ 0.25
Comorbidities
atrial ﬁbrillation −0.12∗ 0.07 −0.57 ∗ ∗∗ 0.12 0.01 0.12 0.03 0.07
heart failure −0.09 0.34 0.53 0.61 1.70 ∗ ∗ 0.74 −4.30 ∗ ∗∗ 0.18
lung disease −0.23 ∗ ∗∗ 0.08 −0.02 0.27 −0.01 0.08 0.28 ∗ ∗∗ 0.09
diabetes −0.12 0.08 −0.37 0.24 0.11 0.08 −0.17∗ 0.09
hypertension 0.05 0.05 −0.43 ∗ ∗∗ 0.15 −0.31 ∗ ∗∗ 0.08 0.02 0.09
renal failure −0.29 ∗ ∗∗ 0.08 0.38 0.26 0.89 ∗ ∗∗ 0.11 0.23 0.15
Others
repair −0.26 0.21 −0.25 ∗ ∗∗ 0.08 0.11 0.12
θα 0.14 0.03 0.00 0.00 0.05 0.03 0.04 0.04
θβ 0.10 0.03 0.00 0.00 0.00 0.00 0.06 0.10
constant 0.79 ∗ ∗∗ 0.31 −4.24 ∗ ∗∗ 0.77 −2.38 ∗ ∗∗ 0.28 −2.54 ∗ ∗∗ 0.34
log likelihood −1544.29 −127.78 −855.70 −445.89
Note: *** p < 0.01, ** p <0.05, * p < 0.1. Robust standard errors are clustered by surgeon. The following comorbidities are included in the regression but are not shown in the table: alcohol abuse,
deﬁciency anemias, rheumatoid arthritis/collagen vascular diseases, chronic blood loss anemia, coagulopathy, depression, drug abuse, hypothyroidism, liver disease, lymphoma, ﬂuid and electrolyte
disorders, metastatic cancer, other neurological disorders, obesity, paralysis, peripheral vascular disorders, psychoses, pulmonary circulation disorders, solid tumor without metastasis, valvular disease,
and weight loss.
2.5.2 Population-Average vs. Patient-Speciﬁc Outcomes
We estimate population-average outcomes of surgeons using the predicted rates of mi-
tral valve repair, complication, readmission and mortality for a patient with average
13We checked the quality model for these three measures without including repair as an explanatory
variable, and obtained similar quality gaps between surgeons.
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characteristics. We follow the approach of New York Cardiac Surgeon Report Card
to determine whether a surgeon is statistically signiﬁcantly diﬀerent from the state
average, which is deﬁned as the mean of all surgeons rates for that measure.14 We
informally label the top performers, who are signiﬁcantly better than the state aver-
age, as “elite surgeons”.15 Figure 2.1 displays mitral valve repair rate as an example
(readmission and complication rates are shown in Appendix A.2). The average repair
rate across all surgeons is around 50%. The conﬁdence intervals are heavily inﬂuenced
by the number of cases. Surgeons with low volumes tend to have wide conﬁdence in-
tervals, and are therefore either indistinguishable from the state average or below it.
While almost all elite surgeons are high-volume surgeons, not all high-volume surgeons
have high mitral valve repair rates.
Figure 2.1: Mitral Valve Repair Rate by Surgeon for A Patient with Average
Characteristics
Figure 2.1, as well as the ﬁgures in Appendix A.2, clearly suggest that some surgeons
are signiﬁcantly better than others. What is not obvious is that the quality gap between
elite and other surgeons is not uniform across patients of diﬀerent demographics and
levels of acuity. To illustrate this point, we deﬁne three patient types with diﬀerent
levels of acuity: “sick” (i.e., 90 years old with comorbidities) patients, “typical” (i.e.,
average) patients, and “healthy” (i.e., 30 years old with no comorbidities) patients. We
calculate the predicted rates of mitral valve repair for the sick and healthy patients in
14An alternative way to calculate the state average is to weight an individual surgeon’s rate by
his/her surgical volume. However, because surgeons are the focus of this analysis and surgical volume
is endogenous and can change over time, we calculate the averages at the surgeon rather than the
patient level.
15We note that there are alternative ways to deﬁne elite surgeons (e.g., using a cut-oﬀ rate). These
alternative deﬁnitions do not change our main conclusion regarding the value of patient-speciﬁc in-
formation.
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the same way as what we did for the typical patients. Figure 2 shows mitral valve repair
rate as an example (complication and readmission rates are shown in Appendix A.3).
In this case, all three groups of patients beneﬁt from visiting elite surgeons, but the
magnitude of beneﬁt diﬀers. For example, the gap in repair rate between a surgeon at
the 95th-percentile and a surgeon at the median for these three patient types is 30.8%
(p=0.032) for the typical patients, 17.0% (p=0.098) for the healthy patients and 23.5%
(p=0.099) for the sick patients, all of which are signiﬁcant at 10% signiﬁcance levels.16
This indicates that neither the sick nor the healthy group of patients beneﬁt as much
as the typical patients from visiting an elite surgeon. A plausible explanation for this
is that many sick patients, with hard-to-repair valves, are likely to get a replacement
regardless of which surgeon they visit, while many healthy patients, with easy-to-repair
valves, are likely to get a replacement from any above-median surgeon. The patients in
between, however, tend to present “diﬃcult but not impossible” repair challenges, and
are therefore substantially more likely to receive a repair from an elite surgeon than
from a median surgeon. Of course, these three sample groups are only illustrative. The
heterogeneity in surgeon impact on patient outcomes may be aﬀected by many patient
characteristics.
Figure 2.2: Mitral Valve Repair Rate by Surgeon for Patients of Diﬀerent Levels of
Acuity
16The quality gap between the top (100th-percentile) surgeon and a surgeon at the median is also
heterogeneous with the healthy patients beneﬁt less than the sick and typical patients. Our simulation
model to be discussed later captures the quality gap between any two surgeons across all patient types.
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2.5.3 Quality-Adjusted Life Expectancy
The single number quality metrics we have used so far are common in the medical
literature (mortality, complication and readmission rates for all surgical procedures and
repair rate for mitral valve surgery). Examining how these vary by surgeon and patient
type highlights the heterogeneity we must quantify to generate patient-speciﬁc outcome
information. But none are entirely satisfactory on their own as characterizations of the
patient experience. One reason is that mortality, complication and readmission rates
capture only short-term issues. Repair rate captures long-term quality of life, but only
partially. It omits the intensity and duration of the quality of life beneﬁts of a repair.
For example, younger and healthier patients have more years to live and, as a result,
their lifetime beneﬁt from a successful repair is greater than that of older and sicker
patients. For patients with the same number of years to live, those suﬀering from
complications such as stroke or bleeding have a lower quality of life than those without
such complications. To account for such diﬀerences, we make use of the Quality-
Adjusted Life Expectancy (QALE) metric (see e.g., Black et al. 2014, Hutton et al.
2011, Zaric et al. 2000).
To compute QALE, we make use of the model in Figure 2.3 to capture both short-
and long-term postoperative risks associated with mitral valve surgery. Short-term risks
include operative mortality, complications (e.g., stroke, wound infection, renal failure,
reoperation and ventilation) observed during hospitalization, and 30-day readmission.
Long-term risks include stroke, bleeding, reoperation due to valve deterioration, and
mortality incurred during the remainder of a patient’s life. We assess these risks of
treatment by elite and other surgeons according to patients’ age and major comor-
bidities (e.g., atrial ﬁbrillation, heart failure, lung disease, diabetes, hypertension and
renal failure).
To calculate the quality-adjusted life expectancy of patient type i treated by sur-
geon j (denoted as QALEij), we let QoLij(t) denote the patient’s quality of life at time
t, t ∈ [0, Tij], where 0 is the time of treatment, and Tij is the survival time. Then the pa-
tient’s quality-adjusted life expectancy can be described as QALEij =
∫ Tij
0
QoLij(t)dt.
The right-hand side of this equation cannot be calculated directly, because the upper
bound of integration Tij depends on patient survival. To address this issue, we re-write
QALEij as a function of the survival function Sij(t). Let TRij denote the treatment
(repair or replacement) received by patient i at surgeon j. Rij(t, TRij) denote the
occurrence of one or more major risks to patient i at time t after being treated by
surgeon j, where the set of major risks include mortality, readmission, and complica-
tions. In particular, we deﬁne Rsij and R
l
ij to distinguish short-term and long-term risks
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Figure 2.3: Related Events and Decision Process for Patients with Mitral Valve Diseases
Note: ICU and SVD stand for intensive care unit and structural valve deterioration, respectively.
described earlier. Let t ≤ t1 and t > t1 indicate short and long terms, respectively.
We then calculate the expected QALEij as follows (Hwang et al. 1996)
QALEij =
∫ ∞
0
Sij(t)QoLij(t)dt (2.2)
= ETRij
[ ∫ ∞
0
Sij(t|TRij)ERij(t,TRij)
[
QoLij(t|Rij(t, TRij))
]
dt
]
= ETRij
[ ∫ t1
0
Sij(t|TRij)ERij(t,TRij)
[
QoLij(t|Rsij(t, TRij))
]
dt
+
∫ ∞
t1
Sij(t|TRij)ERij(t,TRij)
[
QoLij(t|Rlij(t, TRij))
]
dt
]
To parameterize this model, we estimate operative mortality, short-term complica-
tion and 30-day readmission rates using quality models similar to Equation 2.1 pre-
sented in Section 2.4.3. In particular, we estimate the probability of each type of com-
plication separately and consider the occurrence of each complication as independent
when calculating the joint probability of multiple complications (see Appendix A.4).
We also distinguish biological replacement from mechanical replacement in calculating
the probability of receiving such treatment, as well as the state of health conditional
on each type of treatment.
Because the current data does not allow us to analyze long-term risks and quality of
life, we follow approaches of existing studies (see e.g., Black et al. 2014 and Zaric et al.
2000) to estimate them from several sources in the medical literature. We estimate risks
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of stroke, bleeding, structural valve deterioration and mortality based on Bourguignon
et al. (2014), Daneshmand et al. (2010), Gelsomino et al. (2011), Ray et al. (2006),
Ruel et al. (2004), Russo et al. (2008). We estimate quality of life based on Cox et al.
(2007), Jideus et al. (2009), Regier et al. (2006), Shah and Gage (2011), Sullivan and
Ghushchyan (2006), Windisch et al. (2003). Details about these resources and value
of each model element are provided in Appendix A.5.
To illustrate the heterogeneous beneﬁts patients obtain from elite surgeons, Figure
2.4 summarizes the quality-adjusted life expectancy a patient gains from visiting a
95th-percentile instead of 50th-percentile surgeon. In this case, the additional beneﬁt
from visiting the elite surgeon ranges from 3.3–10.8 months depending on patients’ age
and comorbidities. Generally speaking, younger and healthier patients beneﬁt more,
because they have more years to live and their quality of life is higher. However,
the relationship between patients’ age and beneﬁts is not monotonic, because neither
the quality gap between surgeons nor quality of life diﬀerence between procedures is
a monotonic function of age.17 Of course, these are only illustrative examples. The
expected gain in quality-adjusted life years will diﬀer across all patient groups and
diﬀerent surgeons. The model (i.e., Equation 2.1) described in Section 4 can be used
to estimate surgeon performance, and hence quality gaps, for all patient groups.
Figure 2.4: Diﬀerence in Quality-Adjusted Life Expectancy (Months) between 95th-
percentile and 50th-percentile Surgeons
Note: These results will be used to describe patient utility in the next section when we formulate patients’ choice
of surgeon as a queueing system. The relationship between patients’ age and beneﬁts is not monotonic, because
neither the quality gap between surgeons nor quality of life diﬀerence between procedures is a monotonic functions
of age.
17One reason for this is that if an older patient must receive a replacement valve, he/she will receive
a biological implant. A younger patient will receive a mechanical implant, which will last longer but
carries risk of clots causing a stroke.
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2.6 Estimating the Value of Patient-Speciﬁc Infor-
mation
The primary goal of a rating system that scores or ranks health care providers is to help
ensure that patients are treated by an appropriate provider. It is almost tautological
that better information about provider quality should enable better matching of patient
to provider. How much it helps, however, depends on how capacity constraints on the
elite providers aﬀect the allocation of their services to patients. Hence, we must ﬁrst
model this allocation before we can evaluate the value of patient centric information
in provider rankings.
Capacity allocation is straightforward in centrally planned healthcare systems, such
as the nationalized UK system or the single-payer Canadian system, where priorities
can be set according to various criteria (e.g., age, health status) in the pursuit of a
socially optimal allocation. Under such a system, patient-speciﬁc quality information
simply provides another criterion (i.e., medical beneﬁt from treatment by an elite
provider) that can be used in the optimization. But we leave analysis of the impact
of patient-speciﬁc information on centrally planned healthcare systems to others and
focus instead on the US.
The hybrid healthcare system of the US occasionally uses central planning (e.g., to
set priorities for transplant organs), but usually relies on market mechanisms, under
which patients pay (e.g., for elective cosmetic surgery) or wait (e.g., to get on the
schedule of a busy surgeon). In the case of mitral valve disease, there is no centrally
planned system for assigning patients to surgeons. Also, because (unlike elective cos-
metic surgery) mitral valve surgery is covered by medical insurance, surgeons do not
compete on price. Hence, the allocation of elite mitral valve surgeon time relies on
patient waiting time. It will generally take longer to be treated by a busy elite surgeon
than by a less busy average surgeon. To account for this, we will make use of a choice
model in which patients consider surgeon quality and waiting time, as well as travel
distance, in selecting a surgeon.
From a policy standpoint, we are particularly interested in the eﬀect of patient-
speciﬁc information on how elite surgeon capacity is allocated and the impact this has
on overall patient outcomes. Rankings based on population-average information imply
that the clinical beneﬁt from treatment by an elite surgeon is the same for all patients.
Hence, who winds up being treated by an elite surgeon will be determined only by
travel distance and waiting time. Patients who can wait longer or travel further will
be more likely to go to an elite surgeon, irrespective of how much they beneﬁt from
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doing so.
In contrast, rankings based on patient-speciﬁc information reﬂect the diﬀerences in
the clinical beneﬁt from treatment by an elite surgeon across patient types. Therefore,
patients who make use of such rankings will be able to consider their personal clinical
beneﬁt, as well as waiting time and travel distance, in choosing a surgeon. So, if waiting
time and travel distance are equal for two patients, the patient who beneﬁts more from
treatment by an elite surgeon is more likely to wait for and travel to that elite surgeon.
Note that no coercion or optimization is needed to achieve the improvement in social
outcome. Patients make their own choices to maximize personal utility. But, since
patients who beneﬁt more from an elite surgeon will wait longer and travel further, the
elite surgeons will naturally wind up treating the patients who beneﬁt most from their
specialized skills.
2.6.1 Patient Choice Model
To evaluate the magnitude of the overall beneﬁt to society of patient-speciﬁc quality
information in mitral valve surgery, we make use of a patient choice model, in which
patients select providers based on quality (QALE), distance, and wait time. To model
wait time, we represent surgeons and patients as a system of parallel M/M/1 queues.
We deﬁne a server as a cardiac surgeon who performs mitral valve surgery, so there
are in total 188 servers in this study. The service rate of surgeon j, denoted as μj, is
deﬁned as the maximum number of elective mitral valve surgeries he/she can perform
in a month. The arrival rate of patients, denoted as λ, is deﬁned as the monthly
rate at which patients in need of elective mitral valve surgery arrive at one of the 188
surgeons. Patient i decides whether to join queue j based on the expected quality-
adjusted life expectancy from surgeon j (QALEij), the travel distance to surgeon j
(Distanceij) and the waiting time (WaitT imeij). We compute the expected quality-
adjusted life expectancy with population-average and patient-speciﬁc information so
we can make comparisons. Assuming service times are exponential, we can express
patient i’s expected waiting time for surgeon j as (Nij + 1)/μj, where Nij represents
the number of patients in queue ahead of patient i. Patient i chooses a surgeon that
maximizes his/her utility:
argminj Utilityij = QALEij − αDistanceij − βWaitT imej (2.3)
= QALEij − αDistanceij − β(Nij + 1)/μj
Obviously this model simpliﬁes reality in many ways. Most importantly, it assumes
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the relative weights patients place on quality-adjusted life expectancy, distance and
waiting time are the same across all patients. In reality, patient preferences may vary
depending on age, medical condition and other individual characteristics. However, as
we will show later, considering heterogeneous patient preferences only reinforces our
main conclusions.
For the case of population-average information, we let Ratej denote the population-
average repair rate for provider j and compute QALEij = qiRatej, where qi indicates
expected increase in quality-adjusted life expectancy for patient i per percentage point
increase in repair rate. A patient chooses a surgeon under the assumption that his/her
utility is computed using qiRatej−αDistanceij−β(Nij+1)/μj. For the case of patient-
speciﬁc information, we let Rateij denote the likelihood of a repair when patient i is
treated by surgeon j. A patient chooses a surgeon under the assumption that his/her
utility is computed using qiRateij − αDistanceij − β(Nij + 1)/μj.
To evaluate the impact of patient-speciﬁc information at the social level, we deﬁne
the social value as the total patient utility (i.e., SocialV alue =
∑
i[maxj(QALEij −
αDistanceij−βWaitT imej)]). Then we simulate the queueing system based on param-
eter values that are consistent with empirical data. As described previously, the service
rate of a surgeon is deﬁned as the maximum number of elective mitral valve surgeries
he/she can perform in a month as observed from the data. The arrival rate of patients
is deﬁned as the average number of patients treated by any of the 188 surgeons in a
month. The units of QALEij, Distanceij and WaitT imej are days, miles and months,
respectively. Speciﬁcally, the quality-adjusted life expectancy for patients at diﬀerent
ages and with diﬀerent comorbidities is obtained from the model (i.e., Equation 2.2)
discussed earlier.
Because the weight on quality-adjusted life expectancy has been normalized to
one, the values of α and β can be interpreted as equivalent quality-adjusted life days
per mile and month, respectively. We reviewed the relevant literature to calibrate
reasonable values of α and β. Finlayson et al. (1999) reported that most patients are
willing to travel to a regional hospital if this will reduce mortality rate by 20%. The
baseline mortality rate and travel distance were not speciﬁed. But we can make a rough
estimation of the α coeﬃcient if we assume that the mortality rate at a local hospital
is 2%, the extra travel distance to a regional hospital is 30 miles, and a patient’s
remaining life expectancy is 20 years. Under these assumptions, the increase in life
days from a 20% reduction of the 2% mortality rate is 20 yrs × 365 days/yr × 0.4%
= 29.2 days. This suggests that α is around 29.2 life days ÷ 30 miles = 0.97 life days
per mile. To create a range around this estimate, we specify three levels of weights on
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travel distance (α), denoted as Low, Medium and High, to be 0.5, 1 and 5. Similarly, in
another study, Dixon et al. (2010) reported that patients value each month of waiting
time as worth 40–60 minutes of travel time. This implies the weight patients place on
waiting time is 40–60 if we assume that 1 hour of travel is roughly equivalent to 60
miles of distance. Again, to create a plausible range, we specify three levels of weights
on waiting time (β), denoted as Low, Medium and High, to be 10, 50 and 100. Other
results that support these estimates can be found in Burge et al. (2005) and Gaynor
et al. (2010).
To simulate the arrival of patients, we randomly draw with replacement from the
2,718 patients in this study. The draws occur according to a Poisson process with an
average rate of 57 (i.e., 2,718/48) per month. To evaluate queueing in steady state, we
skip the ﬁrst 1,000 observations (i.e., the warm-up period) and focus on the subsequent
5,000 patients for analyses.
2.6.2 Simulation Results
We consider 27 diﬀerent variants of the simulation described earlier (three capacity
levels, three distance weights and three waiting time weights) under both population-
average and patient-speciﬁc information. The results are summarized in Table 2.4,
where columns (1) and (2) show the weights on travel distance and waiting time,
columns (3)–(7) show the expected number of repairs, and columns (4)–(8), (5)–(9)
show the average travel distance and waiting time per patient. To compare results
across diﬀerent scenarios, we convert utilities to Convenience Adjusted QALEs, which
represent equivalent quality-adjusted life days after adjusting for inconvenience of trav-
elling and waiting. The results are summarized in (6)–(10).
To interpret these results, we ﬁrst recall that the 2,718 New York mitral valve pa-
tients we considered in our empirical analysis traveled an average distance of 19 miles to
receive surgery and that 1,557 (or 57%) had their valves successfully repaired. In terms
of clinical outcomes this is worse than the case with population-average information
and High weights on distance and waiting time (because equivalent quality-adjusted
life days per mile is 5, and equivalent quality-adjusted life days per month is 100),
which results in 2,057 (or 76%) repairs, an average travel distance of 18 miles and an
average waiting time of 15 days.
At ﬁrst glance, this might suggest that patients behaved as if they were strongly
travel and wait averse. But it doesn’t seem reasonable that an average patient would
be willing to sacriﬁce more than 5 days of life to avoid traveling 1 extra mile and
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Table 2.4: Comparison of the Eﬀectiveness of Patient-Speciﬁc Information and Capac-
ity Increase
Weight on Weight on Expected Average Average Convenience Expected Average Average Convenience
Distance Waiting Time Number of Distance Waiting Adjusted Number of Distance Waiting Adjusted
Repairs (miles) (months) QALE*(days) Repairs (miles) (months) QALE*(days)
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Patient-Speciﬁc (current capacity) Population-Average (current capacity)
Low 2,174 26 5.8 258 2,104 26 5.7 244
Low Medium 2,160 28 1.1 255 2,101 28 1.1 242
High 2,152 30 0.5 256 2,095 30 0.5 244
Low 2,162 22 5.6 247 2,103 22 5.8 234
Medium Medium 2,151 23 1.1 244 2,095 24 1.1 232
High 2,147 24 0.5 246 2,095 25 0.5 234
Low 2,135 17 5.3 178 2,076 17 5.5 164
High Medium 2,118 17 1.0 174 2,060 17 1.1 160
High 2,099 17 0.5 173 2,057 18 0.5 162
Population-Average (10% capacity increase) Population-Average (20% capacity increase)
Low 2,127 26 5.7 252 2,142 26 5.6 256
Low Medium 2,122 28 1.1 251 2,141 28 1.1 257
High 2,121 30 0.5 251 2,135 30 0.5 257
Low 2,120 22 5.4 242 2,141 23 5.5 247
Medium Medium 2,114 24 1.1 240 2,131 24 1.1 245
High 2,110 25 0.5 241 2,132 25 0.5 248
Low 2,094 17 4.8 175 2,117 18 4.7 182
High Medium 2,086 18 1.0 169 2,102 18 1.0 175
High 2,077 18 0.5 168 2,104 18 0.5 176
Actual 1,557 19
Note: This table compares scenarios when patients choose surgeons based on patient-speciﬁc information (with current capacity)
and population-average information (with 0–20% capacity increases). We consider Low, Medium and High weights patients place
on travelling and waiting. Equivalent quality-adjusted life days per mile for Low, Medium and High weights on travelling are 0.5,
1, 5. Equivalent quality-adjusted life days per month for Low, Medium and High weights on waiting are 10, 50, 100. *For the ease
of comparison, a ﬁxed amount of one quality-adjusted life years has been subtracted from Convenience Adjusted QALE for both
patient-speciﬁc and population-average cases.
waiting 1.5 more days. Indeed, many studies of patient choices of health care providers
have found that patients are willing to travel and wait for better care. For example,
Finlayson et al. (1999) found that most patients are willing to bypass a local hospital
in favor of a more distant regional hospital if this will result a 20% reduction in the
likelihood of mortality. Groux et al. (2014) found that 36%–41% of cancer patients
surveyed are willing to travel any distance to receive the best available treatment.
Gaynor et al. (2010) found that the average waiting time for coronary artery bypass
surgery is around 2–3 months. With these in mind, we conclude that the behavior of
New York patients is not primarily driven by travel or wait aversion.
A second possible explanation for the failure of patients to travel or wait for better
care is that their choices are limited by their insurance providers. But our empirical
analysis showed that patients with non-restrictive coverage (e.g., Medicare) are almost
as likely to receive inferior local treatment as are patients with more restrictive (e.g.,
HMO) coverage.18 So, while insurance may play a role, it does not seem to be the
dominant driver of surgeon choice.
A third explanation is that patients either fail to ﬁnd outcome data, or, if they
do, fail to understand or trust it. Without information with which to distinguish the
performance of diﬀerent surgeons, patients fall back on other criteria like convenience or
18Based on NY data from 2009–2012, we calculated that 64% of Medicare and 63% of HMO patients
were treated by non-elite surgeons.
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familiarity when choosing a surgeon. Since the studies cited above imply that patients
are willing to act on quality information if they have it, many scholars (e.g., Emmert
and Schlesinger 2016, Sinaiko et al. 2012) have conjectured that better presentation
of medical quality information would cause patients to make more use of it in their
decisions. A feature that is often cited as desirable is personalized information tailored
to individual patients (Paddock et al. 2015, Sinaiko et al. 2012). The implication is
that more usable information could make the better outcomes in Table 2.4 (i.e., those
with low weights on distance and waiting time) possible.
Table 2.5 compares the values of using population-average and patient-speciﬁc in-
formation under current surgeon capacity. Columns (1) shows the weights on dis-
tance. Columns (2)–(4) show the change in the number of mitral valve repairs for Low,
Medium and High weights on waiting time, respectively. Columns (5)–(7), (8)–(10)
and (11)–(13) show the changes in the number of total quality-adjusted life years, av-
erage travel distance and waiting time per patient when information is switched from
population-average to patient-speciﬁc for Low, Medium and High weights on waiting
time.
To interpret these results, we use Medium weights on travel distance and waiting
time for illustration. In this scenario, the expected number of repairs under population-
average information is 2,095 (see Table 2.4). To achieve this, patients would have to
travel an average of 24 miles and wait around 1.1 months. If patient-speciﬁc information
is used, then the expected number of repair increases to 2,151 (a 2.7% increase). The
additional 56 repairs relative to the population-average information case is the result of
more patients who beneﬁt most being treated by elite surgeons. Importantly, achieving
this better outcome does not require additional travel distance or waiting time. It
simply requires using diﬀerent math to compute provider rankings.
From Table 2.5, we see that, depending on the weights patients place on travel
distance and waiting time, patient-speciﬁc information increases the number of repairs
by 42–70, increases total quality-adjusted life years by 56–105, changes average travel
distance per patient by less than 1 mile, and reduces average waiting time per patient
by 0–0.2 months. Intuitively, the overall beneﬁts of patient-speciﬁc information tend
to increase as the weights on distance or waiting time decrease, since patients become
more willing to wait and travel for higher quality care.
Another way to assess the value of patient-speciﬁc information is to look at how
much physician capacity must increase under population-average information to achieve
the same results with patient-speciﬁc information and current capacity. To compute
this, we increase service rates under population-average information and re-simulate
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Table 2.5: Comparison of the Values from Using Patient-Speciﬁc and Population-
Average Information
Diﬀ. in Num. Diﬀ. in Total Diﬀ. in Average Diﬀ. in Average
of Repairs QALE (year) Travel Dist.(mile) Wait Time(month)
Weight on Weight on Waiting Weight on Waiting Weight on Waiting Weight on Waiting
Distance Low Medium High Low Medium High Low Medium High Low Medium High
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13)
Low 70 60 57 105 88 87 0 0 1 0.0 0.0 0.0
Medium 59 56 52 81 79 74 0 0 0 -0.2 0.0 0.0
High 60 58 42 86 88 56 0 0 0 -0.2 0.0 0.0
Note: This table summarizes the changes in total number of repairs, quality-adjusted life years, average travel distance and waiting time
per patient when information is switched from population-average to patient-speciﬁc. We consider Low, Medium and High weights patients
place on travelling and waiting. Equivalent quality-adjusted life days per mile for Low, Medium and High weights on travelling are 0.5, 1,
5. Equivalent quality-adjusted life days per month for Low, Medium and High weights on waiting are 10, 50, 100.
the queues. We ﬁnd, for instance, with Medium weights on distance and waiting time,
a 20% increase in surgeon capacity results in an average convenience adjusted QALE
of 245 days. This is almost identical to the results with current capacity under patient-
speciﬁc information. In the population-average case, the improvement is achieved by
enabling the elite surgeons with the highest repair rates to treat more patients. In
the patient-speciﬁc case, the improvement is achieved by having the elite surgeons
treat the right patients. From Table 2.4, we see that the average convenience adjusted
QALEs from using patient-speciﬁc information are comparable to those achievable by
enabling the best surgeons to treat 10%–20% more patients under population-average
information, depending on the weights patients place on distance and waiting time.
While increasing surgeon capacity is likely to be expensive (e.g., involving adding
operating rooms or surgical staﬀ personnel) or impossible, providing patient-speciﬁc
information is merely a matter of math.
As we noted earlier, patients in the real world will place diﬀerent weights on travel
distance and waiting time. Dixon et al. (2010) found that old patients are more averse
to travelling than young patients and equivalent travel distance per month of waiting
are 40 miles for patients above 60 years old and 56–80 miles for patients below 60
years old. To account for these heterogeneous preferences, we deﬁne the disutility to
patients above 60 as Disutilityoldij = AdverseEventij+1.25αDistanceij+βWaitT imej
and that to patients below 60 asDisutilityyoungij = AdverseEventij+0.75αDistanceij+
βWaitT imej. This means that patients below 60 are likely to travel 67% further than
those above 60. The simulation results for diﬀerent values of α and β are summarized
in Appendix A.6. We see that the relative gap between convenience adjusted QALEs
achievable from using patient-speciﬁc and population-average information and the per-
centage increase in capacity needed for population-average information to achieve the
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same beneﬁt as patient-speciﬁc information are similar to the results in Table 2.5.
We obtain consistent results when we vary the weights of waiting time similarly. If
anything, heterogeneous weights on travel distance and waiting time make it easier to
distribute patients among surgeons in a patient pleasing manner.
2.6.3 Generalizing Our Results
Although we have restricted our analysis in this paper to elective mitral surgery in
New York State, our methodology is applicable to a wide range of health care settings.
The key prerequisite for applying our approach to a given medical procedure is an
outcome metric that (a) accurately represents quality from a patient perspective and
(b) is measured and recorded consistently across providers at the individual patient
level. In this paper, we used quality adjusted life expectancy (QALE) because it
takes into account short-term experience (e.g., complications), long-term survival (life
expectancy), and functional outcome (repair or replacement). We were able to compute
QALE by combining statistics on mortality, readmission, complication and repair rate
with results from the literature that characterize the impact of surgical outcomes on
life expectancy and medical complications. While not trivial, similar approaches could
be used to evaluate QALE for other surgical procedures.
However, QALE is not the only reasonable option for an outcome metric. It is
plausible to use either a less or more sophisticated metric. The less sophisticated cat-
egory includes the commonly used metrics of mortality, readmission and complication
rates. While none of these is a comprehensive metric, they may be useful proxies in
certain settings. In procedures where mortality rates are high (e.g., laparotomy, partial
colectomy, liver transplants), mortality rate may be a reasonable proxy for quality. In
procedure where mortality rates are very low and functional outcomes are not highly
variable (e.g., coronary artery bypass graft, cataract surgery, inguinal hernia repair),
complication rate may serve as a proxy for quality. Since mortality and complica-
tion rates are universally tracked, it would be straightforward for hospital rating sites,
such as those maintained by the Centers for Medicare and Medicaid Services, Leapfrog
Group, the Society of Thoracic Surgeons and Consumer Reports, to compute and re-
port patient speciﬁc versions of these traditional statistics.
Our approach could also be used to generate even more patient-speciﬁc outcome
statistics by allowing individual patients to choose customized weights. A simple ver-
sion of this could be achieved by using a weighted average of mortality rate, complica-
tion rate, and functional outcome as the outcome metric. For example, two patients
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considering total hip replacement surgery might choose very diﬀerent weights based on
their risk preferences. A patient primarily concerned about mobility will place a heavy
weight on functional outcome (measured by the Harris Hip Score or Oxford Hip Score,
see Nilsdotter and Bremander 2011), while a patient worried about surgical side eﬀects
will shift weight from functional outcome to complication rate. Customized weights
could also be used within a QALE metric to adjust weights of the short- and long-term
factors.
2.7 Conclusion and Managerial Implications
The past decade has seen increasing eﬀorts by the US government, payers and health
care providers to improve health care quality and control health care costs. Signiﬁ-
cant energy has been devoted to improving information transparency in the hope of
helping patients ﬁnd the best providers. In addition to being complex and diﬃcult
to use, currently available quality information about healthcare providers is based on
population averages. Our results show that population-average information is valuable
to patients, but that patient-speciﬁc quality information is even more valuable. Used
properly, patient-speciﬁc information can help patients ﬁnd the providers that are best
for them and for society as a whole.
This study addresses the challenges of measuring provider quality from a patient-
speciﬁc perspective and use it to help patients ﬁnd better care. With mitral valve
surgery as the clinical setting, we studied the quality of cardiac surgeons in New York
based on diﬀerent quality metrics, including a new quality-adjusted life expectancy
(QALE) metric that incorporates both short- and long-term eﬀects. We used a mul-
tilevel probit model to capture hospital and surgeon volume eﬀects, as well as their
speciﬁc eﬀects, on patient outcomes. This analysis shows that some surgeons are per-
forming statistically signiﬁcantly better than the state average, but that patients of
diﬀerent demographics and levels of acuity beneﬁt diﬀerently from these elite surgeons.
We compared the eﬀectiveness of providing patient-speciﬁc quality information and
that of increasing surgeon capacity when patients choose a surgeon that maximize
their utility. We estimate that providing patient-speciﬁc quality information in place of
population-average information oﬀers societal beneﬁts comparable to those achievable
with a 10%–20% increase in surgeon capacity.
With population-average information, cardiologists are inclined to refer all patients
to elite surgeons. However, armed with patient-speciﬁc information, they will appro-
priately refer some patients to non-elite surgeons, because these surgeons’ quality is
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comparable to that of elite surgeons for some patients. This will not only help spread
the workload across surgeons but also help non-elite surgeons improve their skills by
giving them some patient volume.
To be eﬀective, a metric must capture patients’ concerns about quality, while also
being understandable to patients. Experimental research will be needed to determine
how best to strike such a balance via eﬀective design of the web sites that distribute
patient-speciﬁc outcome information. One way to provide patient-speciﬁc information
is via an interactive web site that ﬁrst asks a patient to enter his/her demographics,
conditions and weights on diﬀerent quality metrics, and then presents comparative
health care information customized to that patient. Existing web sites such as the
Online STS Adult Cardiac Surgery Risk Calculator and Heart Risk Calculator allow
patients to enter their demographics and conditions but do not compare outcomes
of diﬀerent providers. In contrast, existing hospital rating systems such as Hospital
Compare and US News do not require input from patients as they compare providers
for only an average patient. New web sites with both features would allow patients to
ﬁnd more tailored health care information. These sites could also be integrated with
health care portals to provide context relevant information. For example, the primary
care division at Massachusetts General Hospital oﬀers online decision aids targeted at
patient needs when patients log into their health portals.19
Posting patient-speciﬁc information online will only lead to better patient decisions
if patients understand it. Experimental research is needed to determine how to strike
the right balance between information accuracy and simplicity. Today’s rankings based
on population-average estimates of individual statistics (e.g., mortality rate) are simple
to understand but not at all accurate as gages of provider quality. A customized ranking
based on patient-speciﬁc estimates of custom weighted QALE metrics is highly accurate
but may not be comprehensible to many people.
If research shows that even well-designed web sites do not make patient-speciﬁc
outcome information understandable to average patients, an alternate channel for dis-
seminating this information is health care providers. For example, a site could be
designed to be used by primary care physicians who refer patients to surgeons.
Payers can also play an important role in inﬂuencing patient choices. Although
hospitals with elite surgeons tend to charge a premium on the surgical procedure itself,
their lifetime treatment costs are often lower due to avoidance of complications and
readmissions (Wang et al. 2018). This implies that payers have incentive to use of
patient-speciﬁc information to guide patients (via reduced co-pays for patients and/or
19http://www.massgeneral.org/decisionsciences/research/About Shared Decision Making.aspx
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value-based compensation of hospitals and surgeons) to providers that oﬀer both better
clinical outcomes and lower lifetime costs.
Finally, government agencies and employers can make use of patient-speciﬁc out-
come data to identify the best providers for groups of patients and encourage patients
to choose the best provider for them by subsidizing travel costs. An example of such a
travel subsidy is the Healthcare Travel Costs Scheme in the UK, which was set up to
provide ﬁnancial assistance to patients who do not have a medical need for ambulance
transport, but who require assistance with their travel costs.20 Employer examples in-
clude Walmart and Lowes, who joined Paciﬁc Business Group On Health to subsidize
employees’ costs of traveling and lodging when treated at Centers of Excellence for
high risk procedures such as heart surgery or knee/hip replacement.21
One potential limitation of the approach in this study is that it implicitly assumes
patients have the same set of elite surgeons. In some settings, it may be possible that a
surgeon performs well on some patients (e.g., young patients) but not so well on other
patients (e.g., old patients). In theory, it is possible to address this issue by interacting
surgeon dummies with patient characteristics (e.g., age, gender, race, comorbidities).
However, when there is a large number of patient characteristics, this approach will cre-
ate computational burdens as well as generate many statistically insigniﬁcant estimates.
Future research is needed to characterize such heterogeneous surgeon eﬀects. Another
potential limitation is that, since patients are not randomly assigned to providers, our
estimates may be biased. There may be characteristics (e.g., echocardiogram) that
providers and/or patients themselves observe but we as researchers cannot, which may
aﬀect provider/patient selection and patient outcome. To assess whether such biases
may aﬀect our conclusion, we use distance-based instruments for surgical volumes and
ﬁnd that our conclusion regarding the beneﬁts from using patient-speciﬁc information
still holds. Even though this approach does not fully address potential selection issues,
it shows that our conclusion is likely robust to potential selection biases.
20http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Travelcosts.aspx
21Walmart, Lowe’s and Paciﬁc Business Group On Health Announce A First Of Its Kind National
Employers Centers Of Excellence Network. Walmart News & Views. October, 2013.
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CHAPTER 3
An Instrumental Variable Tree Approach
for Detecting Heterogeneous Treatment
Eﬀects in Observational Studies
3.1 Introduction
The big data revolution presents many opportunities for organizations to personalize
their oﬀerings to the heterogeneous needs of their stakeholders. For example, online
retailers can use consumer search and clickstream data to understand how consumers
respond diﬀerently to advertisements; healthcare providers can use clinical and mobile
health data to understand how patients respond diﬀerently to drugs or treatments;
managers can use employee activity and performance data to understand how employ-
ees respond diﬀerently to reward programs; educators can use data from online learning
platforms to understand how students respond diﬀerently to pedagogical methods. By
understanding heterogeneous responses of diﬀerent subjects and the factors that drive
heterogeneity, organizations can personalize products and services.
A standard approach to analyzing heterogeneous treatment eﬀects is to partition
subjects into subgroups based on their features such as demographics and then estimate
conditional average treatment eﬀect for each subgroup. For example, a researcher can
partition subjects based on gender and estimate average treatment eﬀects separately
for the female and male subgroups. However, there are several problems with this
approach. First, it is unclear which features should be used for partitioning. Given a
large number of observations and features, it is almost always possible to ﬁnd a feature
that appears to be associated with treatment eﬀect heterogeneity. This may lead
to dubious results and willful manipulation if a researcher selectively reports results.
Second, if there are limited data, it is diﬃcult to partition subjects into subgroups or
detect signiﬁcant diﬀerences of treatment eﬀects due to a reduced sample size. Third,
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treatment eﬀect heterogeneity might still exist within a given subgroup. For example,
in the female subgroup, it is possible for young female and old female to respond
diﬀerently to the same treatment.
A more sophisticated approach interacts features with the treatment in a regression
model. One problem with this approach is that it assumes the eﬀects of diﬀerent
features are linearly additive. Another problem is that, if there are a large number of
features but a limited number of observations, it can be challenging to obtain reliable
estimates of many interaction terms. A third problem with this approach is that it
does not explicitly identify subgroups of subjects that have heterogeneous treatment
eﬀects. As a result, this approach does not oﬀer a clear reference group with which to
compare eﬀects. An alternative approach is to interact predeﬁned subgroups instead
of features with the treatment. But how many subgroups to have and which subjects
should be in each subgroup are precisely the questions we seek to answer.
Advances in the development of machine learning techniques provide new insights
into subgroup analysis. The regression tree approach (Breiman et al. 1984) partly
addresses these challenges by recursively partitioning subjects into smaller subgroups
such that subjects in the same subgroup have similar outcomes and those in diﬀerent
subgroups have diﬀerent outcomes. It uses cross-validation to decide on the complexity
of a tree. However, the regression tree approach cannot be used for our purpose, because
the main purpose of a regression tree is to predict outcomes whereas our purpose is to
predict treatment eﬀects.
Recently, Athey and Imbens (2016) proposed a causal tree for analyzing hetero-
geneous treatment eﬀects when objects are randomly assigned to receive a treatment.
This approach partitions subjects into subgroups such that subjects in the same sub-
group have similar treatment eﬀects and those in diﬀerent subgroups have diﬀerent
treatment eﬀects. In randomized controlled experiments, because treatment assign-
ment is not confounded with features, it is straightforward to estimate the treatment
eﬀect using the average outcome diﬀerence between the treatment and control groups.
While randomized controlled experiments are ideal for causal inference, sometimes,
it is unethical, unaﬀordable or impossible to carry out large-scale randomized con-
trolled experiments. Despite the diﬃculty in meeting the strict inclusion and exclusion
criteria during participant recruitment, randomized controlled experiments are often
expensive and take a long time to complete. For example, in context of health care,
randomly assigning patients to a treatment that is potentially harmful raises serious
ethical concerns. Ethical concerns may also arise when a patient is prevented from
receiving a better and more suitable treatment. Finally, there are cases when ran-
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domized controlled experiments are infeasible due to legal issues or unavailability of
participants. For example, it would be illegal to recruit adolescents to study the impact
of smoking at a young age on the development of a lung cancer.
In the absence of randomized controlled experiments, researchers and policy mak-
ers have turned to observational data. A major problem with observational data is
that there are potential endogeneity issues because observational data often do not
include all features that aﬀect treatment assignment and outcome. In the context of
health care, there are patient features such as diagnosis results that physicians or pa-
tients themselves observe but we as researchers do not. If these features aﬀect both
the treatment assignment and medical outcome, simply taking the average outcome
diﬀerence between the treatment and control groups will lead to biased estimates of
the treatment eﬀects.
A number of studies have assumed that assignment of subjects to the treatment
or control group is independent of potential outcomes after controlling for observable
features of the subjects (i.e., unconfoundedness assumption) and have used propensity
score matching to estimate the treatment eﬀects (see e.g., Hahn, Murray and Carvalho
2017, Powers et al. 2017, Wager and Athey 2018, Xie et al. 2012). However, this
approach matches subjects in the treatment group to those in the control group based
on only observable features. Hence, it is not guaranteed that subjects in the two
groups have similar unobservable features. A number of studies have pointed out that
propensity score matching does not properly address the endogeneity issue when the
unconfoundedness assumption does not hold (see e.g., Breen et al. 2015, King and
Nielsen 2016).
The instrumental variable method has been widely used in the operations manage-
ment literature to correct for potential endogeneity issues (see e.g., Bartel, Chan and
Kim 2016, Chan et al. 2016, Freeman et al. 2016, Ho et al. 2000, KC and Terwiesch
2011, KC and Terwiesch 2012, Kim et al. 2014, Lu et al. 2017, McClellan et al. 1994,
Xu et al. 2017). A valid instrument induces changes in treatment assignment but has
no independent eﬀect on the outcomes, which allows a researcher to uncover the causal
eﬀect of the treatment on the outcome. However, use of the instrumental variable
method has been limited to regression models. It has not been applied to tree-based
approaches.
We address the gap by developing a new instrumental variable tree (hereinafter
referred to as “IV tree”) that combines the causal tree approach with the classical
instrumental variable method to study heterogeneous treatment eﬀects using obser-
vational data. This approach addresses the inability of the causal tree to account
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for endogeneity and does not rely on the unconfoundedness assumption. It allows re-
searchers to perform heterogeneous treatment eﬀect analysis and, at the same time,
correct for potential endogeneity biases with observational data.
3.2 Literature Review
A large body of literature on treatment eﬀect analysis has focused on estimation of the
average eﬀect of a treatment (see e.g., Lacy et al 2002, Lieberman et al. 2005, Moss et
al. 2003). This literature implicitly assumes that treatment eﬀect is homogenous for
individual subjects. But, recognizing that average treatment eﬀect presents only the
mean eﬀect of a treatment and does not indicate how an individual subject responds
to a treatment, a number of scholars have called for heterogeneous treatment eﬀect
analysis (Kent et al. 2007, Kravitz et al. 2004, Mant 1999, Vuik et al. 2016).
A parametric approach for heterogeneous treatment eﬀect analysis describes re-
sponses as a function of subject features and the treatment, as well as the interaction
of some features with the treatment, in a regression model. Because it is challenging to
estimate a large number of interaction variables, a number of studies have used Least
Absolute Shrinkage and Selection Operations (LASSO) or LASSO-based methods to
reduce the dimension of the problem and to identify features that signiﬁcantly aﬀect
treatment eﬀect heterogeneity (see e.g., Imai and Ratkovic 2013, Signorovitch 2007,
Taddy et al. 2015, Tian et al. 2014).
Tree-based approaches have gained increasing popularity in the recent years. The
conventional Classiﬁcation And Regression Trees (CART) method focuses on outcome
prediction and cannot be applied directly to analyze heterogeneous treatment eﬀects.
Building on the ideas of the CART method, studies in the machine learning and statis-
tics literatures have developed new tree-based approaches to focus speciﬁcally on het-
erogeneous treatment eﬀect analysis (see e.g., Athey and Imbens 2016, Chipman et al.
2010, Hothorn et al. 2006, Su et al. 2009, Wager and Athey 2018, Zeileis et al. 2008).
Both the LASSO- and tree-based approaches discussed above are designed for ran-
domized experimental studies and cannot be used for observational studies where treat-
ments may be endogenously determined. A few studies have made the unconfound-
edness assumption and used propensity score matching to homogenize subjects in the
treatment and control groups based on observable features (Hahn, Murray and Car-
valho 2017, Powers et al. 2017, Wager and Athey 2018, Xie et al. 2012). However, the
unconfoundedness assumption is not guaranteed to be satisﬁed in observational studies
(Breen et al. 2015, Xie et al. 2012). For example, in the context of health care, there
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are often features that patients or health care providers observe, but we as researchers
do not (Listl et al. 2016, Velentgas et al. 2013). If these features aﬀect both outcome
and treatment assignment, matching may not solve the issue.
The endogeneity issue can be corrected when there is an instrumental variable,
which correlates with the treatment assignment but has no direct impact on outcomes.
The instrumental variable method has been widely used in the operations management
literature (see e.g., Bartel, Chan and Kim 2016, Chan et al. 2016, Freeman et al. 2016,
Ho et al. 2000, KC and Terwiesch 2011, KC and Terwiesch 2012, Kim et al. 2014,
Lu et al. 2017, McClellan et al. 1994, Xu et al. 2017). These studies all recognized
potential endogeneity issues in observational studies and used the instrumental variable
method to correct for biases. However, they focused only on measuring the average
treatment eﬀect. We contribute to this literature by proposing a tree-based approach
that incorporates the instrumental variable method to study heterogeneous treatment
eﬀects.
In parallel with our work, Athey et al. (2019) developed a generalized random for-
est approach to partition observations into subgroups based on a set of local moment
conditions. They noted that their approach can be used to estimate heterogeneous
treatment eﬀects via instrumental variables. However, there are three key diﬀerences
between their method and ours. First, their approach uses a gradient-based approx-
imation for tree splitting, which results in a loss of eﬃciency, whereas our approach
uses the exact loss function for tree splitting. Second, their splitting rule considers
only the mean of treatment eﬀects, which leads to unstable trees, whereas our splitting
rule considers both the mean and variance of estimated treatment eﬀects to balance
relevance (smaller subgroup size) with reliability (less estimation noise). And third,
because their approach partitions observations based on moment conditions, which re-
quire all exogenous features to be orthogonal to the error term, the splitting criterion
of the generalized random forest is inﬂuenced by features directly aﬀecting outcomes,
whereas our approach focuses only on estimating treatment eﬀects and thus is more
resistant to irrelevant features.
3.3 Problem Formulation and the IV Tree Ap-
proach
Suppose we have access to N independently and identically distributed observations,
indexed by i = 1, ..., N , each of which consists of a d-dimensional feature vector Xi =
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{Xi1, Xi2, ..., Xid}, an outcome variable Yi, and a binary variable Ti ∈ [0, 1] indicating
whether subject i received the treatment or not. In addition to Xi, there may be
unobservable features that aﬀect both outcome variable and treatment assignment,
which creates an endogeneity issue. The problem is to determine if there exist distinct
subgroups of subjects across which treatment eﬀects are heterogeneous, and if so, how
to estimate the treatment eﬀect for each subgroup.
3.3.1 Regression Approach
When the dimension of the feature vector is small, a parametric regression model
may be used for heterogeneous treatment eﬀect analysis. To illustrate this, consider
a simple example with a three-dimensional vector of binary features. That is, Xi =
{Xi1, Xi2, Xi3}, where Xij ∈ [0, 1] for j = {1, 2, 3}. Because we do not know a prori
which features and how their interactions aﬀect the treatment eﬀect, we include all
features and their interactions with the treatment in a regression model:
Yi = α0 + α1Xi1 + α2Xi2 + α3Xi3 + α4Xi1Xi2 + α5Xi1Xi3 + α6Xi2Xi3 + α7Xi1Xi2Xi3
+β0Ti + β1Xi1Ti + β2Xi2Ti + β3Xi3Ti + β4Xi1Xi2Ti + β5Xi1Xi3Ti + β6Xi2Xi3Ti
+β7Xi1Xi2Xi3Ti + i
(3.1)
The parameters of interest are β0, β1, ..., and β7. To understand if the treat-
ment eﬀect is heterogeneous, we need to predeﬁne subgroups and compare the joint
distribution of βs related to the predeﬁned subgroups. For example, if we want to
compare the treatment eﬀects for Subgroup 1 with feature {Xi1 = 1, Xi2 = 1, Xi3 = 1}
and Subgroup 2 with feature {Xi1 = 1, Xi2 = 1, Xi3 = 0}, we need to test if
β0 + β1 + β2 + β3 + β4 + β5 + β6 + β7 (i.e., sum of Subgroup 1 related coeﬃcients)
is signiﬁcantly diﬀerent from β0 + β1 + β2 + β4 (i.e., sum of Subgroup 2 related coef-
ﬁcients), which is equivalent to test if β3 + β5 + β6 + β7 is signiﬁcantly diﬀerent from
zero.
This approach presents four major challenges when the dimension of the feature
vector is large. First, the number of terms in the regression model increases expo-
nentially with the dimension of the feature vector. In the case of N binary features,
there are a total of 2N unique combinations of features that could aﬀect the treatment
eﬀect. There are even more terms when some of the features are continuous instead of
binary. Second, this approach does not explicitly identify subgroups of subjects that
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have heterogeneous treatment eﬀects. That is, it is unclear how many distinct sub-
groups there are and which subjects belong to the same subgroup. Third, estimates of
the βs will be biased if there are unobservable features that aﬀect both the outcome
variable and treatment assignment. It is impractical to address the endogeneity issue
using the IV approach in this case, because this approach requires a large number of
instruments (e.g., 2N in the case of binary features). Fourth, this parametric approach
assumes that the eﬀects of diﬀerent features are linearly additive, whereas in reality the
features may interact in a complicated and nonlinear way. To address these challenges,
we use a tree-based approach as what we will discuss next.
3.3.2 Tree-Based Approaches
In the machine learning literature, a tree-based approach is a non-parametric method
that recursively partitions subjects (based on one feature at a time) into subgroups such
that those in the same subgroup have similar parameters of interest (e.g., outcome or
treatment eﬀect) and those across diﬀerent subgroups have diﬀerent parameters of
interest. It is called a tree-based approach because the set of splitting rules used
to partition subjects can be summarized in a tree. The most well known tree-based
approach is the regression tree, which partitions subjects into heterogeneous subgroups
based on outcomes. The regression tree is not suitable for heterogenous treatment eﬀect
analysis, because the features that aﬀect the outcome variable may be diﬀerent from
those aﬀect the treatment eﬀect.
The causal tree approach extends the regression tree for heterogeneous treatment
eﬀect analysis when subjects are randomly assigned to receive the treatment or control.
Because there is no confounding features that aﬀect both the outcome variable and
treatment assignment, the treatment eﬀect βlj for subgroup lj with feature xlj (i.e.,
xlj = {xk : Xik = xk, ∀i ∈ lj}) can be estimated using the average outcome diﬀerence
between the treatment and control groups (denoted as y1lj and y0lj , respectively). That
is
βˆCT (xlj) = y1lj − y0lj = 1N1lj
∑
i∈lj ,Ti=1 Yi − 1N0lj
∑
i∈lj ,Ti=0 Yi, (3.2)
where N1lj and N0lj denote the numbers of subjects (in subgroup lj) that received the
treatment and control, respectively, and Ti indicates whether subject i received the
treatment or not.
Because observations in subgroup lj are independently and identically distributed,
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the variance of βˆCT (xlj) can be estimated as
V ar[βˆCT (xlj)] =
S21lj
N1lj
+
S20lj
N0lj
, (3.3)
where S21lj and S
2
0lj
are within-group variances of outcomes of the subjects that received
the treatment and control, respectively.
The causal tree uses the “honest” approach (see e.g., Green and Kern 2010, Heller
et al. 2009) to randomly divide the data into two parts – one part (denoted as Str)
for training the tree model and the other part (denoted as Ses) for estimating the
treatment eﬀects. Let N tr and N es denote the sizes of training and estimation samples,
respectively. The causal tree starts at the root of the tree where all subjects are in the
same group and recursively partitions subjects into two smaller subgroups based on
the feature that reduces −(1/N tr)∑j βˆCT (xlj)2+(1/N tr+1/N es)∑j V ar[βˆCT (xlj)] by
the greatest amount. The process is repeated until a stopping criterion is reached. It
then prunes the initial large tree to obtain a set of subtrees and uses cross-validation
to select the best subtree.
When the treatment is not randomly assigned, as is often the case in observa-
tional studies, taking the diﬀerence of the average outcomes of the treatment and
control groups, 1
N1lj
∑
i∈lj ,Ti=1 Yi− 1N0lj
∑
i∈lj ,Ti=0 Yi, will lead to biased estimates of the
treatment eﬀects. As a result, the causal tree may partition subjects into incorrect
subgroups and provide biased estimates of the treatment eﬀects. We propose the IV
tree approach to address this issue.
3.3.3 The IV Tree Approach
To describe the IV tree approach, we let εi denote unobservable features that correlate
with both the outcome variable (i.e., Cov(Yi, εi) = 0) and treatment assignment (i.e.,
Cov(Ti, εi) = 0), and ξi denote an idiosyncratic error. The potential outcome Yi of
subject i in candidate subgroup lj can be written as
Yi = αi(Xi) + βi(Xi)Ti + i, ∀i ∈ lj, (3.4)
where αi(Xi) and βi(Xi) are functions that describe how features aﬀect mean outcomes
and treatment eﬀects, respectively, and i = εi + ξi. For notational convenience, we
will suppress the dependence of αi and βi on Xi in cases where it is unambiguous.
In general, we cannot estimate fully personalized treatment eﬀects for individual
subjects, because all statistical parameters of interest (e.g., βi in our study) can be
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computed only at the subgroup level. A common approach to addressing this issue
is to temporarily ignore individual-level heterogeneity within a subgroup and focus
on conditional average treatment eﬀects by assuming that observations in the same
subgroup have the same treatment eﬀect (Athey and Imbens 2016, Wager and Athey
2018, Xie et al. 2012). As what we will show later, the instrumental variable tree
approach proposed in this study recovers some degree of individual-level heterogeneity
by partitioning observations into subgroups with more homogeneous features as sample
size increases.
Suppose there exists a variable Zi that correlates with the treatment assignment,
Cov(Zi, Ti) = 0, (i.e., satisfying the relevant condition) but does not correlate with the
error term, Cov(Zi, i) = 0, (i.e., satisfying the exogeneity condition). We can then use
the variable Zi as an instrument for the treatment dummy Ti (Greene 2003). Given a
subgroup lj with feature xlj and average treatment eﬀect βlj , the treatment eﬀect βlj
can be estimated as
βˆIV (xlj) =
Cov(Yi,Zi|i∈lj)
Cov(Ti,Zi|i∈lj) . (3.5)
The variance of βˆIV (xlj) is
V ar[βˆIV (xlj)] =
V ar(i|i∈lj)
NljV ar(Ti|i∈lj)[Cor(Ti,Zi|i∈lj)]2
, (3.6)
where Nlj is the number of subjects in subgroup lj. A consistent estimator of
V ar(i|i ∈ lj) is (
∑
i∈lj ˆ
2
i )/(Nlj − 2), where ˆi = Yi − αˆi − βˆiTi, and αˆi and βˆi are
the IV estimates. Note that Nlj − 2 is used for the degrees of freedom correction.
The challenge now is to partition subjects into proper subgroups such that subjects
in each subgroup have similar treatment eﬀects. To construct a tree-based algorithm,
we begin with a root in which all subjects are in the same node. The tree grows by
selecting a node (called a “parent node”) and partitioning subjects into two nodes
(called “child nodes”) based on diﬀerences in a feature. Partitions could be made on
a binary feature such as gender or a non-binary feature such as age by using a cutoﬀ
value.
The key to the performance of a tree-based approach is the splitting rule, i.e., how
to choose a feature to split on and, if the feature is not binary, how to choose a cutoﬀ
value. As the ﬁnal goal of a tree is to predict treatment eﬀects for new subjects,
we grow the IV tree in a way that minimizes the mean-squared error of estimated
treatment eﬀects. Given a testing sample Ste used to evaluate tree performance and an
estimation sample Ses used to estimate treatment eﬀects, we let βte(Xi) and βˆ
es
IV (Xi)
denote the true and estimated treatment eﬀects for subject i with feature Xi, and
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deﬁne the mean-squared error of a tree π as
MSE(Ste, Ses) = 1
Nte
∑
i∈Ste [β
te(Xi)− βˆesIV (Xi)]2. (3.7)
The loss function, EMSE(Ste, Ses), is equal to the expectation of MSE(Ste, Ses)
over testing and estimation samples in the honest approach. Let β(Xi) denote the
conditional average treatment eﬀects for subject i ∈ lj. By the law of conditional
expectation and observing that ESte [β
te(Xi)
2] does not depend on the tree structure,
we have (see Appendix B.1 for more details)
EMSE(Ste, Ses) = −EXi [β(Xi)2] + EXi,Ses [V ar(βˆesIV (Xi))]. (3.8)
where the ﬁrst and second terms relate to the mean and variance of estimated treatment
eﬀects, respectively.
The ﬁrst term, EXi [β(Xi)
2], can be estimated using the square of the estimated
treatment eﬀects from the training sample, βˆtrIV (Xi)
2, minus an estimate of its variance
weighted by the fractions of observations (of the training sample) in the terminal
nodes: EˆXi [β(Xi)
2] =
∑
j(Nltrj /N
tr)× [βˆtrIV (xlj)2 − V ar(βˆtrIV (xlj))], where βˆtrIV (xlj) and
V ar(βˆtrIV (xlj)) are estimated using the IV method described earlier.
The second item, EXi,Ses [V ar(βˆ
es
IV (Xi))], can be calculated as a weighted sum of
within-group variances, where the weights are the fractions of observations (of the
estimation sample) in the terminal nodes. Within-group variances can be calculated
using estimates of V ar(i|i ∈ lj), V ar(Ti|i ∈ lj), and Cov(Ti, Zi|i ∈ lj)2 from the
training sample.
3.3.4 IV Tree Algorithm
In this section, we describe an algorithm for constructing an IV tree. The algorithm
consists of three major steps: (1) growing an initial large tree using the splitting rule
discussed earlier; (2) recursively pruning the initial large tree based on the weakest
links to obtain a set of subtrees; and (3) selecting the best subtree via cross-validation
and estimating the treatment eﬀect for each subgroup using the honest approach.
3.3.4.1 Growing An Initial Large Tree
To grow an IV tree, we evaluate all nodes, candidate features and all possible cutoﬀ
values for each feature and partition subjects in a selected parent node into two child
nodes based on the feature and cutoﬀ point that reduces EMSE(Ste, Ses) by the
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greatest amount. We then treat each child node as a parent node and repeat the
process of partitioning until reaching a stopping criterion (e.g., each node must include
at least 30 observations). This recursive partitioning process leads to an initial large
tree.
3.3.4.2 Prune the Tree Based on the Weakest Links
A very large tree (e.g., each terminal node having a single observation) will have a
poor out-of-sample goodness of ﬁt due to overﬁtting of the training data. A very small
tree (e.g., a single node including all observations) may also have a poor out-of-sample
goodness of ﬁt, because it does not capture the important underlying structure of
the data. Our objective is to ﬁnd the right-sized subtree, deﬁned as a tree that can
be obtained by pruning the initial large tree (including no pruning), that provides the
best out-of-sample goodness of ﬁt. We achieve this objective by ﬁrst pruning the initial
large tree to obtain a set of subtrees and then using cross-validation to select the best
subtree.
We identify the set of subtrees using the weakest link pruning approach proposed
by Breiman et al. (1984).1 To describe this pruning approach, we let Mπi denote
the complexity (i.e., number of terminal nodes) of tree πi, h be an internal node
of the initial large tree π0, and π1(h) be a subtree of π0 after deleting all branches
connecting to h. The weakness of node h is calculated as Wh(π0) = (EMSEπ0 −
EMSEπ1(h))/(Mπ0 − Mπ1(h)). By comparing the weakness of all internal nodes, we
identify the weakest link of π0 as the node with the largest value of Wh(π0), i.e.,
h∗ = argmaxh{(EMSEπ0 −EMSEπ1(h))/(Mπ0 −Mπ1(h))} and use it for pruning. We
then prune tree π1(h
∗) in the same way as we did for π0. Repeating this pruning process
leads to a series of subtrees, π0 ⊂ πi ⊂ π2 ⊂ · · · ⊂ πN , where πN is the single-node tree
with all subjects in the node.
3.3.4.3 Select the Best Subtree and Estimate Treatment Eﬀects
We choose the best subtree using ﬁve-fold cross-validation.2 That is, to evaluate the
performance of subtree πi, we randomly divide the training data into ﬁve equal folds.
Each time we hold out one fold of the data for validation and use the other four folds
for training. Let EMSEπi(S
j, Ses) denote the expected mean-squared error of πi when
1This approach is also called cost complexity pruning, as the weakest link is the node associated
with the largest ratio of the change in cost to the change in complexity.
2We use ﬁve-fold instead of ten-fold cross-validation, because we follow the honest approach that
uses one half of the data for training and the other half for estimation.
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the jth fold of the data is held out. The average expected mean-squared error of πi
from cross-validation is AEMSE(πi) =
1
5
∑5
j=1EMSEπi(S
j, Ses).
The best subtree is deﬁned as the one that minimizes the average expected mean-
squared error π∗ = argminπiAEMSE(πi). After choosing the best subtree, it is
straightforward to estimate treatment eﬀects for terminal nodes using the estimation
sample with the IV method. Subjects in the same terminal node are expected to have
the same treatment eﬀect.
The algorithm for constructing an IV tree is summarized below:
IV Tree Algorithm
1. Start with the root node where all subjects are in the same group L = {Str}. For
each subgroup l0 ⊂ L that is not a terminal node, do the following:
a. Calculate the loss function EMSEl0(S
te, Ses);
b. For each feature X (and a possible cutoﬀ value if X is continuous), do the
following:
  partition subjects in l0 into two subgroups, l1 and l2, based on X (and
the cutoﬀ value),
  calculate the loss functions EMSEl1(S
te, Ses) and EMSEl2(S
te, Ses),
  if EMSEl0(S
te, Ses) × Nl0 ≥ EMSEl1(Ste, Ses) × Nl1 +
EMSEl2(S
te, Ses) × Nl2 and Nl1 , Nl2 ≥ 30, replace l0 with l1 and
l2; otherwise, let l0 be a terminal node;
2. Start with the initial large tree Π obtained from Step 1. For each subtree π0 ⊂ Π
that is not a single node, do the following:
a. Calculate EMSEπ0(S
te, Ses) and tree complexity Mπ0 (i.e., number of terminal
nodes);
b. For each internal node h ∈ π0, delete all branches connecting to h to obtain
subtree π1(h), and calculate EMSEπ1(h)(S
te, Ses) and tree complexityMπ1(h);
c. Identify the weakest link h∗ = argmaxh{(EMSEπ0 − EMSEπ1(h))/(Mπ0 −
Mπ1(h))}, prune π0 based on h∗, and replace π0 with π1(h∗);
3. Randomly divide the training sample into ﬁve folds:
45
a. For each fold j, do the following:
  hold out fold j and use the remaining four folds for tree growing and
pruning,
  use fold j for cross-validation and calculate EMSEπi(S
j , Ses);
b. Calculate AEMSE(πi) =
1
5
∑5
j=1EMSEπi(S
j , Ses), and select the best sub-
tree π∗ = argminπiAEMSE(πi);
4. Estimate the treatment eﬀect for terminal node lj using βˆ
es
IV (xlj ).
3.3.5 Asymptotic Properties
Our analysis of the asymptotic properties of the IV tree builds on the ideas developed
by Breiman et al. (1984), who studied the asymptotic properties of the regression tree
method. In this section, we state a few assumptions that guarantee the consistency of
the proposed estimator. All proofs of the lemma, theorem, and corollary are provided
in Appendix B.2.
Assumption 1: Let xlj denote the feature of subgroup lj (i.e., xlj = {xk : Xik =
xk, ∀i ∈ lj}) and d(xlj) denote the largest dissimilarity between any two subjects in
subgroup lj. That is, d(xlj) = sup
i,j∈lj
|Xi −Xj|, where |X| = (x21 + x22 + ... + x2d)1/2. We
assume that lim
N→∞
dN(xlj) = 0 in probability.
This assumption has been made in a number of studies (see e.g., Breiman et al.
1984, Chapter 12.2) for proving the asymptotic property of tree-based approaches. It
states that the dissimilarity between any two subjects in a terminal node approaches
zero as the sample size increases to inﬁnity. Intuitively, a larger sample size allows a
tree to be more capable of detecting treatment eﬀect heterogeneity across subjects and
split more on feature space, leading to subgroups of subjects with more homogeneous
features.
Example: Consider observations with two dimensions of binary features, {male,
female} and {young, old}, and a tree that partitions subjects into two subgroups
based on gender. Then the features of the two subgroups are {male} and {female},
respectively. The dissimilarity of a subgroup equals one if it includes both young
and old patients. As the overall sample size increases, we now consider a larger tree
that partitions subjects into four subgroups based on both gender and age. Then the
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features of the four subgroups are {male, young}, {female, young}, {male, old}, and
{female, old}, respectively, and the dissimilarity of each subgroup equals zero.
Assumption 2: The treatment eﬀect βi is a continuous function of observable
feature Xi. That is, lim
Xi→Xj
βi(Xi) = βj(Xj).
First, we assume that the treatment eﬀect is a function of observable features.
Because it is impossible to partition subjects based on unobservable features, all stud-
ies performing subgroup analysis are implicitly making this assumption. Second, we
assume that the function linking treatment eﬀect and observable features is continu-
ous. This implies that, as the dissimilarity between two subjects approaches zero, the
treatment eﬀect diﬀerence between the two subjects approaches zero.
Example: Suppose the eﬀect of warfarin on reducing blood clots is a function of pa-
tient weight and height only. We assume that, as a patient’s weight or height changes,
the treatment eﬀect of warfarin remains the same or changes continuously. This as-
sumption is reasonable as we do not expect a jump in the treatment eﬀect of warfarin
when a patient has a slight increase in height or decrease in weight.
With Assumptions 1 and 2, we can state the following lemma:
Lemma 1: Suppose Assumptions 1 and 2 hold. For all i ∈ lj, there exists βlj such
that βi
p→ βlj , where βlj = βi( lim
Nlj→∞
xi) = βi(xlj). Also, Cov(βiTi, Yi)
p→ Cov(βljTi, Yi).
Assumption 3: Let Vi denote the product of the IV and error term (i.e., Vi =
Zii) and Qlj denote the expected product of the IV and treatment dummy (i.e.,
Qlj = E[ZiTi], ∀i ∈ lj). We assume that both Vi and Qlj are bounded.
The ﬁrst part of the assumption ensures that the moment-generating function of
Vi is bounded. The second part of the assumption is a standard assumption in the
literature to prove the consistency of IV estimators (see e.g., Greene 2003, Chapter
5.4). In practice, because the IV and outcome measure in observational studies are
usually bounded, it is reasonable to assume that Vi and Qlj are bounded.
Example 1 : Lee et al. (2017) studied the impact of operative time (i.e., the empiri-
cal treatment) on graft survival (i.e., the outcome variable) after liver transplantation.
They used average risk-adjusted operative time of the most recent cases performed by
the same surgeon as an instrument for operative time of the focal patient. Our as-
sumption is valid in this case because both operative time and post-transplant survival
are bounded.
Example 2 : Gowrisankaran and Town (1999) compared the morality rate (i.e., the
outcome variable) of diﬀerent hospitals (i.e., the empirical treatments) for pneumonia
care in Southern California. They used the travel distance from a patient to a hospital
as an instrument for the hospital dummy, as travel distance correlates with the choice
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of a hospital but does not correlate with patient sickness. Our assumption is also valid
in this case because both distance and mortality rate are bounded.
Assumption 4: Let N and Nlj denote the overall sample size and number of
subjects in subgroup lj, respectively. There exists a sequence of positive numbers kN
such that lim
N
kN = ∞ and Nlj/logN ≥ kN .
This assumption states that the number of subjects in a terminal node increases as
the overall sample size increases and the rate of increase (i.e., dNlj/dN) is larger than
kN/N . We make this assumption to ensure that there are suﬃciently many observations
in each terminal node as the total number of observations increases. This is to guarantee
that the estimator of the treatment eﬀect for any subgroup is asymptotically consistent.
Example: Consider observations with two dimensions of features, {male, female}
and {young, old}, and a tree that partitions subjects into four subgroups, {male,
young}, {female, young}, {male, old}, and {female, old}. This assumption states
that, as the overall sample size increases (e.g., N = {10, 100, 1000, ...}), there exists a
sequence of positive numbers (e.g., kN = {1, 2, 3, ...}) such that the number of subjects
in each subgroup increases accordingly (e.g., Nlj ≥ logN × kN = {1, 4, 9, ...}, ∀j =
1, 2, 3, 4).
With Assumptions 3 and 4, we can state the following lemma:
Lemma 2: Let a and b denote the lower and upper bounds of Vi (i.e., a ≤ Vi ≤
b) and ψi(t) denote the moment-generating function of Vi (i.e., ψi(t) = E[e
tVi ]). If
Assumptions 3 and 4 hold, we have ψi(t) ≤ e t
2(b−a)2
8 . Also, for any w > 0, we have
Pr(V ≥ w) ≤ N−7w2kN/[8(b−a)2], where kN is a sequence of positive numbers with
lim
N
kN = ∞.
To prove consistency of the proposed estimator, we write the potential outcome of
subject i in subgroup lj as Yi = αi + βiTi + i, where βi is the treatment eﬀect for
subject i. Our goal is to prove that βˆIV (xlj) = Cov(Yi, Zi|i ∈ lj)/Cov(Ti, Zi|i ∈ lj) is
a consistent estimator for βi, for all lj ∈ π and i ∈ lj. That is, we want to show that
βˆIV (xlj)
p→ βi, ∀lj ∈ π, ∀i ∈ lj. Because βi p→ βlj (from Lemma 1), it suﬃces to show
that βˆIV (xlj)
p→ βlj , ∀lj ∈ π, ∀i ∈ lj. We now state the main theorem of this paper:
Theorem 1: Under Assumptions 1–4, βˆIV (xlj) is a consistent estimator of βi for
all lj ∈ π and i ∈ lj. That is
max
lj∈π
sup
i∈lj
|βˆIV (xlj)− βi| p→ 0
in probability as N → ∞.
When there are endogeneity issues, the causal tree does not provide consistent
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estimates of treatment eﬀects. We formally state this point in the following corollary:
Corollary 1: Let εi and βˆCT (xlj) denote unobservable features and estimators of
the causal tree, respectively. If Cov(εi, Ti) = 0, there exists i ∈ lj such that βˆCT (xlj) p
βi.
3.4 Performance on Synthetic Data
We conduct simulation studies to assess the performance of the IV tree. The objective
of these simulation studies is to understand whether the IV tree eﬀectively corrects for
endogeneity biases and, if so, how its performance changes with (1) number of features,
(2) feature type (i.e., continuous or binary), (3) error distribution (e.g., normal, expo-
nential, or uniform), (4) model speciﬁcation (e.g., linear or nonlinear), (5) severity of
endogeneity, (6) strength of instrument, and (7) sample size. By constructing the data,
we know what the true treatment eﬀects are, so we can compare IV tree estimates with
the true treatment eﬀects to see how much they are diﬀerent from each other.
3.4.1 IV Tree Performance and Comparison with Causal Tree
Because the IV tree extends the causal tree for observational studies, we use the per-
formance of the causal tree as a benchmark for assessing the performance of the IV
tree. In the next subsection, we construct an IV forest based on modiﬁed IV trees and
compare its performance with the generalized random forest.
3.4.1.1 Synthetic Data Construction
To construct the data, we let Xαi denote the set of features that aﬀect mean outcomes,
and Xβi denote the set of features that aﬀect the treatment eﬀect of subject i. We
note that Xαi and X
β
i may have common elements if there are features that aﬀect both
outcomes and treatment eﬀects. Let εi and ξi denote unobservable features and an
idiosyncratic error, respectively. By construction, εi correlates with treatment assign-
ment (i.e., Cor(εi, Ti) = 0) but ξi does not (i.e., Cor(ξi, Ti) = 0). Without loss of
generality, we generate outcome Yi as a function of αi(X
α
i ), βi(X
β
i ), Ti, εi, and ξi as
follows
Yi = αi(X
α
i ) + βi(X
β
i )Ti + εi + ξi. (3.9)
We consider eight designs (see Table 3.1) to assess the performance of the IV tree
under various conditions discussed at the beginning of this section. In Designs 1–2, we
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consider instances with a total number of features equal to 5, 10, and 20 to understand
the performance of the IV tree as the size of the problem increases. Comparing Designs
1 and 2 allows us to understand the performance of the IV tree when the features are
binary instead of continuous. Designs 3–6 allow us to understand the performance of
the IV tree when the error term has a diﬀerent distribution or when the model has a
diﬀerent speciﬁcation. Designs 7–8 allow us to understand how the performance of the
IV tree changes with the severity of endogeneity and the strength of the instrument.
Finally, we increase the sample size incrementally from 1,000 to 5,000 to understand
the small and large sample properties of the IV tree.
Table 3.1: Designs of the Simulation Study
Design Model #Features Notes
1 Yi =
∑3m
k=1 xik +
∑m
k=1 xikTi + εi + ξi {5, 10, 20} xik, εi ∼ Norm(0, 1)
2 Yi =
∑3m
k=1 xik +
∑m
k=1 xikTi + εi + ξi {5, 10, 20} xik, εi ∼ Bern(0.5)
3 Yi =
∑6
k=1 xik +
∑2
k=1 xikTi + εi + ξi 10 ξi ∼ Expo(10)
4 Yi =
∑6
k=1 xik +
∑2
k=1 xikTi + εi + ξi 10 ξi ∼ Unif(0, 1)
5 Yi =
∑6
k=1 xik +Π
2
k=1xikTi + εi + ξi 10 nonlinear model
6 Yi =
∑6
k=1 xik +
∑2
k=1  {xik > 0}xikTi + εi + ξi 10 nonlinear model
7 Yi =
∑6
k=1 xik +
∑2
k=1 xikTi + εi + ξi 10 Corr(εi, T1i) = 0.3
8 Yi =
∑6
k=1 xik +
∑2
k=1 xikTi + εi + ξi 10 Corr(Zi, T1i) = 0.4
Note: In Designs 1–2, m = {1, 2, 4} indicates the number of features that aﬀect the treatment eﬀect. Un-
less speciﬁed otherwise in the note column, we let xi ∼ Norm(0, 1), εi ∼ Norm(0, 1), ξi ∼ Norm(0, 0.01),
Ti ∼ Bern(0.5), Corr(εi, Ti) = 0.5, and Corr(Zi, Ti) = 0.6.
In all designs, the features under consideration include both relevant (i.e., those
aﬀect mean outcomes, treatment eﬀects, or both) and irrelevant (i.e., those do not aﬀect
mean outcomes or treatment eﬀects) features. Some of these features are unobservable
to the researchers (e.g., εi in Design 1), so they are unavailable for analysis. Features
that do not appear in the models (e.g., xi7, xi8, and xi9 in Designs 3–8) are irrelevant
features. Because in practice we do not know a priori which features are relevant, we
include all features for analysis and assess whether the IV tree splits on only features
that aﬀect the treatment eﬀect.
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3.4.1.2 Performance Metrics
Following existing machine learning literature, we evaluate the performance of the IV
and causal trees using coverage rate and mean-squared error of the estimated treatment
eﬀects. The coverage rate is deﬁned as the proportion of instances the estimated conﬁ-
dence intervals (e.g., 95%) cover the true values of treatment eﬀects. Mathematically,
let βi denote the true treatment eﬀect for subject i, CIi denote a conﬁdence interval
of the estimated treatment eﬀect for subject i, and  {βi ∈ CIi} denote a binary in-
dicator function indicating whether the conﬁdence interval covers the true treatment
eﬀect. Then coverage rate is calculated as Coverage = 1
Nte
∑Nte
i=1  {βi ∈ CIi}, where
N te denotes the number observations in the test sample.
Coverage rate alone is not suﬃcient to measure the performance of a tree approach,
because an estimator with a large variance may have a high coverage rate. We there-
fore use mean-squared error as a second performance metric. Let βˆ(Xi) denote the
estimated treatment eﬀect for subject i using a tree approach. The mean-squared er-
ror is calculated as MSE = 1
Nte
∑Nte
i=1(βˆ(Xi)− βi)2. The mean squared error measures
how much estimated treatment eﬀects deviate from the true treatment eﬀects. For an
unbiased estimator, the mean squared error measures the variance of the estimator.
For a biased estimator, the mean squared error is aﬀected by both the variance and
bias of the estimator.
3.4.1.3 Estimation Results
Table 3.2 summarizes the coverage rate and mean-squared errors of the IV and causal
trees. All results are based on a testing sample of size 5,000 and 10 runs of the
simulations. We use bootstrap to estimate the 95% conﬁdence interval of the IV tree.
Mean-squared error is calculated using the diﬀerence between the estimated and true
values of treatment eﬀects. We now discuss the performance of the IV tree under
various conditions.
Number of Features : As expected, the coverage rate of the IV tree is higher and
mean-squared error is smaller when the underlying model is simpler, because there are
fewer features aﬀecting the treatment eﬀect. In all scenarios, the IV tree have a better
coverage rate and smaller mean-squared error than the causal tree.
Binary Features : Comparing Designs 1 and 2, we see that the IV tree performs
better when the underlying models have binary instead of continuous features, due to
the natural subgroups implied by binary features. The performance gap between the
IV and causal trees is even more substantial when the underlying model has binary
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Table 3.2: Comparison of IV Tree (IVT) and Causal Tree (CT)
Sample Size
#Features Approach 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000
Design 1 Design 2
Coverage MSE Coverage MSE
5
IVT 0.90 0.95 0.97 0.69 0.40 0.31 0.95 0.97 0.92 0.12 0.06 0.05
CT 0.33 0.13 0.09 1.50 1.23 1.20 0.00 0.00 0.00 1.10 1.04 1.04
10
IVT 0.91 0.91 0.95 1.59 1.15 0.99 0.99 0.99 1.00 0.29 0.11 0.09
CT 0.74 0.75 0.74 2.19 1.88 1.77 0.23 0.06 0.01 1.32 1.12 1.08
20
IVT 0.83 0.91 0.93 4.62 3.24 2.80 0.89 0.93 0.97 1.00 0.52 0.35
CT 0.70 0.82 0.85 4.98 4.02 3.77 0.56 0.53 0.51 1.76 1.58 1.47
Design 3 Design 4
Coverage MSE Coverage MSE
10
IVT 0.95 0.95 0.95 1.27 0.94 0.84 0.95 0.94 0.95 1.25 0.94 0.84
CT 0.86 0.84 0.65 2.04 1.68 1.62 0.85 0.81 0.71 2.06 1.71 1.58
Design 5 Design 6
Coverage MSE Coverage MSE
10
IVT 0.87 0.87 0.86 1.36 1.13 1.05 0.98 0.98 0.98 0.74 0.51 0.46
CT 0.44 0.42 0.39 2.12 1.89 1.77 0.42 0.34 0.27 1.59 1.45 1.38
Design 7 Design 8
Coverage MSE Coverage MSE
10
IVT 0.95 0.96 0.96 1.26 0.94 0.83 0.93 0.94 0.95 1.85 1.14 0.98
CT 0.92 0.96 0.97 1.44 1.07 0.96 0.84 0.83 0.68 2.06 1.68 1.59
Note: Designs 1 and 2 have the form Yi =
∑3m
k=1 xik +
∑m
k=1 xikTi + εi + ξi, where m = {1, 2, 4}, xik, εi ∼ Norm(0, 1) in
Design 1 and xik, εi ∼ Bern(0.5) in Design 2, ξi ∼ Norm(0, 1), Corr(εi, Ti) = 0.5, and Corr(Zi, Ti) = 0.6. Designs 3 and 4
have the same form as Design 1 with m = 2 except that ξi ∼ Expo(10) in Design 3 and ξi ∼ Unif(0, 1) in Design 4. Designs
5 and 6 have the forms Yi =
∑6
k=1 xik+Π
2
k=1xikTi+εi+ξi and Yi =
∑6
k=1 xik+
∑2
k=1  {xik > 0}xikTi+εi+ξi, respectively.
Designs 7 and 8 have the same form as Design 1 with m = 2 except that Corr(εi, Ti) = 0.3 in Design 7 and Corr(Zi, Ti) = 0.4
in Design 8. Coverage rate is calculated as the proportion of instances the 95% bootstrap conﬁdence intervals cover the true
values of treatment eﬀects. Mean-squared error is calculated using the diﬀerence between the estimated and true values of
treatment eﬀects. Results are aggregated over 10 runs of the simulations.
52
features.
Error Distribution: Comparing Designs 3 and 4 with Design 1 with 10 features, we
see that the distribution of the error term in the underlying model does not signiﬁcantly
aﬀect the coverage rate or mean-squared error of the IV tree.
Model Speciﬁcation: As expected, the underlying model speciﬁcation aﬀects the
performance of the IV tree, because the IV tree uses a simple regression model to
estimate the treatment eﬀect for each subgroup. Comparing Designs 5 and 6 with
Design 1 with 10 features, we see that the performance of the IV tree decreases slightly
when features interact with the treatment in a more complex way.
Severity of Endogeneity : Comparing Designs 7 with Design 1 with 10 features, we
see that performance of the IV tree remains almost the same and that of the causal tree
improves when there is less endogeneity, so the performance gap of the two approaches
decreases. However, the IV tree still has a better performance than the casual tree
when Corr(εi, Ti) = 0.3.
Strength of Instrument : Comparing Designs 8 with Design 1 with 10 features, we
see that performance of the IV tree decreases and that of the causal tree remains
almost the same when the instrument is weaker, so the performance gap of the two
approaches decreases. However, the IV tree still has a better performance than the
casual tree when Corr(Zi, Ti) = 0.4.
Sample Size: From Table 3.2, we see that the coverage rate of the IV tree increases
and mean-squared error decreases as sample size increases. These results are consistent
with the theoretical results presented in Section 3.3.5. Note that the performance gap
between the IV and causal trees does not become smaller as sample size increases.
Fundamentally, this is because estimates from the causal tree are biased when the
treatment is not randomly assigned, and such biases do not diminish as the sample
size increases.
In summary, the results of the simulation studies suggest that the causal tree has
poor coverage rates and large mean-squared errors when endogeneity is a concern.
These results suggest that the estimated treatment eﬀects from the causal tree are
very diﬀerent from the true treatment eﬀects and conﬁdence intervals of the estimated
treatment eﬀects may not cover the true treatment eﬀects. Equipped with an exogenous
instrument, the IV tree eﬀectively corrects for these biases and signiﬁcantly improves
the coverage rate and reduces mean-squared errors of the estimates. The superior
performance of the IV tree is consistent under diﬀerent numbers of features, error
distributions, model speciﬁcations, and feature types. The relative gap between the IV
and causal trees decreases when there is less endogeneity or if the instrument is weak.
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The performance of the IV tree increases as sample size increases whereas the coverage
rate of the causal tree does not always improve with increasing sample size.
3.4.2 Comparison with the Generalized Random Forest
The generalized random forest (GRF) approach (Athey et al. 2019) can also be used to
estimate heterogeneous treatment eﬀects using IVs. The GRF method can be thought
of as a “generalist” that can be used to estimate a broad range of parameters using
moment conditions whereas the IV tree can be thought of as a “specialist” that is
tailored for detecting heterogeneous treatment eﬀects in observational studies. As such,
the two approaches are complementary in the big data analytics tool kit. In this section,
we conduct simulation studies to compare the accuracy and interpretability of these two
approaches for analyzing heterogeneous treatment eﬀects in observational data with
unobservable features that aﬀect both outcome variable and treatment assignment.
To allow comparison with the GRF method, we make some modiﬁcations to the IV
tree described earlier. First, because directly comparing a tree to a forest is not fair,
we grow an equal number of IV trees (which we refer to as an “IV Forest (IVF)”) to
compare with the GRF.3 Second, following much of the existing literature on random
forests (e.g., Breiman 2001), we use over-ﬁtted instead of well-pruned trees to construct
the IVF. Finally, we use the same local centering approach as in Athey et al. (2019,
p21). That is, we ﬁrst regress out the eﬀect of the features on all the outcomes and
then construct a forest using centered outcomes instead of original outcomes.
3.4.2.1 Synthetic Data Construction
We consider four designs to compare the performance of the two approaches. The ﬁrst
two designs are the same as those described in Section 3.4.1.1. The third and fourth
designs are the same as those described in Athey et al. (2019). The details of each
design are presented in Table 3.3. For each of the four designs, we consider instances
with the number of features equal to 5, 10 and 20, with the sample size ranging from
1,000 to 5,000. Both the IVF and GRF are constructed using 100 trees and all features
are used for splitting.4 We compute mean-squared errors and split frequencies based on
3For a fair comparison, our forest is constructed using methods consistent with those in Athey et
al. (2019). However, to formally extend a tree method to a random forest, more parameters need to
be carefully evaluated and ﬁne-tuned, which we leave for future research.
4As a default and in the simulation of Athey et al. (2019), the GRF considers all features for
splitting when the number of features is less than or equal to 20 (see https://github.com/swager/grf
for more details). Its performance remains almost the same or becomes worse when we restrict the
number of features (e.g., to one-third or square root of the total number of features) for splitting.
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a testing sample of size 5,000 and aggregate results based on 10 runs of the simulations.
3.4.2.2 Accuracy Comparison
Table 3.3 summarizes mean-squared errors of the IVF and GRF. We see that the
IVF has smaller mean-squared errors in all scenarios except Designs 3 and 4 with ﬁve
features and sample size of 1,000. The relative gap between the two approaches remains
the same or increases as the sample size increases. When sample size equals 5,000, the
relative gap ranges from 33% to 93%, depending on the scenarios. The primary reason
the IVF generates more accurate estimates of treatment eﬀects is that it uses the exact
loss function for tree splitting whereas the GRF uses a gradient-based approximation.
Table 3.3: Mean-Squared Errors of IV Forest (IVF) and Generalized Random Forest
(GRF)
Sample Size
#Features Approach 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000
Design 1 Design 2 Design 3 Design 4
5
IVF 0.18 0.10 0.06 0.02 0.01 0.00 0.43 0.15 0.11 0.49 0.21 0.13
GRF 0.35 0.18 0.12 0.18 0.13 0.06 0.39 0.20 0.19 0.44 0.27 0.21
10
IVF 0.74 0.37 0.26 0.15 0.02 0.02 0.46 0.19 0.13 0.35 0.16 0.11
GRF 1.28 0.64 0.42 0.28 0.17 0.12 0.50 0.31 0.22 0.55 0.35 0.26
20
IVF 2.85 1.90 1.48 0.58 0.28 0.21 0.48 0.18 0.15 0.39 0.19 0.12
GRF 3.68 2.58 2.19 0.77 0.51 0.33 0.62 0.31 0.26 0.66 0.40 0.32
Note: Designs 1 and 2 have the form Yi =
∑3m
k=1 xik +
∑m
k=1 xikTi + εi + ξi, where m = {1, 2, 4}, and xik ∼ Norm(0, 1)
in Design 1 and xik ∼ Bern(0.5) in Design 2. Designs 3 and 4 have the form Yi = μ(Xi) + τ(Xi)Ti + ξi, where μ(Xi) =∑2
k=1max{0, xik}, τ(Xi) =
∑4
k=3max{0, xik} in Design 3 and μ(Xi) = max{0,
∑2
k=1 xik}, τ(Xi) = max{0,
∑4
k=3 xik} in
Design 4. All forests have 100 trees, and results are aggregated over 10 runs of the simulations.
3.4.2.3 Interpretability Comparison
In addition to estimating treatment eﬀects, we also care about subject groupings.
For example, in medical applications knowing which patients respond similarly to a
treatment and which do not can provide clues to the underlying mechanism and thereby
guide research into improved treatment alternatives. To evaluate the interpretability
of the trees generated by the IVF and GRF approaches, we compare frequencies of
splitting on both relevant and irrelevant features at each split depth, which is deﬁned
as the number of edges to the root node. A higher proportion of splits on relevant
features implies greater interpretability. A shallower tree with a smaller number of
subgroups is also easier to interpret.
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Table 3.4: Split Frequencies of IV Forest (IVF) and Generalized Random Forest (GRF)
in Design 2
Sample Size
Split on Approach 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000 1,000 3,000 5,000
Depth 0 Depth 1 Depth 2 Depth 3
Relevant Feature
IVF 979 1,000 1,000 10 0 0 2 0 0 0 0 0
GRF 554 650 811 371 361 272 421 336 117 9 439 101
Irrelevant Features
IVF 21 0 0 756 687 685 231 372 314 0 91 74
GRF 446 350 189 1,579 1,601 1,677 2,659 3,325 3,484 66 5,413 5,733
Note: Design 2 has the form Yi =
∑3
k=1 xik+xi3Ti+εi+ ξi, where xik ∼ Bern(0.5). All forests have 100 trees, and results are aggregated
over 10 runs of the simulations.
Table 3.4 summarizes split frequencies at the ﬁrst four depths for Design 2, where
x3 is the only relevant feature and x1, x2 and x4 are irrelevant features. At depth zero,
the split frequency is 1,000 for 10 runs of the simulations for both approaches. We see
that 979–1,000 trees in an IVF (compared with 554–811 trees in a GRF) split on x3
at depth zero. At all depths, the GRF splits more on irrelevant features than does the
IVF. Finally, most trees in the IVF have a depth of four or less whereas trees in the
GRF are much deeper than those shown in Table 3.4. The combination of deeper trees
and more splits at each depth leads to more subgroups with smaller sizes in GRF.
A main reason the GRF splits on irrelevant features is that it estimates parameters
from moment conditions that require both the instrument and other exogenous features
to be orthogonal to the error term. As a result, its splitting criterion is determined by
both features that aﬀect treatment eﬀects and features that directly aﬀect outcomes.
In contrast, the objective of the IVF is to ensure the accuracy of treatment eﬀect
estimation. Its splitting criterion is determined (almost) exclusively by features that
aﬀect treatment eﬀects.
Finally, an important reason the GRF has deep trees with small subgroups is that
it takes into account only the mean of estimated treatment eﬀects during splitting.
It partitions observations into two child subgroups as long as the two subgroups have
diﬀerent average treatment eﬀects. In contrast, the IVF considers both the mean and
variance of estimated treatment eﬀects (see ﬁrst and second terms of Equation (3.8)) for
tree splitting. It therefore balances the tradeoﬀ between relevance (smaller subgroup
size) and statistical reliability (less estimation noise).
56
3.5 Empirical Example: Teaching vs. Non-
Teaching Hospitals
As mentioned in the Introduction, the IV tree proposed in this study can be applied to
a wide array of applications, by deﬁning a treatment to represent diﬀerent things. In
this section, we apply this approach to analyze the eﬀect of teaching (vs. non-teaching)
hospitals on outcomes for patients requiring colectomy. There has been a long-standing
debate on whether teaching hospitals are better than non-teaching hospitals. While
advocates for teaching hospitals argue that teaching hospitals are better because of the
advanced technology, involvement in medical research, and treatment of rare diseases
and complex patients, advocates for non-teaching hospitals argue that teaching hos-
pitals are worse because of the substantial involvement of inexperienced residents and
the attenuated role of senior physicians.
A number of studies in the medical literature have examined the outcome (e.g.,
mortality or complication rates) diﬀerences between teaching and non-teaching hos-
pitals and found mixed results. For example, Masoomi et al. (2014), Thornlow et
al. (2006), and Vartak et al. (2008) found that the diﬀerence between teaching and
non-teaching hospitals is not statistically signiﬁcant and teaching status is not a sig-
niﬁcant predictor of health care outcomes. Gopaldas et al. (2012) and Taylor et al.
(1999) found that teaching hospitals are associated with lower complication rates and
better survival. On the other hand, Duggirala et al. (2004), Fineberg et al. (2013),
and Nandyala et al. (2014) found that teaching hospitals have higher post-operative
complication rates than non-teaching hospitals.
Comparing teaching and non-teaching hospitals presents two major challenges.
First, analyses based on observational data (e.g., medical records or administrative
data) are subject to selection bias or unobserved confounding factors such as patients’
preferences or adherence to treatment recommendations (Ayanian andWeissman 2002).
Second, outcome diﬀerences between teaching and non-teaching hospitals may be het-
erogeneous across diﬀerent procedures (Khuri et al. 2001) and patient subgroups. If
teaching hospitals are better for some patient subgroups but worse (or similar) for
other patient subgroups, studies focusing on the average outcome diﬀerence may not
ﬁnd signiﬁcant results. The IV tree proposed in this study can address the these two
challenges, because it corrects for potential endogeneity issues and partitions patients
into subgroups with heterogeneous outcome diﬀerences.
To illustrate how the IV tree performs on real data, we focus on laparoscopic colec-
tomy and use complication rate as the outcome measure to compare teaching and
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non-teaching hospitals. Laparoscopic colectomy is one type of colectomy that removes
part or all of the large intestine (i.e, colon) to treat or prevent diseases of the colon
including (a) inﬂammation of the digestive or gastrointestinal tract, (b) ulcers of the
colon and rectum, and (c) malignant (cancerous) tumor in the colon or rectum.5 This
procedure is relatively complicated as it requires surgeons to pass a tiny video camera
through one incision and special surgical tools through the other incisions. Around
22% of patients who underwent the procedure between 2005 and 2008 experienced at
least one post-operative complication (Strasberg et al. 2011).
3.5.1 Data Description, Outcome Measure, and Feature Space
Our data consist of patient-level records for all inpatient discharges from all hospitals
in New York State in 2011. They contain detailed hospital and patient information
such as hospital identiﬁers, patient demographics and comorbidities, and principal
and secondary diagnoses. The diagnosis codes allow us to identify surgery-related
complications during hospitalization. We identify hospitals’ teaching status through
the web site of American Hospital Association (http://www.aha.org/).
Major complications of colectomy include wound infection, urinary tract infection,
organ space infection, pneumonia, unplanned intubation, prolonged ileus/obstruction,
bleeding, cardiac arrest, septic shock, systematic sepsis, myocardial infarction, renal in-
suﬃciency, deep venous thrombosis, pulmonary compromise, renal failure, cerebrovas-
cular accident, and dehiscence. We focus on hospital-acquired instead of pre-existing
complications to compare teaching with non-teaching hospitals. We are able to separate
the two sources of complications, because the data indicate whether a complication was
present on admission. The data do not allow us to track a patient’s health status after
he/she was discharged, so we focus on complications acquired during hospitalization.
In our data, 30.1% of patients had at least one of the 18 complications and 11.7%
had two or more complications. Because a sizeable number of patients had more than
one complication and diﬀerent complications have diﬀerent severity levels, we cannot
simply use a binary variable to indicate whether a patient experienced at least one
complication or simply count the total number of complications a patient experienced.
To quantify both the number and severity of complications a patient experienced during
his/her hospital stay, we convert complications into a numeric number that weights each
complication by its severity.
The Accordion Severity Grading System is a scoring system that has been widely
5https://www.facs.org/media/ﬁles/education/patient.
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used in the medical literature to systematically measure surgical complications by
their severity levels (see e.g., Porembka et al. 2010, Strasberg et al. 2011). It stratiﬁes
complications into six grades, where Grade 1 and 2 complications are regarded as
minor, Grade 3 as moderate, Grade 4 as serious and Grade 5 as life-threatening. Grade
6 complications refer to those that result in death of the patient and include death from
any cause. These six grades of complications are associated with disutilities of 0.11,
0.26, 0.37, 0.60, 0.79, and 1.00 for Grades 1 to 6, respectively.
Strasberg et al. (2011) applied the Accordion Severity Grading System to analyze
postoperative complications after laparoscopic colectomy and four other abdominal
procedures. The severity score of a complication is calculated as the weighted sum of
disutilities, where the weights are probabilities of the complication being classiﬁed into
diﬀerent grades. Table 4.2 summarizes relevant results from Strasberg et al. (2011).
For the ease of discussion, we multiply all severity scores by 100. In our sample, the
severity scores range from 11 to 100 with renal insuﬃciency being the least severe and
death being the most severe complications. The incidence rates of the 18 complications
range from 0.1% to 10.5% with cardiac arrest being the most rare and prolonged
ileus/obstruction being the most common complications.
The features used to construct an IV tree include age group (below 50, 50-60, 60-70,
70-80, 80-90, and above 90), gender (male, female), race (white, black, Hispanic, Asian,
Native American, and others), payer (Medicare, Medicaid, private insurance, self-pay,
and others), location (urban, large rural, small rural, and isolated rural), income levels
(from 1 to 4), and 29 diﬀerent comorbidities.
3.5.2 Instrumental Variable Construction
We follow the approaches of KC and Terwiesch (2011) to construct a distance-based
IV for teaching status. We ﬁrst calculate the Euclidean distance between the centroid
of patient i’s zip code and that of hospital j, denoted as Distij, using 5-digit zip
codes included in the data. Though the actual travel distance is not the same as
the Euclidean distance, existing studies have shown that the two distances are highly
correlated with each other (Boscoe et al. 2012). We then estimate the probability of
patient i going to hospital j, denoted as pij, using a multinomial logit model, pij =
exp(δDistij)/
∑J
j=1 exp(δDistij), where J indicates the total number of hospitals in
patient i’s choice set. Finally, we calculate the expected teaching status for each patient
by summing up products of the probability of choosing a hospital and the hospital’s
teaching status over all hospitals: T̂ eachi =
∑J
j=1 Teachj × pij. We use T̂ eachi as an
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Table 3.5: Severity Score and Incidence Rate of Diﬀerent Complications
Complication Severity Score Number of Cases Rate of Incidence
bleeding 60 255 9.4%
cardiac arrest 26 4 0.1%
cerebrovascular accident 79 6 0.2%
death 100 25 0.9%
deep venous thrombosis 26 13 0.5%
dehiscence 44 32 1.2%
myocardial infraction 26 20 0.7%
organ space infection 35 33 1.2%
pneumonia 26 112 4.1%
prolonged ileu/obstruction 26 291 10.7%
pulmonary compromise 37 131 4.8%
renal failure 60 95 3.5%
renal insuﬃciency 11 50 1.8%
septic shock 66 15 0.6%
systematic sepsis 41 79 2.9%
unplanned intubation 79 89 3.3%
urinary tract infection 26 77 2.8%
wound infection 20 149 5.5%
Note: The severity score of a complication is calculated as the weighted sum of
disutilities, where the weights are probabilities of the complication being classiﬁed
into diﬀerent grades (Strasberg et al. 2011). For the ease of discussion, we multiply
all severity scores by 100.
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IV for Teachi.
Expected teaching status thus deﬁned is a valid IV for our study, because it (1)
correlates with the probability of choosing a teaching hospital and (2) does not cor-
relate with unobservable sickness of a patient. That is, the closer a patient lives to
a teaching hospital, the more likely the patient chooses a teaching hospital. How-
ever, how far a patient lives from a teaching hospital does not correlate with his/her
sickness. The ﬁrst condition is satisﬁed by construction. We follow existing studies
(see e.g., Bartel et al. 2016, KC and Terwiesch 2012) to check the second condition
by comparing observable sickness of patients with diﬀerent levels of expected teaching
status. We provide empirical evidence to support these two conditions in the Results
and Discussion section.
In 2011, a total of 2,794 New York patients underwent elective laparoscopic colec-
tomy surgeries at 156 hospitals. However, some of the patients do not have recorded
zip code information, which is required to calculate the distance between a patient’s
home and a hospital in order to construct an IV for hospital teaching status. Exclusion
of these patients results in a total of 2,723 patients discharged from 150 hospitals.
3.5.3 Results and Discussion
We check the strength of the IV by regressing teaching status over the instrument (i.e.,
expected teaching status) and other exogeneous variables for each subgroup of patients
(i.e., the ﬁrst stage of two-stage least square (2SLS) regression). The coeﬃcients are
signiﬁcant at the 1% signiﬁcance level in all cases. These results suggest that the IV
has a strong ﬁrst stage.
To check if patients living closer to a teaching hospital are sicker or healthier, we
ﬁrst stratify patients into three groups (with roughly one third of patients in each
group) based on their distance to the nearest teaching hospital (Table 3.6) or their
expected teaching status (Table 3.7) and then follow existing studies (see e.g., Bartel
et al. 2016, KC and Terwisch 2012) to compare observable patient characteristics such
as age, number of chronic conditions, and number of comorbidities. The results in
Tables 3.6 and 3.7 suggest that travel distance and expected teaching status do not
correlate with patient sickness.
We apply the IV tree and causal tree to the data and predict outcome diﬀerences
between teaching and non-teaching hospitals for each patient. To provide an overall
view of the diﬀerence between IV and causal trees in predicting outcome diﬀerences
between teaching and non-teaching hospitals, we ﬁrst categorize patients into four
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Table 3.6: Relationship between Distance to Teaching Hospital and Patient Charac-
teristics
Number of
Distance Number of Patients’ Chronic Number of
Patients Mean Age Conditions Comorbidities
Short 932 63.5 (14.4) 4.4 (2.4) 2.1 (1.5)
Medium 883 64.4 (15.3) 4.5 (2.5) 2.0 (1.6)
Long 908 63.7 (14.5) 4.6 (2.7) 2.1 (1.7)
Total 2,723 63.8 (14.7) 4.5 (2.5) 2.1 (1.6)
Note: We stratify patients based on their distance to the nearest teaching hospital and
analyze if patients living closer to a teaching hospital are sicker. Standard deviations
are displayed in parentheses.
Table 3.7: Relationship between Expected Teaching and Patient Characteristics
Number of
Expected Number of Patients’ Chronic Number of
Teaching Patients Mean Age Conditions Comorbidities
Low 908 63.8 (14.4) 4.7 (2.7) 2.1 (1.6)
Medium 912 63.9 (15.4) 4.6 (2.5) 2.1 (1.6)
High 903 63.8 (14.5) 4.3 (2.3) 2.1 (1.5)
Total 2,723 63.8 (14.7) 4.5 (2.5) 2.1 (1.6)
Note: We calculate expected teaching status for a patient by summing up products of
his/her probability of choosing a hospital and the hospital’s teaching status over all
hospitals. We stratify patients based on their expected teaching status and analyze
if patients with higher expected teaching status are sicker. Standard deviations are
displayed in parentheses.
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categories based on the statistical signiﬁcance indicated by the IV tree and causal tree
and then calculate the number of patients in each of the four categories (Table 3.8). We
are most interested in Categories A and B, because patients in these groups highlight
the diﬀerence between the two tree approaches. There are in total 703 patients (or
25.8%) in Categories A and B, suggesting that around one quarter of the patients
could be misguided if we neglect the endogeneity issues and use the causal tree instead
of the IV tree to compare hospitals. Table 3.9 compares the results of the IV and
causal trees for 20 patients as examples.
Table 3.8: Comparison of IV Tree (IVT) and Causal Tree (CT) by Statistical Signiﬁ-
cance
IVT CT
Category Description Cases mean min max mean min max
A IVT signiﬁcant, CT insigniﬁcant 455 9.51 7.71 10.99 6.57 −0.84 18.57
B IVT insigniﬁcant, CT signiﬁcant 248 8.5 3.36 13.65 10.94 6.11 19.41
C IVT signiﬁcant, CT signiﬁcant 80 9.69 7.75 10.99 10.17 7.52 18.05
D IVT insigniﬁcant, CT insigniﬁcant 1,940 6.69 3.36 13.65 5.96 −0.97 18.16
Total 2,723
Note: We apply the IV tree and causal tree to analyze the outcome diﬀerences between teaching and non-teaching
hospitals across diﬀerent patients. We categorize patients into four categories based on the statistical signiﬁcance
indicated by two trees and calculate the number of patients in each category.
To get a better sense of which patient subgroups beneﬁt the most from non-teaching
hospitals, we regroup patients by age, gender, and race. The average outcome diﬀer-
ences between teaching and non-teaching hospitals for each subgroup are summarized
in Figure 3.1. Generally speaking, male patients in their 90s beneﬁt the most, followed
by male patients in their 50s. Male patients in their 80s beneﬁt the least. From Figure
3.1, we also see that that average outcome diﬀerences predicted by the causal tree are
diﬀerent from those predicted by the IV tree. For example, the causal tree predicts that
female Asian patients in their 60s and 80s beneﬁt the most and male Asian patients in
their 50s beneﬁt the least.
3.6 Conclusion
The big data revolution is driving a personalization revolution in diverse applications
including customized marketing, precision medicine, and many others. Heterogeneous
treatment eﬀect analysis is a systematic and data-driven approach for personalization
that stratiﬁes individual subjects by their responses to a treatment. It oﬀers organiza-
tions the potential to improve performance by personalizing their products and services
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Table 3.9: Comparison of IV Tree (IVT) and Causal Tree (CT) for Diﬀerent Patients
IVT CT
Category Patient Patient Characteristics mean s.e. mean s.e.
1 50s, male, no comorb 7.71∗ 6.00 8.31 6.84
2 70s, female, 5 comorb 10.87∗ 8.21 13.29 11.40
A 3 70s, female, 5 comorb 9.50∗ 6.14 7.75 9.00
4 60s, female, 5 comorb 9.88∗ 6.27 8.74 7.75
5 90s, female, 3 comorb 9.51∗ 6.11 8.29 7.55
6 60s, male, 2 comorb 10.59 8.75 9.55∗ 7.35
7 50s, female, 3 comorb 5.08 5.93 8.90∗ 6.45
B 8 80s, female, 3 comorb 9.15 7.23 9.05∗ 6.81
9 60s, male, 1 comorb 7.93 6.40 9.23∗ 6.18
10 70s, male, 1 comorb 7.71 8.59 9.94∗ 7.66
11 80s, female, 2 comorb 9.51∗ 6.11 9.92∗ 6.86
12 80s, female, 1 comorb 9.61∗ 6.11 9.63∗ 7.48
C 13 60s, female, 2 comorb 9.99∗ 6.24 9.92∗ 7.13
14 70s, female, 3 comorb 9.61∗ 6.11 9.30∗ 7.10
15 70s, female, 0 comorb 9.61∗ 6.11 10.00∗ 7.47
16 60s, female, 4 comorb 11.51 12.28 9.31 7.49
17 60s, male, 4 comorb 6.15 5.35 6.27 5.91
D 18 60s, male, 3 comorb 6.60 7.31 6.48 8.93
19 60s, male, 3 comorb 6.15 5.35 6.56 5.73
20 40s, female, 2 comorb 3.50 5.30 5.92 5.73
Note: We compare the outcome diﬀerences between teaching and non-teaching hospitals
estimated by the IV tree and causal tree for 20 sample patients. * p < 0.1.
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Figure 3.1: Outcome Diﬀerences between Teaching and Non-Teaching Hospitals by
Patient Subgroup
Note: Patients are regrouped by gender, age group, and race. We ﬁrst estimate the outcome
diﬀerences between teaching and non-teaching hospitals for each patient using the IV tree and
causal tree, respectively. We then calculate the average outcome diﬀerences for a patient subgroup
using all patients belonging to that group.
to individual customers.
We propose a new IV tree approach to address the challenges of using big ob-
servational data for heterogeneous treatment analysis. This approach combines the
advantages of the recently developed causal tree and the classical IV method. It ef-
fectively partitions subjects into subgroups such that subjects in the same subgroup
have similar treatment eﬀects while those across diﬀerent subgroups have diﬀerent
treatment eﬀects. Our numerical studies demonstrate that the IV tree and IV forest
methods are more accurate in estimating heterogeneous eﬀects and more interpretable
in understanding these eﬀects than available alternatives.
We illustrate the use of IV tree by applying it to compare the outcomes of teaching
and non-teaching hospitals for patients requiring laparoscopic colectomy. We ﬁnd that
outcome diﬀerences between teaching (designated as treatment) and nonteaching (des-
ignated as control) hospitals are heterogeneous across diﬀerent patients, which is an
important insight that links the debate about the roles of teaching and non-teaching
hospitals with the conversation about personalized health care. This sample applica-
tion also illustrates that the IV tree method can have a substantial impact on important
treatment decisions.
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CHAPTER 4
Personalized Health Care Outcome
Analysis of Cardiovascular Surgical
Procedures
4.1 Introduction
Choosing a health care provider for a major medical procedure can be literally a life or
death decision. However, because they have historically lacked clear quality information
about providers, most patients have made these important choices based on proximity
or familiarity.1 Even patients who have relied on physician referrals have been unable
to rigorously evaluate their options, because the physicians themselves have also lacked
objective data and therefore have had to rely on subjective reputation information.
Recognizing the critical need for more and better information about health care
providers, government and private organizations have made various eﬀorts to provide
patient-oriented hospital ratings. For example, the Center for Medicare & Medicaid
Services (CMS) maintains the Hospital Compare web site to compare Medicare-certiﬁed
hospitals across the country and the US News provides aggregate hospital ratings for
broad categories of procedures such as heart surgery and cancer. These, and other
rating systems like them, compare hospitals based on risk-adjusted rates of mortality,
complication and/or readmission, and assign scores or star ratings to hospitals based
on their outcome measures.
However, a widely overlooked feature of these ratings is that they are based on pop-
ulation averages (hereinafter referred to as “population-average information”), which
imply that the same hospitals are best for all patients. But this is an assumption built
into population-average based ratings, rather than an empirical fact. To illustrate how
1http://www.infographicsarchive.com/health-and-safety/2014-healthgrades-american-hospital-
quality-report-nation/
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such ratings can be misleading, consider a simple example of three hospitals and two
procedures — Coronary Artery Bypass Grafting (CABG) and Mitral Valve Surgery.
Suppose the mortality rates of the three hospitals are 1%, 4% and 2%, respectively,
for CABG patients, and 5%, 2% and 3% for mitral patients. If all three hospitals have
a 50/50 mix of CABG and mitral patients, the overall mortality rates will be 3%, 3%
and 2.5%, respectively. If hospitals are ranked according to overall mortality rate, then
the third hospital will come out on top, even though it is not best for either procedure.
Hence a population-average ranking on overall mortality rate will misguide patients
(and their primary care physicians) in the choice of a hospital. By suggesting the same
hospital for everyone, it will also contribute to a capacity imbalance.
In recognition that a hospital may perform well for some procedures and not as
well for others, some states such as New York and Pennsylvania have begun publishing
hospital quality report cards for individual cardiac surgeries such as coronary artery
bypass grafting, aortic valve and mitral valve surgeries. Table 4.1 summarizes the
risk-adjusted mortality rates and the relative ranking of six hospitals for three cardio-
vascular surgeries based on New York Cardiovascular Surgery Quality Report Cards
2011-2013.2 The results show clearly that outcome diﬀerences are indeed heterogenous
across procedures.
Table 4.1: Relative Performance of Hospitals for Diﬀerent Procedures
Procedures
Lenox Hill
Hospital
Mount
Sinai
NYP-
Columbia
NYP-
Weill
Cornell
Rochester
General
St.
Francis
Hospital
Coronary Count 256 385 419 176 306 658
Artery Bypass Mortality 2.23% 1.80% 1.10% 1.74% 1.65% 1.54%
Grafting Rank 6 5 1 4 3 2
Valve- Count 479 1820 2228 1303 1025 1831
Related Mortality 3.30% 3.10% 2.88% 2.63% 4.91% 3.28%
Surgeries Rank 5 3 2 1 6 4
Percutaneous Count 1551 4522 2541 1298 1569 2289
Coronary Mortality 0.59% 0.92% 1.05% 1.50% 0.99% 0.82%
Intervention Rank 1 3 5 6 4 2
Source: New York Cardiovascular Surgery Quality Report Cards 2011-2013.
But this still does not provide true patient-centric information, because patients
requiring the same procedure diﬀer in their demographics and severity of illness (Huck-
man and Kelly 2013). Hospital outcomes may be sensitive to these diﬀerences and the
best hospital may be diﬀerent for diﬀerent patients.3 To see whether outcome diﬀer-
2https://www.health.ny.gov/statistics/diseases/cardiovascular/
3For example, diabetic patients in need of coronary bypass surgery have generally not been
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ences are also heterogenous across other dimensions of patient characteristics, we need
a way to group patients to generate statistically valid patient-centric outcomes.
Patient-centric ratings have obvious use in helping individual patients choose a hos-
pital. But they have other important uses as well. The US government and private
insurers are devoting considerable energy to designing payment structures that incen-
tivize hospitals to improve quality. Most prominently, CMS has developed programs to
link Medicare payments to hospital performance. For example, it launched the Read-
mission Reduction Program (RRP) in 2013 to penalize hospitals with excessive 30 day
readmission rates and the Hospital Acquired Conditions Reduction Program (HACRP)
in 2015 to penalize low performers with regard to hospital acquired infections.4 In both
programs, if a hospital’s performance is below a threshold, the hospital is penalized
for all its Diagnosis-Related Groups (DRGs). In 2015, more than 2,000 hospitals were
penalized under RRP and more than 700 hospitals were penalized under HACRP.
A problem with both RRP and HACRP is that they rely on population-average
data. As a result, they penalize some hospitals for all their procedures and do not
penalize other hospitals for any procedure. As we noted above, low average performance
does not necessarily mean that the hospital is poor at treating all patients, and high
average performance does not necessarily mean a hospital provides good treatment to
all patients. The result is a misalignment between the penalties (or lack of them) and
hospital performance, and hence misalignment in the incentives to improve. Using
patient-centric ratings allows payers such as CMS to assess hospital quality by patient
group and thereby direct penalties more accurately at areas of poor performance.
In this paper, we examine six cardiovascular surgeries at thirty-ﬁve NY hospitals
and address three key questions: (1) Are outcome diﬀerences between hospitals het-
erogenous across patient types? (2) If they are, how valuable is patient-centric infor-
mation (that accounts for heterogeneity) to patients in selecting a provider? and (3)
What impact would patient-centric information have on pay-for-performance systems
in which providers reimbursements are based on patient outcome metrics?
Addressing these questions requires that we identify patient groups that exhibit
treated using the Bilateral Internal Thoracic Artery (BITA) grafting technique, because of con-
cerns that they are at higher risk of infection involving the breast bone. However, the Cleve-
land Clinic found recently that BITA grafting can work very well for diabetic patients, except for
those that are very overweight with diﬀuse atherosclerosis or widespread hardening of the arteries
(see https://health.clevelandclinic.org/2014/11/the-best-bypass-surgery-option-for-diabetic-patients/
for more details). Similarly, surgeons at the Greenville Health System have found that patients with
end stage renal disease (ESRD) require special care because they are at a higher risk for complications
and death after surgical procedures including bypass grafting (Schneider et al. 2009).
4https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html
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signiﬁcant diﬀerences in outcomes. A standard approach is to include interaction terms
between provider indicators and patient characteristics as covariates in a multivariate
regression model. This method works well when there is a small number of patient
characteristics, but quickly breaks down when, as is the case here, the number of
patient characteristics is large, because the combinations of characteristics increases
exponentially with the number of patient characteristics.
An alternative approach is a nonparametric method that partitions patients into
groups such that patients within the same group have similar outcome diﬀerences
between providers. Unfortunately, while simple to state, it is not straightforward to
ﬁnd the best way to group patients. If we use all possible combinations of patient
characteristics, we will have the same combinatorial problem as above. This will lead
to groups that do not diﬀer statistically and have sample sizes too small to yield good
estimates of outcomes. But there is no natural way to divide patients into a priori
groups.
Besides partitioning patients into heterogenous groups, we need to address poten-
tial endogeneity issues when using observational data to estimate outcome diﬀerences
between providers. Unlike randomized controlled experiments where patients are ran-
domly assigned to providers, patients in observational studies can choose providers
based on available information. This non-randomized nature may create endogeneity
issues if what drives patients’ choice of providers is correlated with medical outcomes.
We therefore use the instrumental variable tree approach, which combines the instru-
mental variable method with tree-based approach, to partition patients into groups
and, at the same time, correct for potential endogeneity issues.
However, because the instrumental variable tree approach was designed to iden-
tify binary treatment eﬀects, to identify heterogeneous provider eﬀects when there are
multiple providers, we must overcome three challenges. First, in addition to grouping
patients, we also need to group providers because there may not be suﬃcient data to
detect signiﬁcant diﬀerences between all pairs of providers. Second, we need to derive
from our groupings easy-to-understand outcome information for use by individual pa-
tients. Third, we need to ﬁnd an instrument that correlates with the choice of providers
but does not correlate with medical outcomes.
The above approach will enable us to evaluate diﬀerences in hospital outcomes and
their heterogeneity across patient groups (Question 1). To address Question 2 about
the value of patient-centric information in improving patient outcomes, we compare
scenarios in which patients use patient-centric and population-average information to
select the best provider for them. This enables us to characterize the magnitude of
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beneﬁt to individual patients of having patient-centric, instead of population-average,
data. Finally, we address Question 3 by using our estimates of patient outcomes
under patient-centric and population-average information to examine how accounting
for patient heterogeneity would impact Medicare pay-for-performance policies and the
responses of hospitals to them.
4.2 Literature Review
There is growing interest in hospital quality from both the medical and operations
management communities. The medical literature has focused primarily on identifying
hospital characteristics that indicate better performance. For example, Keeler et al.
(1992) compared 197 hospitals and found that teaching, large and urban hospitals
are generally better than non-teaching, small, and rural hospitals for congestive heart
failure, acute myocardial infraction, pneumonia, stroke or hip replacement. Birkmeyer
et al. (2003), Gammie et al. (2009) and Vassileva et al. (2012) found high-volume
hospitals tend to perform better than low-volume hospitals. Tsai et al. (2015) found
that hospitals with boards that pay greater attention to clinical quality and use clinical
quality metrics have more eﬀective management practices and provide higher-quality
care.
The operation management literature has taken a more detailed perspective by fo-
cusing on the impact of speciﬁc provider practices on performance. For example, Barro,
Huckman and Kessler (2006), Clark and Huckman (2012), Huckman and Zinner (2008),
and KC and Terwisch (2011) analyzed the impact of hospital specialization/focus on
productivity and patient outcome; Clark, Huckman and Staats (2013), Huckman and
Pisano (2006), KC and Staats (2012), KC et al. (2013) and Ramdas et al. (2017) ana-
lyzed the impact of related experiences on surgeon performance; Freeman et al. (2016),
Jaeker and Tucker (2016) and Kim et al. (2014) analyzed the impact of workload on
quality and patient outcome; Bavafa et al. (2018), Lu and Lu (2016), and Song et al.
(2015) analyzed the impact of patient-physician communication, mandatory overtime
laws and queue management on productivity and patient outcome.
A common assumption in both literatures is that the eﬀects of quality driver are
homogeneous across patient groups. Any study that gives a single ranking of providers
or a single estimate of the impact of a practice on quality, regardless of patient group,
is implicitly making this assumption. But a number of scholars have recognized the
potential for this assumption to lead to inaccurate information to patients and have
called for heterogeneous eﬀect analysis in both patient care and quality assessment (see
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for example, FDA 2013, Gerteis 1993, IOM 2011, Kattan and Vickers 2004, Kent and
Hayward 2007, Kravitz et al. 2004).
Existing models that incorporate heterogeneity usually assume latent classes of con-
sumers with diﬀerent tastes or that consumer tastes are random draws from a known
distribution. For example, Xu et al. (2017) used a random coeﬃcient multinomial logit
model to characterize heterogeneous patient preferences in choosing doctors. Guajardo,
Cohen and Netessine (2016) also used a random coeﬃcient multinomial logit model to
study the impact of service attributes on consumer demand in the US automobile in-
dustry. Lu et al. (2013) used a similar model to analyze how waiting in queue in the
context of a retail store aﬀects customers’ purchasing behavior. While such modeling
framework is useful in incorporating heterogeneous consumer preferences, they cannot
systematically identify diﬀerent combinations of characteristics that deﬁne heteroge-
neous consumer groups. As a result, it oﬀers little practical guidance to individual
consumers.
The machine learning literature, on the other hand, oﬀers several useful frameworks
to measure heterogeneity and to identify heterogeneous groups. For example, a few
studies have proposed methods to analyze the heterogeneous treatment eﬀects. Evalu-
ating patient diﬀerences in the eﬀect of a single treatment (e.g., a clinical trial of a new
drug) is similar, although not identical, to evaluating patient diﬀerences in the relative
outcomes across a set of providers. Hence, we discuss the literature on identifying
heterogenous treatment eﬀects as a guide to addressing heterogenous provider eﬀects.
In two separate studies of biological markers in high-dimensional genomic data,
Signovitch (2007) and Tian et al. (2014) applied the standard LASSO procedure with
modiﬁed outcomes or covariates to determine from a large set of biological markers the
subset of patients that can potentially beneﬁt from a treatment. Imai and Ratkovic
(2013) modiﬁed the standard LASSO procedure using diﬀerent penalty factors for the
covariates and treatment eﬀects to distinguish the eﬀect of treatment from that of
covariates and to allow for the possibility of treatment eﬀects with small magnitudes.
Since they do not systematically partition patients into groups, these methods require
users to deﬁne patient groups a priori. All of them apply a single global model to
all observations, and assume that eﬀects are linearly additive and errors follow some
distribution.
Realizing that a single global model can not be applied to all observations, Zeileis,
Hothorn and Hornik (2008) proposed to partition the observations into groups and
apply separate local models such as linear regression or maximum-likelihood based
models to individual groups. They proposed using a tree-based method to partition
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observations, where the feature with the highest instability is used to split groups, with
a ﬂuctuation test to analyze the parameter stability at a node. Su et al. (2009) mod-
iﬁed the regression tree method to split the predictor space in a way that maximizes
the square of the t-statistic for testing the null hypothesis that the average treatment
eﬀect is the same in the two potential groups. A tuning parameter is used to penalize
complex trees with many terminal nodes, where the value of the parameter is deter-
mined through cross-validation based on the sum of squares of the split t-statistics.
These methods split the predictor space based on model ﬁt or a test-statistic, and do
not use cross-validation to select the tuning parameter or to assess the goodness of ﬁt
of the estimated model. Furthermore, by their design these methods are better suited
to outcome prediction than to heterogenous treatment eﬀect analysis.
Recently, Athey and Imbens (2016) proposed a causal tree approach to analyze
heterogeneous treatment eﬀects in experimental studies where subjects are randomly
assigned to treatment or control groups. We developed an instrumental variable tree
approach that extends the causal tree approach to analyze heterogenous treatment ef-
fects in observational studies with endogeneity issues (see Chapter 3 for more details).
The instrumental variable tree approach can be applied to analyze the heterogenous
provider eﬀect when there are two providers by interpreting one provider as the “treat-
ment” group and the other provider as the “control” group. However, the instrumental
variable tree approach cannot be used directly when there are multiple providers, be-
cause it is unclear which provider or providers should be designated as the treatment
or control groups. Moreover, while the instrumental variable tree approach can be
applied to each pair of providers, presenting such pairwise comparisons directly to pa-
tients is likely to be confusing since there may be hundreds of comparisons for a patient
to process to come to a conclusion. In this study, we address these issues to derive
easy-to-understand patient-centric information on a set of providers.
Our work also contributes to the recent stream of research to develop and apply
machine learning techniques for better prediction or decision-making in operations
management settings. For example, Ang et al. (2015) developed a new method that
combines queueing theory and the LASSO procedure to improve the prediction of
emergency department waiting time. Bertsimas et al. (2016) used several machine
learning methods (LASSO, random forest and support vector machines) to predict the
outcomes of clinical trials and optimize the test regimes. Bastani and Bayati (2016)
developed a new eﬃcient multi-armed bandit algorithm based on the LASSO estimator
to tailor decision-making at individual levels. They illustrated the superior performance
of this algorithm in warfarin dosing. Ban et al. (2016) introduced performance-based
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regularization to improve portfolio performance. Ferreira et al. (2015) used a regression
tree approach to predict demand and to optimize price, which led to 9.7% revenue
increase in a ﬁeld experiment implemented at an online retailer.
4.3 The Empirical Model
In this section, we ﬁrst describe the needs and challenges of generating patient-centric
outcome information. We then introduce the instrumental variable tree approach from
the machine learning literature and discuss how to extend it to identify heterogeneous
outcome diﬀerences between providers across patient groups.
4.3.1 Problem Description
The basic problem in which we are interested is identifying the provider, or set of
providers, with the highest likelihood of providing a good outcome for a given patient.
The data available to us are the outcomes of prior patients at the various providers.
However, because it is possible that outcomes are inﬂuenced by patient characteris-
tics (e.g., age, comorbidities, etc.), prior patient outcomes are not equally relevant to
the given patient. Patients with characteristics that match those of the given patient
are more likely to be representative, than are patients with radically diﬀerent char-
acteristics. For instance, a 48-year old black woman with mitral valve disease and
hypertension will probably get better information from outcomes of other middle aged
mitral valve patients than she would from patients in their 90s with coronary artery
disease.
While this insight is intuitive, it raises the important question of how similar a
patient must be to provide useful information about likely outcomes. For example, are
gender or race important? Or could a black female patient use outcomes from white
male patients to help evaluate her options? Are only mitral valve patients relevant, or
are patients with aortic valve disease also representative? Does hypertension matter?
Or are outcomes from patients with other comorbidities, or no comorbidities, good
indicators for our patient with hypertension? How much does age matter? Should our
patient look only to outcomes for other 48 year olds, or should she consider patients
within some wider window of ages? And so on. Ideally, a method for generating
outcome information for a speciﬁc patient should also identify the cohort of patients
from which this information should come.
The basic tradeoﬀ involved in selecting a cohort is one of precision versus power. A
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very narrow cohort that closely matches the patient in question along all dimensions
will be highly representative and hence precise in characterizing outcomes, but may
be too small to oﬀer statistical power needed to detect real and important diﬀerences
between providers. A very broad cohort, which contains patients that may not resemble
the patient in question, will be less precise in estimating outcomes but will have more
power due to the larger sample size. The balance between precision and power should
be struck endogenously by making use of the data itself.
A key characteristic of our problem is that we are seeking to characterize diﬀerences
between provider outcomes. In contrast, most analyses focus on outcome prediction.
The latter is relevant if a patient is choosing whether or not to receive a procedure.
For example, to decide whether the risk of heart surgery is justiﬁed by the beneﬁts,
we need an estimate of the mortality rate from the procedure. However, once we have
decided to receive a procedure and must decide on a provider, it is the diﬀerence in
the mortality rates between the candidate providers that matters. In a deterministic
world, where we know the absolute mortality rates, we can compute the diﬀerences via
simple subtraction. But in a statistical world, where we can only estimate the rates, a
method that focuses on prediction of the absolute rates may not yield the most accurate
estimate of the diﬀerences between rates, because the factors that aﬀect outcomes may
not be diﬀerent from those aﬀect outcome diﬀerences. We focus explicitly on estimating
diﬀerences between providers, in the following discussion of instrumental variable tree
approach, and in the subsequent empirical analysis.
Finally, because providers have diﬀerent mixes of patients, we need to control for pa-
tient demographics, common comorbidites and other patient characteristics that aﬀect
patient outcomes. While it is straightforward to control for observable features, there
are often unobservable features that aﬀect both provider choice and patient outcomes.
For example, health conscious patients may be more likely to choose high-performing
providers for a better treatment. They are also more likely to receive better outcomes
due to their healthier living styles. But whether a patient is health conscious or not is
not observable to us as researchers. Endogeneity issues like this will create biases in
estimating the outcome diﬀerences between providers.
4.3.2 Instrumental Variable Tree Approach
We use the instrumental variable tree approach developed in Chapter 3 to analyze
heterogenous diﬀerences between providers for several reasons. First, this approach
recursively partitions patients into heterogenous groups such that patients in the same
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group exhibit similar outcome diﬀerences across providers and those in diﬀerent groups
have diﬀerent outcome diﬀerences. Second, the instrumental variable tree approach in-
corporates the instrumental variable method to correct for potential endogeneity issues,
so we can obtain unbiased estimates of outcome diﬀerences for diﬀerent patient groups.
Third, this semiparametric approach does not assume that eﬀects of diﬀerent features
are linearly additive and allows features to interact in highly nonlinear and complex
ways. Finally, we can use techniques such as cross-validation to compare diﬀerent tree
models and select the one that best balances the tradeoﬀ between prediction error and
model complexity.
The instrumental variable tree approach builds on ideas developed by Athey and
Imben (2016), who proposed the causal tree approach to analyze heterogenous treat-
ment eﬀects in experimental studies (e.g., clinical trial) where subjects are randomly
assigned to treatment or control groups. Because the treatment and control groups
have the same mix of subjects, the causal tree approach estimates the treatment eﬀect
D(xlj) of group lj with feature xlj using the diﬀerence between average outcomes of
the treatment and control groups (denoted as y1lj and y2lj). That is
DˆCT (xlj) = y1lj − y2lj
= 1
N1lj
∑
i∈lj ,T1i=1 Yi − 1N2lj
∑
i∈lj ,T1i=0 Yi
where N1lj and N2lj denote the numbers of subjects in group lj that receive the treat-
ment and control, respectively, and T1i indicates whether subject i receives the treat-
ment.
When subjects are not randomly assigned to treatment or control groups, DˆCT (xlj)
leads to a biased estimate of D(xlj) and the causal tree constructed using the biased
estimates of treatment eﬀects partitions subjects into wrong groups. To address this
issue, we (see Chapter 3) developed the instrumental variable tree approach. The in-
strumental variable tree approach corrects for potential endogeneity issues and thus
obtains unbiased estimates of treatment eﬀects. Below, we ﬁrst describe the instru-
mental variable tree approach and discuss how an analogous approach can be used to
identify heterogenous provider eﬀects when there are two providers, and then extend
the instrumental variable tree approach to identify heterogenous provider eﬀects when
there are multiple providers.
75
4.3.2.1 IV Tree with Two Providers
The instrumental variable tree approach was originally developed to identify binary
treatment eﬀects in observational studies where the treatment is not randomly assigned.
When there are two providers, we can designate one provider as the treatment group
and the other provider as the control group. The treatment eﬀect estimated using the
instrumental variable tree approach can be interpreted as the provider eﬀect in this
study. To describe the instrumental variable tree approach, we let T1i = 1 indicate
whether patient i receives the treatment from provider 1 (instead of provider 2), Si
denote unobservable features (e.g., echocardiogram) that aﬀect both patient outcomes
and the choice of a provider, and ξi be the idiosyncratic error. For patient i in group
lj, the potential outcome Yi can be written as
Yi = α0lj + α1ljT1i + i, ∀i ∈ lj
where i = α2ljSi + ξi.
The parameter of interest is α1lj , which describes the average provider eﬀect for
group lj. Let Zi be an instrumental variable (e.g., proximity to a provider) that (1)
correlates with the choice of a provider T1i (i.e., satisfying the relevance condition), and
(2) does not correlate with the error term i (i.e., satisfying the exogeneity condition).
The instrumental variable tree approach estimates provider eﬀect α1lj using
DˆIV (xlj) =
Cov(Yi,Zi)
Cov(T1i,Zi)
, ∀i ∈ lj
and the variance of DˆIV (xlj) using
V ar[DˆIV (xlj)] =
V ar(i)
NljV ar(T1i)[Cor(Tli,Zi)]
2 , ∀i ∈ lj
where Nlj denotes the number of subjects in group lj. To estimate V ar(i), the in-
strumental variable tree approach uses the residuals εˆi = Yi− αˆ0lj − αˆ1ljT1i, where αˆ0lj
and αˆ1lj are the instrumental variable estimates. A consistent estimator of V ar(i) is
(
∑
i∈lj εˆ
2
i )/(Nlj − 2), where Nlj − 2 is used for the degrees of freedom correction.
To prevent the model from identifying spurious correlation between the features
and outcomes as treatment eﬀects, the instrumental variable tree approach splits data
into two parts — one part for training (Str) and the other part for estimation (Ses).
The splitting criteria of the instrumental variable tree approach was derived by mini-
mizing the expected mean-squared error (denoted as EMSEIV ) over testing (Ste) and
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estimation samples
EMSEIV (Ste, Ses) = ESte,SesMSE(S
te, Ses)
= −ESte [DˆtrIV (Xi)2] + ESte,Ses [V ar(DˆesIV (Xi))]
where DˆtrIV (Xi) and Dˆ
es
IV (Xi) denote the estimates of provider eﬀects for patient Xi ∈
Ste based on the training and estimation samples, respectively.
The instrumental tree approach starts at the top of the tree, which consists of a
single group called the “parent group”, and successively makes binary splits of groups
based on the feature that reduces EMSEIV (Ste, Ses) the most. This recursive par-
titioning process leads to a very large initial tree, which is then pruned recursively
based on the weakest links to obtain a series of subtrees. Similar to the classiﬁ-
cation and regression tree approaches, the instrumental variable tree approach uses
a tuning parameter α to balance expected mean-squared error and tree complexity,
EMSEIV (Ste, Ses) + αM , where M denotes the number of terminal nodes of a sub-
tree, and uses cross-validation to choose the subtree that minimizes average mean
squared errors. Finally, the outcome diﬀerence for each terminal node is estimated
using an independent estimation sample using the instrumental variable method.
4.3.2.2 IV Tree with Multiple Providers
While it is straightforward to apply the instrumental variable tree approach to analyze
heterogeneous provider eﬀects for two providers, we need to clear several hurdles to
extend the method to multiple providers. Recall that the instrumental variable tree
approach splits on features in a way that minimizes EMSEIV (Ste, Ses). When there are
multiple providers, it is unclear which provider or set of providers should be considered
as the treatment group and which as the control group. This implies that we must
partition providers, as well as patient groups. Note that partitions of providers can be
diﬀerent for diﬀerent patient groups and vice versa.
There are several options for addressing this issue. Some of these require pre-
deﬁned provider groups, while others involve modiﬁcations of the splitting criteria of
the instrumental variable tree approach to accommodate diﬀerences of all pairs of
providers. For instance, the instrumental tree approach can be applied directly if a
provider itself is considered as a group and all the other providers are considered as
another group. We can build the instrumental variable tree using patient characteristics
and the provider indicator as features. If the tree splits on the provider indicator,
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it indicates that the provider diﬀers from the other providers as a group. We can
estimate outcome diﬀerence between the provider and the other providers using the
procedures discussed earlier. The problem with this approach, however, is that the
derived outcome information can be confusing, because the baseline group changes as
we move to compare another provider with its peers. As a result, a patient cannot
directly compare the outcomes of two providers when his/her choices of providers are
limited.
An alternative is to modify the splitting criteria. For instance, we can parti-
tion patients into groups such that, within each group, there is a large outcome
variation across all providers. To do this, the splitting criteria can be modiﬁed to
−ESte [D˜trIV (Xi)2] + ESte,Ses [V ar(D˜esIV (Xi))], where D˜IV (Xi) captures the average out-
come diﬀerences between all pairs of providers for patient i. That is, D˜IV (Xi) =
1
N
[
∑
j =k |DˆIVjk (Xi)|], where N denotes the number of unique pairs of providers. The
problem with this approach, however, is that the groups diﬀerentiating one pair of
providers may be diﬀerent from those diﬀerentiating another pair of providers. Con-
sider a simple example where Provider 1 is better than Provider 2 only for young
patients and Provider 3 is better than Provider 4 only for male patients. The instru-
mental variable tree approach with above modiﬁed objective function is not suitable
because it will result in a universal partition that is homogeneous across all provider
pairs, and hence is not sensitive to the heterogeneous diﬀerences across provider pairs.
We address these issues by applying the instrumental variable tree approach to each
pair of providers. While the approach is methodologically sound, it poses signiﬁcant
interpretation diﬃculties. For example, a patient considering 10 providers would have
to examine 45 pairwise comparisons, which is likely to lead to confusion. To avoid
this, we develop a two-stage approach. In the ﬁrst stage, we analyze pairwise provider
diﬀerences. In the second stage, we condense the results into a form that enables a
patient to make direct comparisons between any provider and the state average. More
speciﬁcally, we ﬁrst estimate the outcome diﬀerence between a provider j and any of the
other providers. To do this, we build N − 1 instrumental variable trees using provider
j and the other N − 1 providers one at a time. From these trees, we can estimate
the outcome diﬀerences between providers j and k for patient i, DˆIVjk (Xi), ∀j = k. We
then use the estimated results to derive patient-centric outcome information based on
the outcome diﬀerence between each provider and the state average. To formalize this,
we let Dj,SA(Xi) denote the diﬀerence between provider j and the state average of H
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providers,
Dj,SA(Xi) = E[Yj(Xi)− 1H (Y1(Xi) + Y2(Xi) + ...+ YH(Xi))]
= 1
H
∑
k =j E[Yj(Xi)− Yk(Xi))]
= 1
H
∑
k =j Djk(Xi)
Intuitively, we can estimate Dj,SA(Xi) using
1
H
∑
k =j Dˆ
IV
jk (Xi). Note that, be-
cause we partition patients into groups based on the outcome diﬀerences between two
providers, the groups we identify by comparing providers j and k may be diﬀerent from
those identiﬁed by comparing providers j and l. For example, if provider j is better
than provider k at treating male patients but better than provider l at treating white
patients, the causal trees will partition patients into {male, female} when comparing
providers j and k and {white, non-white} when comparing providers j and l. However,
this does not aﬀect our estimation of outcome diﬀerences between provider j and the
state average.
4.4 Empirical Setting and Data
We choose cardiovascular diseases (commonly known as heart diseases) as the empir-
ical setting for personalized health care outcome analysis for several reasons. First,
cardiovascular diseases are the leading cause of death worldwide (WHO 2011). Each
year, about 17.5 million people die from cardiovascular diseases, which accounts for
one in every four deaths, and this number is expected to grow to more than 23.6 mil-
lion by 2030.5 Second, cardiovascular surgeries are relatively complicated procedures.
They require sophisticated skills, advanced technology and intensive post-surgical care,
which makes them candidates for sizable variations across providers (hospitals or sur-
geons). Third, cardiovascular surgeries include several diﬀerent types of procedures,
each requiring a diﬀerent set of skills and technology. As a result, a hospital may
perform well for some procedures but not as well for others.
Cardiovascular diseases refer to (a) conditions when the blood vessels are narrowed
or blocked, which can lead to heart attack, (b) chest pain or stroke, and (c) conditions
that aﬀect the heart’s muscles, valves or rhythm. Cardiovascular surgeries are opera-
tions performed by surgeons on the heart and blood vessels to repair the damage caused
5https://www.heart.org/idc/groups/ahamah-public
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by diseases or disorders of the cardiovascular system. In this study, we focus specif-
ically on three cardiac surgeries — Mitral Valve Replacement (MVR), Aortic Valve
Replacement (AVR) and Coronary Artery Bypass Grafting (CABG), and three vascu-
lar surgeries — Abdominal Aortic Aneurysm (AAA) repair, Carotid Endarterectomy
(CE) and Lower Extremity bypass Graft (LEG).
4.4.1 Data Description and Preparation
Our study makes use of data from New York State that consist of patient-level records
of all in- and out-patient discharges from all hospitals in New York from 2008–2012.
The data contain detailed clinical and resource use information, including admission
status, patient demographics and comorbidities, hospital identiﬁers, and principal and
secondary diagnoses. For each discharge, the data indicate the type of surgery a patient
underwent. They also record whether a patient experienced any complications during
the procedure or post-surgery hospitalization.
We identify discharges related to the six cardiovascular procedures under this study
by using related clinical codes in the International Classiﬁcation of Disease (9th revi-
sion). From 2008–2012, a total of 124,895 patients with cardiovascular diseases were
discharged from 144 hospitals. Because some of the hospitals did not perform car-
diovascular surgeries every year or had a low volume, we restrict attention to the 41
cardiac hospitals compared by the New York State of Health for Cardiovascular Surgery
Quality Report Cards. However, six of these hospitals did not perform vascular surg-
eries, so we further narrow our focus to the other 35 hospitals that perform all the six
cardiovascular surgeries discussed earlier. This results in a total of 107,252 discharges
over the ﬁve year period. We focus on isolated surgeries and exclude patients who
underwent multiple types of surgeries (6,950 of the sample). This allows us to charac-
terize patient outcomes at each hospital for each surgery type. In addition, we exclude
patients with missing information such as admission status. Our ﬁnal sample contains
a total of 99,378 discharges.
4.4.2 Outcome Measure and Feature Space
We focus on hospital acquired complications to characterize surgical outcomes, because
they capture a wide range of negative patient experiences and show substantial vari-
ation across hospitals. But outcome diﬀerences between providers can be evaluated
in terms of other metrics such as readmission, mortality, or a composite score that
combines them, without changing the overall conclusions of this study. We identify
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complications using the diagnosis codes provided in the data and focus on hospital ac-
quired conditions rather than pre-existing conditions. We are able to separate the two
types of complications because the data indicate whether each diagnosis was present
at admission. We focus on 23 cardiovascular surgery related complications6 and use
them collectively as an outcome measure (STS 2016, van Tuinen et al. 2005, Williams
et al. 1965).
In our sample, 29.58% patients had at least one of the 23 complications, while
10.55% had two or more complications. Because a sizeable number of patients had more
than one complications, we cannot simply use a binary variable to indicate whether a
patient experienced at least one complication. In addition, the 23 complications have
diﬀerent severity levels. For example, complications such as pulmonary embolism or
insuﬃciency are relatively easy to cure, while complications such as coma and multi-
organ failure are likely to lead to patient deaths (Glance et al. 2007, Reddy et al. 2013).
Therefore, we cannot simply count the number of complications a patient experienced.
To capture both the number and the severity of complications associated with a patient
during the surgery and hospital stay, we need to translate complications into a numeric
score that weights each complication by its severity.
To do this, we adapt the approach inspired by Elixhauser et al. (1998). The
Elixhauser comorbidity index is a vector of 30 binary variables in which each represents
the existence of a comorbidity. To describe the overall sickness of a patient and to
weight the severity of individual comorbidities, van Walraven et al. (2009) modiﬁed
the Elixhauser comorbidity index into a single numeric Elixhauser comorbidity score by
using a backward stepwise multivariate logistic regression to determine the correlation
between each comorbidity and in-hospital mortality. The parameter estimates of the
regression model were translated into a vector of weights by Sullivan et al. (2006).
The Elixhauser comorbidity score, which is calculated as the dot product of the index
vector and the vector of weights, has been widely used in medical research studies
(Kang et al. 2010, Menendez et al. 2014, Silverstein et al. 2008). In this paper,
we use the same approach to develop a complication score for cardiovascular surgical
outcomes. The complications and their weights are summarized in Table 4.2. The
average complication score for each procedure in our study ranges from 0.11 (for CE)
to 1.65 (for AAA) and the average across all procedures is 0.68 (Table 4.3).
6The complications are stroke, aortic dissection, renal failure, ventilation, multi-organ failure, coma,
cardiac arrest, sepsis, gastrointestinal events, tracheal reintubation, surgical complications, tampon-
ade, wound infection, renal dialysis, mediastinum, reoperation for bleeding, pneumonia, pulmonary
embolism, heart block, myocardial infarction, pulmonary insuﬃciency, surgical E codes and other
cardiac complications.
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Table 4.2: Weights of Diﬀerent Complications
Complication Coeﬃcient Std. Err. Weight
Aortic Dissection 3.16 ∗ ∗∗ 0.33 7
Coma 2.76 ∗ ∗∗ 0.25 6
Multi-Organ Failure 2.16 ∗ ∗∗ 0.07 5
Cardiac Arrest 1.79 ∗ ∗∗ 0.09 4
Renal failure 1.46 ∗ ∗∗ 0.05 3
Tracheal Reintubation 1.22 ∗ ∗∗ 0.06 3
Sepsis 1.03 ∗ ∗∗ 0.14 2
Stroke 1.03 ∗ ∗∗ 0.12 2
Surgical Complication 1.11 ∗ ∗∗ 0.15 2
Tamponade 1.02 ∗ ∗∗ 0.14 2
Ventilation 0.85 ∗ ∗∗ 0.07 2
Gastrointestinal Event 0.44 ∗ ∗∗ 0.10 1
Pulmonary Insuﬃciency 0.46 ∗ ∗∗ 0.06 1
Constant −4.93 ∗ ∗∗ 0.04
Note: Robust standard errors are clustered by hospital. The outcome vari-
able is death during hospitalization. Complications dropped from back-
ward stepwise multivariate logistic regression based on statistical signif-
icance include wound infection, renal dialysis, mediastinum, reoperation
for bleeding, pneumonia, pulmonary embolism, heart block, myocardial
infarction, surgical E codes and other cardiac complications.
*** p < 0.01, ** p <0.05, * p < 0.1.
Table 4.3: Summary of Complication Score for Diﬀerent Procedures
Procedure Name Count Mean Std. Dev.
Aortic Valve Replacement 20,061 0.99 2.30
Coronary Artery Bypass Graft 46,098 0.66 1.80
Mitral Valve Replacement 5,097 1.47 2.80
Abdominal Aortic Aneurysm 1,356 1.65 2.86
Carotid Endarterectomy 14,539 0.11 0.77
Lower Extremity Bypass Graft 12,227 0.41 1.47
Total 99,378 0.68 1.90
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The features we use to construct the instrumental variable trees include six car-
diovascular procedures (CE, CABG, LBG, AAA, AVR and MVR), patient genders,
races (white, black, Hispanic, Asian, Native American, and others), admission statuses
(emergent, urgent and elective), six age groups (below 50, 50–60, 60–70, 70–80, 80–90
and above 90) and ﬁve major comorbidities (chronic heart failure, chronic lung disease,
diabetes, hypertension and renal failure) of cardiovascular diseases (STS 2016). Con-
sidering all these features results in a total of 6 procedures × 2 genders × 6 races ×
3 admissions × 6 ages × 25 comorbidities = 41,472 diﬀerent combinations of patient
features.
4.4.3 Instrumental Variable Method
To correct for potential endogeneity issues, we apply the instrumental variable tree
approach and use distance to construct an instrument for the provider indicator. For
patient i and providers j and k, we ﬁrst calculate the Euclidean distances dij and dik
using 5-digit zip codes of patients’ home and hospital addresses. We then compare the
two distances to determine if provider j is closer than provider k to patient i. Then the
indicator function  [dij < dik] can be used as an instrument for the provider indicator
Tji.
Prior studies have used distance or a function of distance as an instrumental variable
to compare providers (McClellan et al. 1994,Brooks et al. 2006, KC and Terwiesch
2011). As in these studies, distance is an appropriate instrument for our purpose
because (1) the distance between a patient and a provider aﬀects the choice of the
provider, and (2) how far a patient lives from a provider does not correlate with the
sickness of the patient. We provide empirical evidence supporting these two criteria in
Appendix C.1.
4.5 Results and Discussion
As described in Section 4.3, to identify hospitals that are statistically signiﬁcantly dif-
ferent from the state average for certain patient groups, we ﬁrst construct instrumental
variables trees for each pair of hospitals, which requires a total of 35×34/2 = 595 trees.
For each patient, we estimate the diﬀerences in complication score between a hospital
and the state average, and estimate the standard errors of the diﬀerences using the
bootstrap method.
Table 4.4 summarizes the results for six example patients each described by a com-
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bination of procedure type, age and comorbidities. The best hospital for each patient
is highlighted in bold. We observe that, while some hospitals (e.g., Hospital 1) are
uniformly better than the state average for all six patients, others (e.g., Hospital 35)
are worse than the state average for majority of the patients. However, for hospitals
that are uniformly better (or worse) than the state average, the magnitude of the
diﬀerences varies for individual patients. For example, Hospital 1 is better than the
state average by 0.24 for the 1st patient (CE, 70s, 4 comorbidities) and by 0.84 for
the 5th patient (AAA, 70s, no comorbidity). There are also hospitals that are better
than the state average for some patients but worse for others. For example, Hospital
12 is better for the 1st (CE, 70s, 4 comorbidities), 2nd (CABG, 70s, 1 comorbidity)
and 5th (AAA, 70s, no comorbidity) patients but worse for the 3rd (AVR, 40s, 2 co-
morbidities), 4th (MVR, 50s, 4 comorbidities) and 6th (LBG, 70s, 4 comorbidities)
patients. These results indicate that outcome diﬀerences between hospitals are indeed
heterogenous across patients, and that diﬀerent patients have diﬀerent sets of hospitals
that are signiﬁcantly better that the state average.
Of course, Table 4.4 only shows six patients as examples. We have analyzed the
outcome diﬀerences across hospitals for all of the patients in this study. To provide
a visual illustration of the heterogeneity in outcomes across hospitals for diﬀerent pa-
tients, we group patients by procedure type, age group and comorbidities, which are
the most important features aﬀecting outcome diﬀerences.7
For each patient group, we use Yijk ∈ {−1, 0, 1} to indicate whether hospital j
is statistically signiﬁcantly worse than, the same as, or better than the state average
at a 10% signiﬁcance level for patient i in group k. Then we calculate the overall
performance of hospital j for patient group k using Y¯jk =
1
Njk
∑Njk
i=1 Yijk and present the
results in a heat map (Figure 4.1), where the yellow/red colors indicate that a hospital’s
overall performance is better/worse than the state average, and the intensity of the
colors indicates the fraction of patients in a cell for which a hospital is better/worse
than the state average.
From Figure 4.1, we observe that many of the cells in the middle (i.e., those asso-
ciated with hospitals 13–30) are orange, which indicates that these hospitals are not
signiﬁcantly diﬀerent from the state average for many patient groups. The majority of
the cells in rows at the top (e.g., those associated with hospitals 1–3) have the color
of yellow, indicating that these hospitals are better than the state average for most
7Note that the actual grouping of patients is determined by the instrumental variable tree approach.
Because it is impossible to summarize all results from the trees in a single ﬁgure or table, we regroup
patients based on the most important features to illustrate the heterogeneity in outcomes across
hospitals for diﬀerent patients.
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Table 4.4: Comparison of Complication Score with the State Average for Diﬀerent
Patients
Hospital CE, 70s CABG, 70s AVR, 40s MVR, 50s AAA, 70s LBG, 70s
Index 4 Comorb 1 Comorb 2 Comorb 4 Comorb 0 Comorb 4 Comorb
(1) (2) (3) (4) (5) (6)
1 −0.24+++ −0.27+++ −0.62+++ −0.59+++ −0.84+++ −0.52+++
2 −0.14 −0.22+++ −0.26++ −0.24++ −0.40++ −0.26+++
3 −0.46+ −0.42+++ −0.30 −0.34++ −0.73+++ −0.28++
4 −0.19 −0.24+ −0.10 −0.12 −0.49+++ 0.02
5 −0.75+++ 0.01 −0.27+++ −0.12 −0.38+++ −0.15
6 −0.56+++ −0.07 −0.28+++ −0.20++ −0.35+++ −0.14
7 −0.45++ −0.06 −0.42+++ −0.10 −0.35++ −0.24+
8 −0.45+++ 0.00 0.31- 0.16 −0.43+++ −0.16++
9 −0.25+++ −0.14++ −0.34+++ −0.34+++ −0.13 −0.35+++
10 −0.11+ −0.12+ −0.33+ −0.33+++ −0.09 −0.30+++
11 −0.40++ −0.29+++ −0.28++ −0.23++ 0.16 −0.29++
12 −0.15++ −0.13+ 0.36- 0.33- −0.28++ 0.31-
13 −0.12 −0.02 −0.21++ −0.20++ −0.27++ 0.05
14 −0.09 −0.10 −0.15 −0.05 0.00 −0.07
15 −0.29++ −0.10+ 0.02 0.13 0.10 0.16-
16 0.09 0.15 −0.13 −0.13 −0.21+ −0.01
17 −0.31 −0.28 −0.53 −0.54 −0.72 −0.48
18 0.11 0.11 0.03 0.18 0.10 0.16
19 0.23 0.00 −0.12 −0.17 0.08 −0.16
20 0.56 −0.11 0.19 −0.13 0.10 0.02
21 0.80 1.19 0.61 0.58 1.43 0.93
22 1.16 −0.07 0.05 0.05 0.36 0.05
23 0.79 0.52 0.50 0.58 0.37 −0.10
24 −0.07 0.23 0.27 0.27 0.29 0.37
25 0.30 −0.27 0.25 0.03 0.00 −0.07
26 0.81 0.67 0.59 0.47 0.69 0.49
27 −0.02 −0.07 −0.05 −0.09 0.37 0.06
28 0.35 0.80 0.53 0.54 0.36 0.49
29 0.37 0.11 0.13 0.02 0.47 0.01
30 −0.12 −0.18 −0.09 −0.11 0.36 0.12
31 0.03 −0.11+ 0.05 0.16 −0.04 0.22-
32 −0.34+++ 0.09 −0.27+++ −0.23++ 0.40-- −0.14+
33 0.04 0.10 0.14 0.19 0.59-- 0.10
34 0.11 0.38--- 0.66--- 0.65--- 0.10 0.54---
35 0.97--- 0.17- 0.20- 0.20- 0.18 0.23--
+++, ++, +: better than state average at 99%, 95% and 90% conﬁdence level
---, --, -: worse than state average at 99%, 95% and 90% conﬁdence level
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patient groups. In contrast, the red color of the cells in rows at the bottom (e.g., those
associated with hospitals 33–35) indicates that these hospitals are worse than the state
average for most patient groups. Rows near the top having colors of yellow and orange
indicate that the corresponding hospitals are better for some patient groups, but are
not statistically diﬀerent from the state average for other patient groups. Likewise,
rows near the bottom with a mixture of red and orange cells indicate that these hos-
pitals are worse for some patient groups but are not signiﬁcantly diﬀerent from the
state average for other groups. Interestingly, there are hospitals (e.g., 11, 14, 16 and
31) that are signiﬁcantly better than the state average for some patient groups but are
signiﬁcantly worse than the state average for other patient groups. Hence, the answer
to Question 1 in the Introduction is yes; outcome diﬀerences between hospitals are
heterogenous across patient types.
Figure 4.1: Comparison of Complication Score for Diﬀerent Patient Groups (IV Tree)
Note: Patients are grouped by age group (i.e., 50s to 90s), comorbidity and surgery. Acronyms for co-
morbidities: HTN - hypertension, DM - diabetes, CHF - chronic heart failure, NA - no comorbidities.
Acronyms for surgeries: CE - carotid endarterectomy, LBG - lower extremity bypass graft, MVR - mitral
valve replacement, AVR - aortic valve repair, CABG - coronary artery bypass grafting.
4.6 Managerial Implications
To address Questions 2 and 3 from the Introduction, we now turn to examination of the
beneﬁts of patient-centric information to patients, payers and providers. To evaluate
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the impacts on patients, we compare the sets of best hospitals and potential outcomes
under population-average and patient-centric information. To illustrate the potential
beneﬁt to payers, we use the Hospital Acquired Condition Reduction Program as an
example of how patient-centric information enables payers to better align payments
with hospital performance. To illustrate the beneﬁts to providers, we discuss how
patient-centric information can help hospitals better align their strategic focus with
their strengthes and focus their process improvement eﬀorts where they will have the
greatest impact.
4.6.1 Implications for Patients
Existing hospital rating systems, such as those of US News and the LeapFrog Group,
and quality report cards, such as the New York Cardiac Surgery Quality Report Cards,
compare hospitals using O/E ratios of observed to expected metrics (e.g., mortal-
ity rate). The expected rates are population averages estimated from a multivariate
logit/probit model that includes patient demographics and comorbdities to control for
patient severity of illness and hospital dummies to capture the ﬁxed eﬀects of individ-
ual hospitals. US News aggregates ratings into broad categories such as heart surgery
and cancer, rather than reporting them for individual procedures such as mitral valve
or aortic valve surgeries. As a result, it captures only the average eﬀect of a hospital
for all discharged patients. The LeapFrog Group and NY quality report cards report
ratings for individual procedures such as CABG, mitral valve, aortic valve surgeries,
so they capture the average eﬀect of a hospital for a procedure. But they still make
use of population-average O/E ratios that do not capture the heterogeneity of outcome
diﬀerences across groups of patients undergoing the same procedure.
Because population-average based rankings assume away heterogeneity in provider
performance across patient groups, they suggest that the same hospitals (or surgeons or
physicians) are best for all patients. This leads to two problems. First, as we discussed
in the previous section, some hospitals that are high performers on average have average
or below average outcomes for some patient groups. So, O/E ratios will guide some
patients to suboptimal choices of providers. Second, because they suggest a “one
size ﬁts all” picture of hospital quality, population-average based rankings encourage
patients to concentrate unnecessarily in a small subset of hospitals. The resulting
capacity overloads will lead to longer patient wait times that could negatively impact
patient outcomes.
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4.6.1.1 Comparison of Best Hospitals
To illustrate the diﬀerence between patient-centric and population-average informa-
tion in terms of their ability to guide patients to the best hospitals, we use each type
of information to identify the best hospital(s) (i.e., those that achieve the minimum
complication score) for each patient group. The diﬀerence between the average compli-
cation score under patient-centric and population-average information is a measure of
the expected incremental value of patient-centric information to a randomly selected
patient who chooses the best hospital for him/her based on the available information.
Because the dependent variable (complication score) is left truncated at zero, we
use a tobit model instead of a logit/probit model to identify the best hospital un-
der population-average information. For all models, we have robust standard errors
clustered by hospital to allow for diﬀerences in the variance/standard errors due to ar-
bitrary intra-group correlation (Jaeker and Tucker 2016, KC and Terwiesch 2011). The
hospital with the smallest O/E ratio is designated as the best hospital for all patient
groups. To rank hospitals using patient-centric information, we use the instrumental
variable tree approach discussed earlier. As we noted earlier, this method can identify
diﬀerent hospitals as best for diﬀerent patient groups. Furthermore, if the outcome dif-
ferences between hospitals are not signiﬁcant, the tree may not diﬀerentiate between
them. As a result, multiple hospitals may be identiﬁed as best for a given patient
group.
Applying these methods to data for NY patients discharged in 2012 after one of
the six cardiovascular surgeries listed earlier generates the results in Table 4.5. These
identify the set of best hospitals (Column 1) and the number of patients for whom
each hospital is best under population-average (Columns 2 and 6) and patient-centric
information (Columns 3 and 7). The diﬀerence in hospital rankings, and the patient
complication scores they produce (Columns 4 and 8 for absolute change, and Columns
5 and 9 for relative change), that occur when we switch from population-average in-
formation to patient-centric information, characterize the value of patient-centric in-
formation to an individual patient who seeks out the best hospital for him/her using
the available information. In addition to guiding patients to hospitals that will re-
duce their expected complication score, patient-centric information guides patients to
a wider range of hospitals, which will be more feasible from a capacity standpoint to
provide patients with the best available treatment.
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4.6.1.2 Comparison of Patient Outcomes
There are two main insights from Table 4.5. The ﬁrst is that the hospital that is best
on average across the entire population is not best for most patients. Patient-centric
information reveals that diﬀerent hospitals are best for diﬀerent patients. For most of
the surgical procedures, the top-ranked hospital under population-average information
is the top hospital only for a minority of patients.
For AVR, the top-ranked hospital under population-average information is only best
for 512 out of 3,979 patients. For MVR, it is optimal for 571 out of 1,026 patients. For
AAA, it is optimal for 63 out of 184 patients. For LBG, the top-ranked hospital under
population-average information is only the best for 50 out of 2,324 patients. And for
CABG, it is optimal for 1,539 out of 7,826 patients. For CE, it is optimal for 613 out
of 2,671 patients.
The second insight from Table 4.5 is that choosing the best hospital on the basis
of patient-centric, rather than population-average, information results in a substantial
reduction in average complication score. This reduction ranges from 0.04 to 0.37 (or
24.3% to 94.1%) across the six cardiac specialties. The average reduction across all
patients is 0.15 (or 66.7%).
To get a better sense of which patient groups beneﬁt most from patient-centric
information, we group patients by procedure type, age group and major comorbidities
(as what we did for the earlier heat maps). The average reduction of complication score
for each patient group is summarized in Figure 4.2. Generally speaking, LBG patients
beneﬁt the most, followed by AVR and CABG patients. CE and MVR patients with
diabetes, chronic heart failure or no comorbidities beneﬁt the least.
Figure 4.3 displays the distribution of percentage reduction in complication score.
From this histogram, we see that around 80% of patients achieve a positive reduction
in their complication score under patient-centric information. A large majority of them
achieve 70-90% reduction in their complication score. Hence, the answer to Question 2
in the Introduction is that patient-centric data is highly valuable to a strong majority
of cardiovascular surgery patients.
4.6.2 Implications for Hospitals and Payers
Payers are increasingly seeking ways to tie hospital reimbursement to performance.
For example, the Hospital Acquired Condition Reduction Program (HACRP) was es-
tablished in 2013 as a response to increasing costs of complications. This program
penalizes low-performing hospitals with regard to the Patient Safety Indicator (PSI)
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Table 4.5: Complication Reduction from Using Patient-Centric Instead of Population-
Average Information in Hospital Selection
Hospital Number of Patients Change in Change in Number of Patients Change in Change in
Index population- patient- Complication Complication population- patient- Complication Complication
average centric Score (absolute) Score (relative) average centric Score (absolute) Score (relative)
(1) (2) (3) (4) (5) (6) (7) (8) (9)
AVR MVR
1 2,804 -0.19 82.4% 1,026 571 0 0%
3 3,979 512 0 0% 149 -0.06 60.8%
5 71 -0.16 35.4% 40 -0.20 30.6%
17 398 -0.22 75.4% 237 -0.07 53.6%
20 23 -0.03 47% 21 -0.11 70.3%
25 170 -0.12 85.5% 6 -0.08 71.2%
32 1 -0.25 26.6% 2 -0.09 7.8%
Overall -0.16 70.2% -0.04 24.3%
AAA LBG
1 184 63 0 0% 1,535 -0.41 96.5%
3 10 -0.05 47.4% 114 -0.32 97.0%
5 2 -0.17 19.3% 2,324 50 0 0%
17 70 -0.10 51.2% 391 -0.34 94.6%
20 8 -0.24 94.4%
25 39 -0.10 59.8% 220 -0.29 96.6%
27 6 -0.29 95.7%
Overall -0.06 31.5% -0.37 94.1%
CABG CE
1 2,522 -0.17 84.1% 2,671 613 0 0%
3 7,826 1,539 0 0% 1 -0.03 77.2%
4 344 -0.04 62.3% 1 -0.01 49.5%
5 67 -0.14 36.0% 185 -0.41 77.5%
6 3 -0.16 27.9%
7 1 -0.14 38.0%
9 7 -0.02 59.2%
11 8 0.00 8.6%
17 1,348 -0.16 76.7% 1,240 -0.14 88.3%
20 57 -0.08 79.5% 5 -0.13 92.4%
25 1,936 -0.09 76.4% 616 -0.10 89.3%
27 3 -0.07 83.1%
32 1 -0.23 26.2%
Overall -0.11 62.8% -0.11 67.4%
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Figure 4.2: Complication Reduction by Patient Group
Note: Patients are grouped by age group (i.e., 50s to 90s), comorbidity and surgery. Acronyms for co-
morbidities: HTN - hypertension, DM - diabetes, CHF - chronic heart failure, NA - no comorbidities.
Acronyms for surgeries: CE - carotid endarterectomy, LBG - lower extremity bypass graft, MVR - mitral
valve replacement, AVR - aortic valve repair, CABG - coronary artery bypass grafting.
Figure 4.3: Complication Reduction under Patient-Centric Information
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90 Composite Index Value (Domain 1) and ﬁve infection measures (Domain 2).8 For
each measure, CMS uses two years of historical data to calculate risk-adjusted infection
rates and then ranks hospitals accordingly. Each hospital is assigned a score between 1
and 10 for each measure based on its relative rank in deciles for that measure. There is
only one score for Domain 1. A hospital’s Domain 2 score is calculated as the average
of the domain’s individual measures. The total score is calculated as the weighted
average of Domain 1 and Domain 2 scores, where the weights are 15% and 85% for the
two domains. In 2015, CMS reduced total payments (i.e., across all patients) by 1%
for hospitals that ranked among the worst quartile with regard to hospital acquired
infections.
4.6.2.1 Impact of Patient-Centric Information on Hospital Payments
The Hospital Acquired Condition Reduction Program is based on population-average
outcome information and so does not recognize heterogenous outcome diﬀerences across
patient groups. Consequently, applying a uniform penalty to these hospitals does not
recognize their acceptable or even high performance for some patient groups. Simi-
larly, hospitals that are not penalized under the HACRP may perform poorly for some
patient groups. In addition to misaligning penalties with performance, an incentive
system based on population-average information can hide areas of poor performance
and discourage hospitals from addressing them. In contrast, patient-centric informa-
tion allows payers to assess hospital performance by patient group and better align
payments with quality to provide shaper incentives for quality improvement.
To illustrate a HACRP-type program under patient-centric information, we group
patients by procedure type, age group and comorbidities. For each patient group, we
use Yijk ∈ {0, 1} to indicate whether hospital j is among the worst quartile for patient i
in group k. We then calculate the overall performance of hospital j for patient group k
using Y¯jk =
1
Njk
∑Njk
i=1 Yijk and display the results in the heat map of Figure 4.4. We see
that only Hospitals 21 and 26 are among the worst quartile across all patient groups.
Hospitals 23, 27, 28, 29 and 33 are among the worst quartile for a majority of patient
groups, but they have areas (e.g., procedure LBG for Hospital 23) that are not among
the worst quartile. Likewise, Hospitals 11, 14 and 25 are not among the worst quartile
8The PSI measures include rates of pressure ulcer, iatrogenic pneumothorax, central venous
catheter-related bloodstream infection, postoperative hip fracture, perioperative pulmonary embolism
or deep vein thrombosis, postoperative sesis, postoperative wound dehiscence and accidental puncture
or laceration. The ﬁve infection measures are rates of central line-associated bloodstream infection,
catheter-associated urinary tract infection, colon and hysterectomy surgical site infection, methicillin-
resistant staphlococcus aureus bacteremia, and clostrium dﬃcile infection.
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for the majority of patient groups, but they have areas (e.g., old MVR patients with
diabetes for Hospital 25) that are among the worst quartile.
Payments would be better aligned with performance if hospitals were penalized for
only their low-performing areas. To see how, in Figure 4.5, we compare scenarios in
which hospitals are penalized based on population-average and patient-centric infor-
mation. Under population-average information, there are nine hospitals with average
performance among the worst quartile, each of which would be penalized by 1% on all
payments. The other hospitals are not penalized at all. In contrast, under patient-
centric information, only ten hospitals are not penalized at all. The rest are penalized
on some portion of their payments. Hence, more hospitals would have a ﬁnancial
incentive to improve under patient-centric than under population-average information.
Figure 4.4: Comparison of Hospitals’ Performance by Patient Group
Note: Patients are grouped by age group (i.e., 50s to 90s), comorbidity and surgery. Acronyms for co-
morbidities: HTN - hypertension, DM - diabetes, CHF - chronic heart failure, NA - no comorbidities.
Acronyms for surgeries: CE - carotid endarterectomy, LBG - lower extremity bypass graft, MVR - mitral
valve replacement, AVR - aortic valve repair, CABG - coronary artery bypass grafting.
4.6.2.2 Impact on Hospital Strategy and Improvement Eﬀorts
Payments based on patient-centric information provide more focused incentives for hos-
pitals to improve quality, because they reward hospitals for incremental improvements.
For example, consider a hospital that discharges 1,000 patients a year, of which 100 are
CABG patients. The infection rate across all patients is 1%, but is 5% for CABG pa-
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Figure 4.5: Percentage Payment under Patient-Centric and Population-Average Mea-
sure
tients. If, under the current HACRP, the hospital is not penalized, it has no economic
incentive to improve. Even if it is penalized, it may be the case that reducing infections
among CABG patients will not have a large enough eﬀect on the overall infection rate
to eliminate the penalty. However, if HACRP penalties were based on patient-centric
information, and therefore individually penalized payments for CABG patients, then
the hospital would have economic incentives to reduce the CABG patient infection
rate, regardless of whether payments for other types of patients were being penalized
or not.
Beyond its use in targeted incentives, transparent patient-centric outcome informa-
tion can help hospitals learn from one another. For example, the heat map in Figure
4.4 shows that Hospital 27 has very low complication scores for hypertension patients,
despite having average performance for other patients. This may indicate that Hos-
pital 27 has made some kind of innovation that enables them to better protect these
patients. Hence, patient-centric information in Figure 4.4 can help hospitals spot best
practices that might be shared to elevate performance across the industry.9
Finally, in addition to supporting incentives for hospitals to improve outcomes for
speciﬁc patient groups, patient-centric information may also incent hospitals to focus
9Competition may hinder sharing of best practices across hospitals. But there are platforms for
such sharing. For example, the Quality Collaborative of the Michigan Society of Thoracic Surgeons
http://mstcvs.org/qc.html has been set up precisely to encourage the open heart programs in the
state of Michigan to share data and practices.
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on the patients they are able to treat most successfully. For example, suppose a hos-
pital has exceptionally good outcomes (e.g., low complication scores), relative to the
state average, for elderly patients, but poor outcomes for younger patients. The penal-
ties from an HACRP-type program would make the younger patients less economically
attractive to the hospital. And, if patient-centric information were transparently avail-
able to patients, demand from younger patients would presumably be weaker as well.
Both factors would encourage the hospital to focus on elderly patients, in its process
design and marketing eﬀorts. Other hospitals might be incented to focus on particu-
lar medical procedures or patient groups (e.g., patients with hypertension, diabetes or
cancer). Over time, this would encourage a network of providers that leverage their
individual strengths to produce better patient outcomes. These observations indicate
the answers to Question 3 in the Introduction is that patient-centric information en-
hances the power of pay-for-performance systems and sharpens the ability of providers
to make quality improvements.
4.7 Conclusion
In recent years, there have been many wide-ranging eﬀorts to improve the delivery of
health care in the United States. Perhaps the most straightforward of these has been
the push for better and more transparent outcome information to help patients ﬁnd the
best available care for them. Unfortunately, as we have shown, the standard approach of
computing risk-adjusted outcomes produces population averages that do not accurately
represent the likely outcomes for all patients. In this paper, we have shown that the
relative performance of hospitals is heterogeneous across patient groups. Consequently,
patient-centric rankings of hospitals are signiﬁcantly diﬀerent than rankings based on
population-average information.
In this study, we have addressed the challenges of generating patient-centric out-
come information and hospital ranking. Using six cardiovascular surgeries as the clin-
ical setting, we studied the outcomes of thirty-ﬁve hospitals in New York state. We
extended the instrumental variable tree approach for multiple hospitals to recursively
partition patients into groups that exhibit signiﬁcant outcome diﬀerences between hos-
pitals. We quantiﬁed the outcome diﬀerences for groups of patients using the instru-
mental variable method and derived patient-centric estimates of outcome diﬀerences
between hospitals for individual patients. Our analysis shows that outcome diﬀerences
between hospitals are heterogeneous not only across procedure types, but also along
other dimensions such as patient age and comorbidities.
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We compared the best hospitals based on population-average and patient-centric
information. We found that, for the majority of patients (around 80%), the best
hospitals are diﬀerent than those indicated as best by a population-average rating.
Furthermore, we found that patient-centric information results in a larger set of best
hospitals, which suggests more opportunities for distributing patient workload across
hospitals to reduce patient waiting time. Most importantly, we compared the potential
outcomes when patients are treated at the best hospitals based on the two types of
information, and estimated that the complication score could be reduced by 66.7% by
using patient-centric information instead of population-average information.
In addition to the manifest beneﬁts to patients, patient-centric information oﬀers
potential beneﬁts to hospitals and payers as well. Using the Hospital Acquired Infection
Reduction Program as an example, we showed that patient-centric information allows
the CMS to better align payments (and penalties) with patient outcomes. This in
turn provides sharper incentives for hospitals to improve quality. Finally, the more
detailed patient-centric information can help hospitals to understand their strengths
and weaknesses, as well as those of their peers. This can help them better align their
strategies with their strengths, and also to learn from one another.
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A.1 Hausman Test Results
Table A.1: Hausman Test Results
Fixed Eﬀects Random Eﬀects Diﬀerence Std. Err.
(F ) (R) (F −R) √diag(VF − VR)
Surgical Volumes
hosp vol 0.56 0.21 0.35 0.52
surg vol −3.29 0.13 −3.42 7.80
Patient Characteristics
age −0.02 −0.02 0.00 0.00
female −0.34 −0.31 −0.03 0.02
black −0.09 −0.17 0.08 0.05
hispanic −0.23 −0.32 0.09 0.06
asian −0.26 −0.29 0.04 0.10
others 0.17 0.13 0.04 0.04
Comorbidities
atrial ﬁbrillation −0.11 −0.12 0.01 0.02
alcohol abuse 0.38 0.28 0.09 0.09
deﬁciency anemias 0.07 0.09 −0.03 0.03
rheumatoid arthritis −0.31 −0.27 −0.04 0.05
blood loss 0.16 0.08 0.08 0.13
heart failure 0.19 −0.09 0.28 0.21
lung disease −0.25 −0.24 −0.01 0.02
coagulopathy −0.11 −0.13 0.02 0.02
depression 0.08 0.07 0.01 0.04
diabetes −0.10 −0.12 0.02 0.02
drug abuse −0.17 −0.11 −0.06 0.08
hypertension 0.05 0.05 0.00 0.02
hypothyroidism 0.09 0.07 0.02 0.03
liver disease −0.31 −0.15 −0.16 0.12
lymphoma −0.22 −0.22 0.00 0.10
electrolyte disorders 0.07 0.04 0.03 0.02
metastatic cancer −0.61 −0.53 −0.08 0.12
neurological disorders 0.11 0.10 0.02 0.05
obesity −0.15 −0.20 0.05 0.03
paralysis −0.12 −0.11 −0.01 0.07
vascular disorders 0.03 0.00 0.03 0.04
psychoses −0.26 −0.31 0.05 0.10
pulmonary disorders −0.47 −0.25 −0.22 0.25
renal failure −0.33 −0.29 −0.04 0.03
solid tumor −0.22 −0.19 −0.04 0.08
valvular disease −0.52 −0.47 −0.05 0.30
weight loss −0.01 −0.05 0.04 0.06
constant 0.01 0.79 −0.79 1.14
Note: Ho = diﬀerence in coeﬃcients not systematic. F = consistent under Ho and Ha; obtained from
probit. R = inconsistent under Ha, eﬃcient under Ho; obtained from multilevel probit.
Test results: χ2(36) = (F −R)′[(VF − VR)−1](F −R) = 33.78, Prob > χ2 = 0.5747.
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A.2 Population-Average Rates of Complication
and Readmission
Figure A.1: Complication Rate by Surgeon for A Patient with Average Characteristics
Figure A.2: Readmission Rate by Surgeon for A Patient with Average Characteristics
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A.3 Patient-Speciﬁc Rates of Complication and
Readmission
Figure A.3: Complication Rate by Surgeon for Patients of Diﬀerent Levels of Acuity
Figure A.4: Readmission Rate by Surgeon for Patients of Diﬀerent Levels of Acuity
100
A.4 Estimation Results of Each Type of Complica-
tion
Table A.2: Estimation Results of Each Type of Complication
Stroke Wound Infection Renal Failure Reoperation Ventilation
Coeﬀ. Std. Err. Coeﬀ. Std. Err. Coeﬀ. Std. Err. Coeﬀ. Std. Err. Coeﬀ. Std. Err.
Surgical Volumes
hosp vol −0.21 ∗ ∗ 0.10 0.12 0.15 0.04 0.06 −0.24 ∗ ∗ 0.10 0.31 ∗ ∗∗ 0.11
surg vol 0.16 ∗ ∗∗ 0.04 0.06 0.06 −0.05 ∗ ∗ 0.03 0.02 0.03 −0.08 ∗ ∗∗ 0.02
Patient Demographics
age 0.02∗ 0.01 0.00 0.01 0.02 ∗ ∗∗ 0.00 0.02 ∗ ∗∗ 0.00 0.02 ∗ ∗∗ 0.01
female 0.17 0.22 0.20∗ 0.10 −0.12∗ 0.06 0.24 ∗ ∗ 0.11 0.18∗ 0.10
black 0.27 0.52 −0.43 0.47 0.35 ∗ ∗ 0.17 −0.07 0.25 0.16 0.20
hispanic 0.79 ∗ ∗ 0.34 −0.20 0.17 0.02 0.15 −0.06 0.24 0.11 0.21
asian 0.57 0.42 −5.07 ∗ ∗∗ 0.38 −0.19 0.18 0.05 0.39 −0.18 0.45
others 0.47 ∗ ∗ 0.24 −0.05 0.26 −0.16 0.13 −0.36 0.23 −0.20 0.26
Comorbidities
atrial ﬁbrillation −0.02 0.17 −0.14 0.18 −0.07 0.08 0.04 0.16 −0.19 0.12
alcohol abuse −5.23 ∗ ∗∗ 0.83 −4.35 ∗ ∗∗ 0.40 −0.09 0.23 −5.16 ∗ ∗∗ 0.33 −0.03 0.58
deﬁciency anemias −0.09 0.33 −0.45 ∗ ∗ 0.22 −0.18 0.13 0.12 0.09 −0.46 ∗ ∗ 0.20
rheumatoid arthritis −4.46 . 0.10 0.44 −0.23 0.24 −0.38 0.49 −4.91 ∗ ∗∗ 0.29
blood loss −4.07 . −4.44 ∗ ∗∗ 1.05 −5.10 ∗ ∗∗ 0.53 0.20 0.49 −4.08 ∗ ∗∗ 0.19
heart failure 0.44 0.34 0.32 0.82 0.29 0.67 −6.15 ∗ ∗∗ 0.51 3.03 ∗ ∗∗ 0.80
lung disease 0.03 0.23 0.12 0.22 0.02 0.10 0.01 0.12 −0.01 0.12
coagulopathy −0.28 0.26 −0.12 0.15 0.32 ∗ ∗∗ 0.04 0.28 ∗ ∗ 0.12 0.28 ∗ ∗∗ 0.10
depression −0.60 0.40 −0.05 0.42 −0.19 0.18 −0.32 0.33 −0.35 0.26
diabetes −0.20 0.24 0.36 ∗ ∗ 0.14 0.07 0.12 −0.11 0.12 0.07 0.16
drug abuse −3.49 . −4.46 ∗ ∗∗ 0.66 −0.17 0.63 −4.71 ∗ ∗∗ 0.27 0.71∗ 0.39
hypertension −0.54 ∗ ∗ 0.24 −0.21 0.15 −0.28 ∗ ∗∗ 0.09 −0.26 ∗ ∗∗ 0.08 −0.37 ∗ ∗∗ 0.13
hypothyroidism 0.05 0.25 −0.46 0.33 −0.08 0.13 0.10 0.14 −0.13 0.32
liver disease −4.85 ∗ ∗∗ 0.76 0.41 0.67 0.66 ∗ ∗∗ 0.25 0.75 ∗ ∗ 0.32 −1.15 ∗ ∗ 0.48
lymphoma −4.72 . −4.81 ∗ ∗∗ 0.36 0.90 ∗ ∗ 0.39 0.19 0.49 −4.30 ∗ ∗∗ 0.23
electrolyte disorders −0.15 0.25 −0.07 0.18 0.42 ∗ ∗∗ 0.12 0.14 0.15 0.14 0.10
metastatic cancer −3.67 . −4.36 ∗ ∗∗ 1.02 −4.58 ∗ ∗∗ 0.21 −4.90 ∗ ∗∗ 0.32 −4.13 ∗ ∗∗ 0.21
neurological disorders 0.71 ∗ ∗ 0.36 −4.79 ∗ ∗∗ 0.33 −0.44 0.33 0.05 0.33 0.25 0.20
obesity 0.37 0.36 0.03 0.27 0.15 0.18 −0.25∗ 0.15 −0.03 0.23
paralysis 2.09 ∗ ∗∗ 0.32 0.62 0.42 −0.18 0.33 0.61∗ 0.32 0.74 ∗ ∗∗ 0.25
vascular disorders −0.55 ∗ ∗ 0.22 0.06 0.26 0.15 0.20 −0.39 0.29 0.42 ∗ ∗ 0.18
psychoses −4.24 . 0.75 0.47 −0.31 0.48 −4.84 ∗ ∗∗ 0.14 0.03 0.40
pulmonary disorders 0.73 0.59 −5.43 ∗ ∗∗ 0.89 0.17 0.76 −6.16 ∗ ∗∗ 0.55 6.94 ∗ ∗∗ 0.26
renal failure 0.26 0.23 0.62 ∗ ∗∗ 0.18 1.11 ∗ ∗∗ 0.11 −0.09 0.15 0.35∗ 0.21
solid tumor −3.98 . 0.73 ∗ ∗∗ 0.28 −0.06 0.41 −4.80 ∗ ∗∗ 0.37 −4.54 ∗ ∗∗ 0.12
valvular disease 0.14 0.42 0.83 0.94 0.50 0.46 1.37 ∗ ∗∗ 0.47 1.25 ∗ ∗∗ 0.44
weight loss 0.76 ∗ ∗∗ 0.29 0.62 ∗ ∗ 0.28 0.56 ∗ ∗∗ 0.12 0.69 ∗ ∗∗ 0.16 1.42 ∗ ∗∗ 0.18
Others
repair −0.20 0.21 −0.46 ∗ ∗ 0.24 −0.18∗ 0.09 −0.11 0.13 −0.24 ∗ ∗∗ 0.09
alpha 0.00 0.00 0.00 0.08 0.00 0.00 0.12 0.06 0.11 0.07
beta 0.00 0.00 0.02 0.05 0.00 0.00 0.02 0.05 0.00 0.00
constant −3.32 ∗ ∗∗ 0.84 −3.21 ∗ ∗∗ 0.88 −3.08 ∗ ∗∗ 0.40 −2.22 ∗ ∗∗ 0.40 −4.45 ∗ ∗∗ 0.65
log likelihood −74.37 −115.87 −594.03 −359.75 −244.36
Note: *** p < 0.01, ** p <0.05, * p < 0.1. Robust standard errors are clustered by surgeon.
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A.5 Model Elements and Sources for the Estima-
tion of QALE
Since there is no single source or paper that provides the value of various parameters in
our model, we draw from several sources in the medical literature to estimate long-term
risks associated with mitral valve repair and replacement and quality of life associated
with diﬀerent risks. Below we discuss our estimates and sources of each model element
for patients of diﬀerent ages and diﬀerent comorbidities.
Stroke: We estimate the risk of stroke based on Russo et al. (2008), who studied
1,344 patients that underwent mitral surgery at the Mayo Clinic from Jan 1980 to Dec
1995, and reported that (1) annual rate of stroke is 1.15% for mitral valve repair, 1.65%
and 2.7% for biological and mechanical valve replacement, respectively, (2) risk ratio of
age is 1.1 per 5 years, and (3) risk ratio of atrial ﬁbrillation is 1.4 for both mitral vale
repair and biological valve replacement. We estimate quality of life after stroke based
on Shah and Gage (2011), who developed a decision-analysis model to compare the
cost and quality-adjusted survival of various antithrombotic therapies on the basis of
the results from Randomized Evaluation of Long Term Anticoagulation Therapy and
other trials, and reported that quality of life after moderate to severe stroke is 0.39.
Bleeding: We estimate the risk of bleeding based on Russo et al. (2008), who
reported that (1) annual rate of bleeding is 0.7% for mitral valve repair, 1.4% and
2.43% for biological and mechanical valve replacement, respectively, (2) risk ratio of
age is 1.14 per 5 years, and (3) risk ratio of atrial ﬁbrillation is 1.52 for both mitral
vale repair and biological valve replacement. We estimate quality of life after stroke
based on Shah and Gage (2011), who reported that quality of life after bleeding is 0.8.
Structural Valve Deterioration (SVD): We estimate the risk of structural
valve deterioration based Bourguignon et al. (2014), who studied 450 patients that
underwent biological valve replacement from 1984 to 2011, and reported that annual
rate of structural valve deterioration is 2.75%, 1.5%, 0.6%, 0.4% for patients at their
50s, 60s, 70s and 80s, respectively. Because structural valve deterioration usually
requires reoperation (Bourguignon et al. 2014), we assume that quality of life after
structural valve deterioration is similar to that after reoperation.
Long-term Survival: We estimate long-term survival of patients with mitral
valve repair based on the US Social Security database, assuming that mitral valve
repair restores patients’ normal life expectancy (Ray et al. 2006). Long-term survival
associated with mitral valve replacement is estimated based on Daneshmand et al.
(2010), who studied 2,064 patients that underwent isolated primary mitral operations,
102
and found that (1) annual mortality rates associated with biological and mechanical
valve replacement are 1.8 and 1.3 times that associated with mitral valve repair, and (2)
risk ratio is 1.4 for diabetes and 1.3 for lung disease. In a similar study, Daneshmand
et al. (2009) found that risk ratio is 2.68 for renal disease and 1.37 for hypertension.
Risk ratio of other comorbidities is estimated to be 1.6 for heart failure (Gelsomino et
al. 2011) and 2.3 for atrial ﬁbrillation (Ruel et al. 2004).
Lastly, quality of life is estimated to be 0.6 for readmission (Cox et al. 2007), 0.45
for reoperation (Regier et al. 2006), 0.7 for ventilation (Windisch et al. 2003) and 0.85
for wound infection (Jide´us et al. 2009). Quality of life for patients with comorbidities
is estimated to be 0.751 for diabetes, 0.636 for heart failure, 0.714 for lung disease,
0.651 for renal failure, 0.789 for hypertension and 0.774 for atrial ﬁbrillation (Sullivan
and Ghushchyan 2006).
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A.6 Numerical Analysis Results with Heteroge-
neous Weights on Travel Distance
Table A.3: Comparison of the Eﬀectiveness of Patient-Speciﬁc Information and Ca-
pacity Increase
Weight on Weight on Expected Average Average Convenience Expected Average Average Convenience
Distance Waiting Time Number of Distance Waiting Adjusted Number of Distance Waiting Adjusted
Repairs (miles) (months) QALE*(days) Repairs (miles) (months) QALE*(days)
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
Patient-Speciﬁc (current capacity) Population-Average (current capacity)
Low 2,174 26 5.7 258 2,104 26 5.8 243
Low Medium 2,163 28 1.1 257 2,090 28 1.1 240
High 2,153 30 0.5 256 2,099 30 0.5 243
Low 2,163 22 5.6 246 2,099 22 5.7 232
Medium Medium 2,152 23 1.1 244 2,095 24 1.1 231
High 2,147 24 0.5 245 2,088 24 0.5 232
Low 2,115 17 5.2 171 2,064 17 5.3 158
High Medium 2,101 17 1.0 168 2,054 17 1.1 155
High 2,087 17 0.5 168 2,044 17 0.5 156
Population-Average (10% capacity increase) Population-Average (20% capacity increase)
Low 2,122 26 5.8 248 2,131 26 5.4 255
Low Medium 2,115 28 1.1 249 2,133 29 1.1 254
High 2,116 30 0.5 249 2,135 30 0.5 256
Low 2,116 22 5.4 240 2,129 23 5.3 245
Medium Medium 2,111 24 1.1 238 2,131 24 1.1 244
High 2,108 25 0.5 238 2,127 25 0.5 245
Low 2,082 17 4.9 167 2,102 17 4.6 175
High Medium 2,074 17 1.0 164 2,095 17 0.9 171
High 2,063 17 0.5 163 2,088 18 0.5 170
Actual 1,557 19
Note: This table compares scenarios when patients choose surgeons based on patient-speciﬁc information (with current capacity)
and population-average information (with 0–20% capacity increases). We consider Low, Medium and High weights patients place
on travelling and waiting. Equivalent quality-adjusted life days per mile for Low, Medium and High weights on travelling are 0.5,
1, 5. Equivalent quality-adjusted life days per month for Low, Medium and High weights on waiting are 10, 50, 100. *For the ease
of comparison, a ﬁxed amount of one quality-adjusted life year has been subtracted from Convenience Adjusted QALE for both
patient-speciﬁc and population-average cases.
Table A.4: Comparison of the Values from Using Patient-Speciﬁc and Population-
Average Information
Diﬀ. in Num. Diﬀ. in Total Diﬀ. in Average Diﬀ. in Average
of Repairs QALE (year) Travel Dist.(mile) Wait Time(month)
Weight on Weight on Waiting Weight on Waiting Weight on Waiting Weight on Waiting
Distance Low Medium High Low Medium High Low Medium High Low Medium High
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13)
Low 71 74 55 108 120 81 0 0 0 -0.1 0.0 0.0
Medium 64 57 59 93 84 89 0 0 0 -0.2 0.0 0.0
High 51 47 43 70 65 59 0 0 0 -0.2 -0.1 0.0
Note: This table summarizes the changes in total number of repairs, quality-adjusted life years, average travel distance and waiting time
per patient when information is switched from population-average to patient-speciﬁc. We consider Low, Medium and High weights patients
place on travelling and waiting. Equivalent quality-adjusted life days per mile for Low, Medium and High weights on travelling are 0.5, 1,
5. Equivalent quality-adjusted life days per month for Low, Medium and High weights on waiting are 10, 50, 100.
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APPENDIX B
Appendix to Chapter 3
B.1 Estimation of Mean Squared Errors
Let β(Xi) denote the conditional average treatment eﬀect for subject i. We have
ESes [βˆ
es(Xi)|Ses] = EXi [βte(Xi)] = β(Xi). The expected MSE is the expectation of
MSE(Ste, Ses) over test and estimation samples:
EMSE = ESte,SesMSE(S
te, Ses)
= ESte,Ses [(β
te(Xi)− βˆes(Xi))2]
= ESte,Ses [(β
te(Xi)− β(Xi))2 + βˆes(Xi)2 − β(Xi)2 + 2βte(Xi)(β(Xi)− βˆes(Xi))]
= ESte,Ses [(β
te(Xi)− β(Xi))2 + βˆes(Xi)2 − β(Xi)2 + 2β(Xi)(β(Xi)− βˆes(Xi))]
= ESte,Ses [(β
te(Xi)− β(Xi))2 + (βˆes(Xi)− β(Xi))2]
= ESte [(β
te(Xi)
2 − 2βte(Xi)β(Xi) + β(Xi)2] + EXi,Ses [(βˆes(Xi)− β(Xi))2]
= ESte [β
te(Xi)
2 − β(Xi)2] + EXi,Ses [V ar(βˆes(Xi))].
Because ESte [β
te(Xi)
2] does not depend on the estimator, minimizing above EMSE is
equivalent to minimizing
EMSE(Ste, Ses) = −EXi [β(Xi)2] + EXi,Ses [V ar(βˆes(Xi))].
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B.2 Proofs of Lemma, Theorem and Corollary
B.2.1 Proof of Lemma 1
The ﬁrst part of Lemma 1 follows directly from Slutsky theorem for probability limits,
which state that, for a continuous function g(Xn), plim(g(Xn)) = g(plim(Xn)). To
prove the second part, we use the Dominated Convergence theorem, which states that,
if XN
p→ X and there is a random variable Z with E[Z] < ∞ such that |XN | < Z for
all N, then E[ lim
N→∞
XN ] = lim
N→∞
E[XN ]. Therefore, we have
lim
N→∞
Cov(βiTi, Yi) = lim
N→∞
(E[βiTiYi]− E[βiT1i]E[Yi])
= lim
N→∞
E[βiTiYi]− lim
N→∞
E[βiTi]E[Yi]
= E[ lim
N→∞
βiTiYi]− E[ lim
N→∞
βiTi]E[Yi]
= E[βljTiYi]− E[βljTi]E[Yi]
= Cov(βljTi, Yi).
The third equality follows from the observation that βiTiYi
p→ βljTiYi and βiTi p→
βljTi (by the Slutsky theorem). Because βi, Ti and Yi are all bounded in practice, there
exist random variables Z1 and Z2 such that E|Z1| < ∞, E|Z2| < ∞, |βiTiYi| < Z1 and
|βiTi| < Z2.
B.2.2 Proof of Lemma 2
We break Lemma 2 into two parts and prove them separately: (a) the moment gen-
erating function of Vi is bounded by e
t2(b−a)2
8 (i.e., ψi(t) ≤ e t
2(b−a)2
8 ), and (b) for any
w > 0, we have Pr(V ≥ w) ≤ N−7w2kN/[8(b−a)2], where a and b are lower and upper
bounds of Vi.
B.2.2.1 Proof of Part A
Because subjects in the same group are independent of each other, we assume the
variable Vi is independent. By Assumption 3, Vi is bounded by a and b, i.e., a ≤ Vi ≤ b,
so we can write Vi as a convex combination of a and b, Vi = λb+(1−λ)a, where λ = Vi−ab−a .
Because the function f(x) = etx is convex, we have
etVi ≤ λetb + (1− λ)eta = Vi − a
b− a e
tb +
b− Vi
b− a e
ta.
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Taking expectation of both sides, we have
E(etVi) ≤ V − a
b− a e
tb +
b− V
b− a e
ta.
Let eg(u) = V−a
b−a e
tb + b−V
b−a e
ta, γ = V−a
b−a , and u = t(b− a). We have
g(u) = log(V−a
b−a e
tb + b−V
b−a e
ta)
= log(eta(V−a
b−a e
tb−ta + b−V
b−a ))
= ta+ log(γeu + (1− γ))
= tV − γu+ log(γeu + (1− γ)).
Note that g(0) = tV , g′(0) = 0 and g′′(u) ≤ 1
4
for all u > 0. By Taylor’s theorem,
there is a ε ∈ (0, u) such that
g(u) = g(0) + ug′(0) +
u2
2
g′′(ε) ≤ tV + u
2
8
= tV +
t2(b− a)2
8
.
Therefore, we have E(etVi) ≤ etV+ t
2(b−a)2
8 . That is, the moment-generating function
of Vi is bounded by e
tV+
t2(b−a)2
8 . From the exogeneity condition, we have V = E[Zii] =
EZi [ZiE(i|Zi)] = 0. Therefore, we have ψi(t) ≤ e
t2(b−a)2
8 .
B.2.2.2 Proof of Part B
Let K = (b− a)2. For any w > 0, from Markov’s Inequality and Part A, we have
Pr(V ≥ w) = Pr(eV wNlj /K ≥ ew2Nlj /K)
≤ 1
e
w2Nlj
/K
E[eV wNlj /K ]
= 1
e
w2Nlj
/K
E[e
(V1+V2+...+VNlj
)w/K
]
= 1
e
w2Nlj
/K
∏Nlj
i=1 ψi(
w
K
)
≤ 1
e
w2Nlj
/K
ew
2Nlj /(8K)
= e−7w
2Nlj /(8K).
Let pN denote the empirical distribution ofXn deﬁned as pN(lj) =
1
N
{n : 1 ≤ n ≤ N
and Xn ∈ lj}. By Assumption 4, we have pN(lj) ≥ kN logNN , where kN are a sequence
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of positive constants and lim
N
kN = ∞, we have
Pr(V ≥ w) ≤ e−7w2Nlj /(8K)
= e−7w
2pN (lj)N/(8K)
≤ e−7w2kN logN/(8K)
= N−7w
2kN/(8K)
= N−7w
2kN/[8(b−a)2].
Similarly, we have Pr(V ≤ −w) ≤ N−7w2kN/[8(b−a)2]. Therefore, we have Pr(|V | ≥
w) ≤ 2N−7w2kN/[8(b−a)2].
B.2.3 Proof of Theorem 1
To prove Theorem 1, we use a fundamental combinatorial result due to Vapnik and
Chervonenkis (1971). Since each group in π is a convex polyhedron in the d-dimensional
Euclidean space with at most M faces, there exists a collection φ of the subsets of the
set {X1, X2, ..., Xn} such that #(φ) ≤ (2N)M(d+2) and φ has the property that, for any
polyhedron j with no more than M faces in the d-dimensional Euclidean space, there
exists an s ∈ φ such that i ∈ lj if and only if Xi ∈ s. Note that, for subgroup lj, we
have βˆIV (xlj)−βlj = ( 1Nlj
∑
i∈lj ZiTi)
−1( 1
Nlj
∑
i∈lj Zii) = Q
−1
lj
V (see e.g., Greene 2003,
Chapter 5). These imply that, for any w > 0, we have
lim
N→∞
Pr(max
j
|βˆIV (xlj )− βlj | ≥ w)
= lim
N→∞
Pr(
⋃
j
{|βˆIV (xlj )− βlj | ≥ w})
= lim
N→∞
Pr(
⋃
j
{|Q−1lj V | ≥ w})
≤ lim
N→∞
(min
j
|Qlj |)−1 × (2N)M(d+2) × 2N−7w
2kN/[8(b−a)2]
= Q∗−1 lim
N→∞
×21+M(d+2)NM(d+2)−7w2kN/[8(b−a)2]
= 0.
where Q∗ = minj|Qlj |. The second inequality follows from Lemma 2 and the funda-
mental combinatorial result; the third equality follows from Assumption 3, which states
that Q is bounded for all subgroups; and the last equality follows from lim
N
kN = ∞
(Assumption 4). Because βi
p→ βlj (from Lemma 1), we have
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lim
N→∞
Pr(max
j
|βˆIV (xlj)− βi| ≥ w)
= lim
N→∞
Pr(max
j
|βˆIV (xlj)− βlj + βlj − βi| ≥ w)
≤ lim
N→∞
Pr(max
j
(|βˆIV (xlj)− βlj |+ |βlj − βi|) ≥ w)
≤ lim
N→∞
Pr(max
j
|βˆIV (xlj)− βlj | ≥ w2 ) or limN→∞Pr(maxj |βlj − βi| ≥
w
2
)
≤ lim
N→∞
Pr(max
j
|βˆIV (xlj)− βlj | ≥ w2 ) + limN→∞Pr(maxj |βlj − βi| ≥
w
2
)
= 0.
B.2.4 Proof of Corollary 1
To prove that the causal tree does not provide a consistent estimator, it suﬃces to
show that there exists lj such that βˆCT (xlj)
p
 βlj .
βˆCT (xlj) = E(Y1i|Ti = 1)− E(Y2i|Ti = 0)
= βlj + [E(εi|Ti = 1)− E(εi|Ti = 0)].
Let p denote the probability of receiving a treatment, i.e., p = P (Ti = 1). By
expanding Cov(Ti, εi), we have
Cov(Ti, εi) = E(Tiεi)− E(Ti)E(εi)
= pE(εi|Ti = 1)− [pE(εi|Ti = 1) + (1− p)E(εi|Ti = 0)]p
= p(1− p)[E(εi|Ti = 1)− E(εi|Ti = 0)].
Because Cov(Ti, εi) = 0 implies that E(εi|Ti = 1) − E(εi|Ti = 0) = 0, we have
βˆCT (xlj) = βlj .
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APPENDIX C
Appendix to Chapter 4
C.1 Evaluation of the Instrument
To check if travel distance correlates with patient sickness, we analyze if patients living
closer to a hospital are sicker or healthier as indicated by their age, number of chronic
conditions and number of comorbidities. The results are summarized below. We do
not see evidence of such correlation.
Table C.1: Relationship between Distance to the Nearest Hospital and Patient Char-
acteristics
Number of
Distance Number of Patients’ Chronic Number of
(in mile) Patients Mean Age Conditions Comorbidities
below 5 47,192 67.6 (12.3) 6.6 (2.4) 2.7 (1.5)
5 to 10 18,015 68.7 (11.8) 6.7 (2.4) 2.7 (1.5)
above 10 32,978 67.6 (11.8) 6.6 (2.5) 2.6 (1.5)
Total 98,185 67.8 (12.1) 6.6 (2.4) 2.7 (1.5)
To provide a sense of the correlation between travel distance and patient choice,
we ﬁrst rank hospitals by travel distance for each patient and then analyze the overall
ranks of the chosen hospitals. Figure C.1 shows the percentage of patients and the
ranks of their chosen hospitals. We see that more than half of the patients chose the
nearest or the second nearest hospitals. We also see that the probability of choosing a
hospital decreases as the distance increases.
We check the strength of the instrumental variable by regressing the provider indi-
cator over the instrumental variable for each group of patients (i.e., ﬁrst stage) when
we compare each pair of providers. The coeﬃcients are signiﬁcant at 1% signiﬁcance
level in 99% of the cases. These results suggest that the instrumental variable has a
strong ﬁrst stage.
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Figure C.1: Rank of the Chosen Hospital by Travel Distance
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